



US009850505B2

(12) **United States Patent**
Reed et al.

(10) **Patent No.:** US 9,850,505 B2
(45) **Date of Patent:** Dec. 26, 2017

(54) **MICROORGANISMS AND METHODS FOR PRODUCING PYRUVATE, ETHANOL, AND OTHER COMPOUNDS**

(71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION**, Madison, WI (US)

(72) Inventors: **Jennifer L. Reed**, Madison, WI (US); **Xiaolin Zhang**, Newark, DE (US)

(73) Assignee: **WISCONSIN ALUMNI RESEARCH FOUNDATION**, Madison, WI (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/848,646**

(22) Filed: **Sep. 9, 2015**

(65) **Prior Publication Data**

US 2016/0068871 A1 Mar. 10, 2016

Related U.S. Application Data

(60) Provisional application No. 62/047,896, filed on Sep. 9, 2014.

(51) **Int. Cl.**

C12N 1/21 (2006.01)
C12P 7/40 (2006.01)
C12P 7/06 (2006.01)
C12N 1/19 (2006.01)
C12N 9/04 (2006.01)
C12N 9/88 (2006.01)

(52) **U.S. Cl.**

CPC **C12P 7/40** (2013.01); **C12N 9/0006** (2013.01); **C12N 9/88** (2013.01); **C12P 7/06** (2013.01); **C12Y 101/01001** (2013.01); **C12Y 401/01001** (2013.01); **Y02E 50/17** (2013.01)

(58) **Field of Classification Search**

CPC C12P 7/40; C12P 7/06; C12N 9/88; C12N 9/0006; Y02E 50/17; C12Y 401/01001; C12Y 101/01001

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2010/0304450 A1 12/2010 Eiteman et al.

FOREIGN PATENT DOCUMENTS

WO WO 99/53035 10/1999

OTHER PUBLICATIONS

Zhou et al., Cell Mol Life Sci 63(19-20):2260-2290, 2006.*
Kozak, M., Gene 234:187-208, 1999.*

Altschul et al., Basic Local Alignment Research Tool, J. Mol. Biol. (1990)215, 403-410.

Asadollahi et al., Enhancing sesquiterpene production in *Saccharomyces cerevisiae* through in silico driven metabolic engineering. Metab Eng. 2009; 11(6):328-34.

Atsumi et al., Non-fermentative pathways for synthesis of branched-chain higher alcohols as biofuels. Nature. 2008;451(7174):86-U13.

Baba et al., Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol. 2006;2. Baumler et al., The evolution of metabolic networks of *E. coli*. Bmc Syst Biol. 2011;5:182.

Beller et al., Genes Involved in Long-Chain Alkene Biosynthesis in *Micrococcus luteus*. Appl Environ Microb. 2010;76(4):1212-23.

Bologna et al., Characterization of *Escherichia coli* EutD: a Phosphotransacetylase of the Ethanolamine Operon. J Microbiol. 2010;48(5):629-36.

Causey et al., Engineering the metabolism of *Escherichia coli* W3110 for the conversion of sugar to redox-neutral and oxidized products: Homoacetate production. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(3):825-32.

Causey et al., Engineering *Escherichia coli* for efficient conversion of glucose to pyruvate. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(8):2235-40.

Datsenko et al., One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(12):6640-5.

Feist et al., BO. Model-driven evaluation of the production potential for growth-coupled products of *Escherichia coli*. Metab Eng. 2010;12(3):173-86.

Fong et al., In silico design and adaptive evolution of *Escherichia coli* for production of lactic acid. Biotechnol Bioeng. 2005;91(5):643-8.

Hawkins et al., Production of benzylisoquinoline alkaloids in *Saccharomyces cerevisiae*. Nat Chem Biol. 2008;4(9):564-73.

Ingram et al., Genetic-Engineering of Ethanol-Production in *Escherichia coli*. Appl Environ Microb. 1987;53(10):2420-5.

Karlin & Altschul, Applications and statistics for multiple high-scoring segments in molecular sequences, Proc. Natl. Acad. Sci. USA, Fol. 90, pp. 5873-5877, Jun. 1993.

Kim et al., Optimal metabolic and regulatory perturbations for metabolic engineering of microbial strains. Bmc Syst Biol. 2010;4.

Leonard et al., Combining metabolic and protein engineering of a terpenoid biosynthetic pathway for overproduction and selectivity control. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(31):13654-9.

(Continued)

Primary Examiner — Delia Ramirez

(74) **Attorney, Agent, or Firm — Daniel A. Blasolie;**
DeWitt Ross & Stevens S.C.

(57) **ABSTRACT**

Microorganisms comprising modifications for producing pyruvate, ethanol, and other compounds. The microorganisms comprise modifications that reduce or ablate activity of one or more of pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase, phosphate acetyltransferase, acetate kinase, pyruvate oxidase, lactate dehydrogenase, cytochrome terminal oxidase, succinate dehydrogenase, 6-phosphogluconate dehydrogenase, glutamate dehydrogenase, pyruvate formate lyase, pyruvate formate lyase activating enzyme, and isocitrate lyase. The microorganisms optionally comprise modifications that enhance expression or activity of pyruvate decarboxylase and alcohol dehydrogenase. The microorganisms are optionally evolved in defined media to enhance specific production of one or more compounds. Methods of producing compounds with the microorganisms are provided.

(56)

References Cited**OTHER PUBLICATIONS**

- Miller et al., Experiments in Molecular Genetics. Cold Spring Harbor Laboratory, (1972), 433 Entire Book Not Provided.
- Mills et al., Cellulosic hydrolysate toxicity and tolerance mechanisms in *Escherichia coli*. Biotechnol Biofuels. 2009;2.
- Nagy et al., Formyltetrahydrofolate Hydrolase, a Regulatory Enzyme That Functions to Balance Pools of Tetrahydrofolate and One-Carbon Tetrahydrofolate Adducts in *Escherichia coli*. Journal of Bacteriology. 1995;177(5):1292-8.
- Nakamura et al., Metabolic engineering for the microbial production of 1,3-propanediol. Curr Opin Biotech. 2003;14(5):454-9.
- Neidhardt et al., Physiology of the bacterial cell: a molecular approach. Sunderland, Mass: Sinauer Associates; 1990.
- Olins et al., A Novel Sequence Element Derived from Bacteriophage T7 mRNA Acts as an Enhancer of Translation of the lacZ Gene in *Escherichia coli*. The Journal of Biological Chemistry, vol. 264, No. 29, pp. 16973-16976 1989.
- Park et al., Metabolic engineering of *Escherichia coli* for the production of L-valine based on transcriptome analysis and in silico gene knockout simulation. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(19):7797-802.
- Peng et al., Global metabolic regulation analysis for *Escherichia coli* K12 based on protein expression by 2-dimensional electrophoresis and enzyme activity measurement. Applied Microbiology and Biotechnology. 2003;61(2):163-78.
- Pfeifer et al., Biosynthesis of complex polyketides in a metabolically engineered strain of *E.coli*. Science. 2001;291(5509):1790-2.
- Reed et al., An expanded genome-scale model of *Escherichia coli* K-12 (iJR904 GSM/GPR). Genome Biol. 2003;4(9).
- Ro et al., Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature. 2006;440(7086):940-3.
- Sawers et al., a glycyl radical solution: oxygen-dependent interconversion of pyruvate formate-lyase. Molecular Microbiology. 1998;29(4):945-54.
- Sawers et al., The glycyl radical enzyme TdcE can replace pyruvate formate-lyase in glucose fermentation. Journal of Bacteriology. 1998;180(14):3509-16.
- Schirmer et al., Microbial Biosynthesis of Alkanes. Science. 2010;329(5991):559-62.
- Schwalbach et al., Complex Physiology and Compound Stress Responses during Fermentation of Alkali-Pretreated Corn Stover Hydrolysate by an *Escherichia coli* Ethanologen. Appl Environ Microb. 2012;78(9):3442-57.
- Siewers et al., Implementation of Communication-Mediating Domains for Non-Ribosomal Peptide Production in *Saccharomyces cerevisiae*. Biotechnol Bioeng. 2010;106(5):841-4.
- Steen et al., Microbial production of fatty-acid-derived fuels and chemicals from plant biomass. Nature. 2010;463(7280):559-U182.
- Tarmy et al., Kinetics of *Escherichia coli* B D-Lactate Dehydrogenase and Evidence for Pyruvate-Controlled Change in Conformation. Journal of Biological Chemistry. 1968;243(10):2587.
- Tomar et al., The effect of acetate pathway mutations on the production of pyruvate in *Escherichia coli*. Applied Microbiology and Biotechnology. 2003;62(1):76-82.
- Toya et al., Metabolic regulation analysis of wild-type and arcA mutant *Escherichia coli* under nitrate conditions using different levels of omics data. Molecular bioSystems. 2012;8(10):2593-604.
- Wang et al., Production of pyruvate in *Saccharomyces cerevisiae* through adaptive evolution and rational cofactor metabolic engineering. Biochem Eng J. 2012;67:126-31.
- Wierckx et al., Engineering of solvent-tolerant *Pseudomonas putida* S12 for bioproduction of phenol from glucose. Appl Environ Microb. 2005;71(12):8221-7.
- Wieschalka et al., Engineering *Corynebacterium glutamicum* for the production of pyruvate. Applied Microbiology and Biotechnology. 2012;94(2):449-59.
- Xu et al., Regulation of thiamine synthesis in *Saccharomyces cerevisiae* for improved pyruvate production. Yeast. 2012;29(6):209-17.
- Zha et al., Improving cellular malonyl-CoA level in *Escherichia coli* via metabolic engineering. Metab Eng. 2009;11(3):192-8.
- Zhang et al., Metabolic evolution of energy-conserving pathways for succinate production in *Escherichia coli*. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(48):20180-5.
- Zhou et al., Evaluation of Genetic Manipulation Strategies on d-Lactate Production by *Escherichia coli*. Curr Microbiol. 2011;62(3):981-9.
- Zhu et al., High Glycolytic Flux Improves Pyruvate Production by a Metabolically Engineered *Escherichia coli* Strain. Appl Environ Microb. 2008;74(21):6649-55.

* cited by examiner




FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 3E




FIG. 3F




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B

1

**MICROORGANISMS AND METHODS FOR
PRODUCING PYRUVATE, ETHANOL, AND
OTHER COMPOUNDS**

**STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH**

This invention was made with government support under DE-FC02-07ER64494, DE-SC0008103 awarded by the U.S. Department of Energy. The government has certain rights in the invention.

BACKGROUND

Over the past decade a number of chemical companies have begun to develop infrastructures for the production of compounds using bio-based processes. Considerable progress has been reported toward new processes for producing commodity chemicals such as ethanol, lactic acid, 1,3-propanediol, and adipic acid. In addition, advances have been made in the genetic engineering of microbes for higher value specialty compounds such as acetate, polyketides, and carotenoids.

Pyruvate is a starting material for synthesizing a variety of biofuels and chemicals. Industrially, pyruvate is produced via dehydration and decarboxylation of calcium tartrate, a byproduct of the wine industry. This process involves toxic solvents and is energy intensive with an estimated production cost of \$8,650 per ton of pyruvate. Microbial pyruvate production is based primarily upon two microorganisms, a multi-vitamin auxotroph of the yeast *T. glabrata* and a lipoic auxotroph of *E. coli* containing an F1ATPase mutation. The estimated cost of pyruvate production via microbial fermentation with such strains is estimated to be \$1,255 per ton of pyruvate, an 85% savings. Increasing the yield of pyruvate would increase the savings even further.

Ethanol is mainly of interest as a petrol additive, or substitute, because ethanol-blended fuel produces a cleaner, more complete combustion that reduces greenhouse gas and toxic emissions. The production of ethanol in the US has increased tremendously in recent years, and demand is projected to increase even further. As a consequence of the surge in demand for biofuels, ethanol-producing microorganisms are of considerable interest due to their potential for the production of bioethanol. To keep in step with the growing demand for biofuels, the engineering of new strains of fermentative microorganisms that can efficiently produce ethanol will be required.

There is a need for microorganisms that efficiently produce pyruvate, ethanol, or other commodity chemicals.

SUMMARY OF THE INVENTION

The present invention addresses the aforementioned needs by providing microorganisms with increased production of pyruvate, ethanol, or other commodity chemicals. Methods of producing commodity chemicals with the microorganisms described herein are also provided.

One aspect of the invention is a microorganism comprising modifications that reduce or ablate activity of one or more enzymes in a first set, one or more enzymes in a second set, and enzymes in a third set. The enzymes in the first set are selected from the group consisting of pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase. The enzymes in the second set are selected from the group consisting of phosphate acetyltransferase, acetate kinase, and pyruvate oxidase. The enzymes in the third set comprise lactate

2

dehydrogenase and one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase; lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase; one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase; or lactate dehydrogenase, one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase, and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase.

In some versions, the one or more enzymes in the first set are selected from pyruvate dehydrogenase.

In some versions, the one or more enzymes in the second set are selected from the group consisting of phosphate acetyltransferase and pyruvate oxidase.

In some versions, the enzymes in the third set comprise lactate dehydrogenase and cytochrome terminal oxidase, lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase, or succinate dehydrogenase and 6-phosphogluconate dehydrogenase.

In some versions, the one or more enzymes in the first set are selected from pyruvate dehydrogenase, the one or more enzymes in the second set are selected from phosphate acetyltransferase, and the enzymes in the third set comprise lactate dehydrogenase and one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase, or lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase.

In some versions, the one or more enzymes in the first set are selected from pyruvate dehydrogenase, the one or more enzymes in the second set are selected from phosphate acetyltransferase, and the enzymes in the third set comprise lactate dehydrogenase and cytochrome terminal oxidase, or lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase.

In some versions, the one or more enzymes in the first set are selected from pyruvate dehydrogenase, the one or more enzymes in the second set are selected from pyruvate oxidase, and the enzymes in the third set comprise one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase.

In some versions, the microorganism further comprises a modification that reduces or ablates activity of an enzyme selected from the group consisting of pyruvate formate lyase and pyruvate formate lyase activating enzyme.

In some versions, the microorganism further comprises a modification that enhances expression of pyruvate decarboxylase and alcohol dehydrogenase.

In some versions, the microorganism is a bacterium or a yeast.

In some versions, an evolved microorganism is produced by sequentially culturing any microorganism described above or elsewhere herein in media comprising decreasing concentrations of a compound such as acetate, ethanol, or another compound. The media each preferably comprise approximately a same amount of total consumable carbon.

3

In some versions, the microorganism is cultured in media comprising decreasing concentrations of acetate. The concentrations of acetate in the media may range from about 0.1 mg/L acetate to about 3 g/L acetate.

Another aspect of the invention is a method of producing a chemical. The method comprises culturing any microorganism described above or elsewhere herein. The chemical may be selected from the group consisting of pyruvate and ethanol. The culturing may comprise culturing the microorganism in a medium comprising a biomass hydrolysate.

The objects and advantages of the invention will appear more fully from the following detailed description of the preferred embodiment of the invention made in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schema showing the central metabolic pathway of wild-type *E. coli*. Genes associated with each reaction in the central metabolic network are shown and flux values are labeled. The metabolic flux distribution for the wild-type strain under aerobic conditions was predicted by flux balance analysis. Glucose uptake rate was set at 10 mmol/gDW/hour. The dashed line represents the ethanol synthesis pathway (PET operon) from *Zymomonas mobilis*.

FIGS. 2A-2D are schemas showing the central metabolic pathway of mutant *E. coli* strains designed for pyruvate production. Genes associated with each reaction in the central metabolic network are shown and flux values are labeled. The reactions marked by bars correspond to the deletion targets calculated computationally. The labeled metabolic flux distribution for each strain was predicted by flux balance analysis. Glucose uptake rate was set at 10 mmol/gDW/hour. Oxygen uptake was unlimited for the strains shown in FIGS. 2B-2D, but limited to 3 mmol/gDW/hour for the strain shown in FIG. 2A. FIG. 2A: Strain designed as $\Delta aceE$, $\Delta cyoA$, $\Delta cydB$, Δpta , $\Delta eutI$, $\Delta idhA$, and Δidd . FIG. 2B: Strain designed as $\Delta lpdA$, Δgnd , $\Delta sdhA$, $\Delta poxB$, $\Delta pflB$, $\Delta pflD$, $\Delta tdcE$, and $\Delta purU$. FIG. 2C: Strain designed as $\Delta aceE$, $\Delta gdhA$, $\Delta poxB$, $\Delta ldhA$, Δidd , $\Delta atpE$, $\Delta pflB$, $\Delta pflD$, and $\Delta tdcE$. FIG. 2D: Strain designed as $\Delta aceE$, Δgnd , $\Delta poxB$, $\Delta ldhA$, Δidd , $\Delta atpE$, $\Delta pflB$, $\Delta pflD$, and $\Delta tdcE$.

FIGS. 3A-3F show growth (FIGS. 3A and 3D), pyruvate production (FIGS. 3B and 3E), and glucose consumption (FIGS. 3C and 3F) of wild-type (BW25113) and mutant *E. coli* strains. Cells were grown in M9 minimal medium containing glucose and acetate. (See Table 2 for media details).

FIG. 4 shows (a) lactate and (b) acetate secretion for parent (BW25113) and mutant *E. coli* strains under aerobic conditions in shake flasks. The shown concentrations are the maximum acid concentrations observed over 60 hours during growth in M9 minimal medium supplemented with glucose and acetate. (See Table 2 for media details). Acetate accumulated in BW25113, PYR001 and PYR002 cultures and lactate accumulated in PYR002 cultures. * indicates concentrations of acetate and lactate that were below the detection level of the HPLC.

FIG. 5 shows growth, glucose consumption, and pyruvate production by PYR004 in bioreactors. Panels (A) and (B) show batch fermentation in minimal salts medium containing 30 g/L glucose with 1.5 g/L acetate (panel A) or 3 g/L acetate (panel B). Panel (C) shows fed-batch fermentation operated in minimal salts medium initially containing 30 g/L glucose and 1.5 g/L acetate. In the fed-batch operation, an additional 7.5 mL of 200 g/L acetate was added at 8.5 hours,

4

indicated by the black arrow, for a total acetate concentration of 3.0 g/L. Experiments were performed in duplicate. Diamond: OD 600. Triangle: glucose concentration. Square: pyruvate concentration.

FIG. 6 shows growth, glucose consumption and pyruvate production by PYR020 in bioreactors. Panels (A) and (B) show batch fermentation in minimal salts medium containing 30 g/L glucose with 0.9 g/L acetate (Panel A) or 1.5 g/L acetate (Panel B). Panel (C) shows fed-batch fermentation operated in minimal salts medium initially containing 30 g/L glucose and 0.6 g/L acetate. In the fed-batch operation, an additional 1.5 mL of 200 g/L acetate was added at 17 hours, indicated by the black arrow. Experiments were performed in duplicate. Diamond: OD 600. Triangle: glucose concentration. Square: pyruvate concentration.

FIG. 7 shows batch production of pyruvate in ammonia fiber expansion (AFEX)-pretreated switchgrass hydrolysate (ASGH) by strain PYR020. Cells were grown in ASGH containing 48 g/L glucose, 27 g/L xylose, and 2.6 g/L acetate. Diamond: OD 600. Square: pyruvate concentration.

FIGS. 8A-8B show product secretion from various strains under anaerobic conditions. Secretion of ethanol, succinate, and formate is shown in FIG. 8A. Secretion of acetate and lactate is shown in FIG. 8B. All experiments were performed anaerobically in hangle tubes in M9 minimal media. Columns marked "a" correspond to fermentations containing 1.98 g/L glucose and 0.02 g/L acetate. Multiple samples were taken over 48 hours, which reduced the culture volume by about 50%. Columns marked (b) correspond to fermentations in M9 medium with 1.98 g/L glucose and 0.02 g/L acetate for 24 hours, but only three samples were taken at 16, 20 and 24 hours. Columns marked (c) correspond to fermentations in M9 minimal medium with more acetate (0.1 g/L) and 1.9 g/L glucose for 24 hours, with only three samples. Error bars represent standard errors among three replicates. Percent of theoretical yield was calculated as the ethanol concentration divided by the theoretical maximum production of ethanol (2 mmol of ethanol per mmol of glucose plus 0.67 mmol of ethanol per mmol of acetate). t-tests were used to determine significant differences in product concentrations between different fermentations (a, b, and c columns) where * and ** indicates the p-value is between 0.01 and 0.05, or less than 0.01, respectively.

DETAILED DESCRIPTION OF THE INVENTION

One aspect of the invention is directed to microorganisms comprising modifications that reduce or ablate the activity of gene products of one or more genes. Such a modification that reduces or ablates the activity of gene products of one or more genes is referred to herein as a "functional deletion" of the gene product. "Gene product" refers to a protein or polypeptide encoded and produced by a particular gene. "Gene" refers to a nucleic acid sequence capable of producing a gene product and may include such genetic elements as a coding sequence together with any other genetic elements required for transcription and/or translation of the coding sequence. Such genetic elements may include a promoter, an enhancer, and/or a ribosome binding site (RBS), among others.

One of ordinary skill in the art will appreciate that there are many well-known ways to functionally delete a gene product. For example, functional deletion can be accomplished by introducing one or more genetic modifications. As used herein, "genetic modifications" refer to any differences in the nucleic acid composition of a cell, whether in

the cell's native chromosome or in endogenous or exogenous non-chromosomal plasmids harbored within the cell. Examples of genetic modifications that may result in a functionally deleted gene product include but are not limited to mutations such as substitutions, partial or complete deletions, insertions, or other variations to a coding sequence or a sequence controlling the transcription or translation of a coding sequence; placing a coding sequence under the control of a less active promoter; blocking transcription of the gene with a trans-acting DNA binding protein such as a TAL effector or CRISPR guided Cas9; and expressing ribozymes or antisense sequences that target the mRNA of the gene of interest, etc. In some versions, a gene or coding sequence can be replaced with a selection marker or screenable marker. Various methods for introducing the genetic modifications described above are well known in the art and include homologous recombination, among other mechanisms. See, e.g., Green et al., *Molecular Cloning: A laboratory manual*, 4th ed., Cold Spring Harbor Laboratory Press (2012) and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Laboratory Press (2001). Various other genetic modifications that functionally delete a gene product are described in the examples below. Functional deletion can also be accomplished by inhibiting the activity of the gene product, for example, by chemically inhibiting a gene product with a small molecule inhibitor, by expressing a protein that interferes with the activity of the gene product, or by other means.

In certain versions of the invention, the functionally deleted gene product may have less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the activity of the non-functionally deleted gene product.

In certain versions of the invention, a cell with a functionally deleted gene product may have less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the activity of the gene product compared to a cell with the non-functionally deleted gene product.

In certain versions of the invention, the functionally deleted gene product may be expressed at an amount less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or about 0% of the amount of the non-functionally deleted gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, or more nonsynonymous substitutions are present in the gene or coding sequence of the gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, or more bases are inserted in the gene or coding sequence of the gene product.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of the gene product's gene or coding sequence is deleted or mutated.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of a promoter driving expression of the gene product is deleted or mutated.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of an enhancer controlling transcription of the gene product's gene is deleted or mutated.

In certain versions of the invention, the functionally deleted gene product may result from a genetic modification in which at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of a sequence controlling translation of gene product's mRNA is deleted or mutated.

In certain versions of the invention, the decreased activity or expression of the functionally deleted gene product is determined with respect to the activity or expression of the gene product in its unaltered state as found in nature. In certain versions of the invention, the decreased activity or expression of the functionally deleted gene product is determined with respect to the activity or expression of the gene product in its form in a corresponding microorganism. In certain versions, the genetic modifications giving rise to a functionally deleted gene product are determined with respect to the gene or coding sequence in its unaltered state as found in nature. In certain versions, the genetic modifications giving rise to a functionally deleted gene product are determined with respect to the gene or coding sequence in its form in a corresponding microorganism.

As used herein, "corresponding microorganism" refers to a microorganism of the same species having the same or substantially same genetic and proteomic composition as a microorganism of the invention, with the exception of

genetic and proteomic differences resulting from the modifications described herein for the microorganisms of the invention.

Some versions of the invention comprise microorganisms configured for increased production of pyruvate. For the production of pyruvate, at least three sets of enzymes are functionally deleted in the microorganism. Enzymes in a first set are selected from the group consisting of pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase. Enzymes in a second set are selected from the group consisting of phosphate acetyltransferase, acetate kinase, and pyruvate oxidase. Enzymes in a third set comprise lactate dehydrogenase and one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase; lactate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase; one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase; or lactate dehydrogenase, one or more enzymes selected from the group consisting of cytochrome terminal oxidase and succinate dehydrogenase, and one or more enzymes selected from the group consisting of 6-phosphogluconate dehydrogenase and glutamate dehydrogenase. Deletion of any gene or any other modification that reduces or ablates the activity of these enzymes or reduces or ablates flux of metabolites through these enzymes is encompassed by the present invention.

Pyruvate dehydrogenases convert pyruvate into acetyl Co-A. Pyruvate dehydrogenases include enzymes classified under any or all of EC 1.2.4.1, EC 2.3.1.12, and EC 1.8.1.4. An exemplary pyruvate dehydrogenase is the pyruvate dehydrogenase of *E. coli*, which is a multi-subunit complex comprising AceE (SEQ ID NO:2) encoded by aceE (SEQ ID NO:1), AceF (SEQ ID NO:4) encoded by acef (SEQ ID NO:3), and Lpd (SEQ ID NO:6) encoded by lpdA (SEQ ID NO:5). AceE has activity classified under EC 1.2.4.1. AceF has activity classified under 2.3.1.12. Lpd has activity classified under 1.8.1.4. Other pyruvate dehydrogenases include homologs of the *E. coli* pyruvate dehydrogenase.

2-Oxoglutarate dehydrogenases convert α -ketoglutarate, NAD⁺, and CoA to succinyl CoA, CO₂, and NADH. 2-Oxoglutarate dehydrogenases include enzymes classified under any one or all of EC 1.8.1.4, EC 1.2.4.2, and EC 2.3.1.61. An exemplary 2-oxoglutarate dehydrogenase is the 2-oxoglutarate dehydrogenase of *E. coli*, which is a multi-subunit complex comprising Lpd (SEQ ID NO:6) encoded by lpdA (SEQ ID NO:5), SucA (SEQ ID NO:8) encoded by sucA (SEQ ID NO:7), and SucB (SEQ ID NO:10) encoded by sucB (SEQ ID NO:9). Lpd has activity classified under EC 1.8.1.4. SucA has activity classified under EC 1.2.4.2. SucB has activity classified under EC 2.3.1.61. Other 2-oxoglutarate dehydrogenases include homologs of the *E. coli* 2-oxoglutarate dehydrogenase. Functionally deleting 2-oxoglutarate dehydrogenase may be performed as an alternative to or in addition to functionally deleting pyruvate dehydrogenase.

Phosphate acetyltransferases convert acetyl-CoA and phosphate to CoA and acetyl phosphate. Phosphate acetyltransferases include enzymes classified under EC 2.3.1.8. An exemplary phosphate acetyltransferase is the phosphate acetyltransferase of *E. coli* (SEQ ID NO:12), which is encoded by pta (SEQ ID NO:11). Other phosphate acetyltransferases include homologs of the *E. coli* phosphate acetyltransferase.

Acetate kinases convert acetate and ATP to acetyl phosphate. Acetate kinases include enzymes classified under EC 2.7.2.-, such as EC 2.7.2.1. An exemplary acetate kinase is the acetate kinase A of *E. coli* (SEQ ID NO:14), which is encoded by ackA (SEQ ID NO:13). Other acetate kinases include homologs of the *E. coli* acetate kinase A. Functionally deleting acetate kinase may be performed as an alternative to or in addition to functionally deleting phosphate acetyltransferase. In some versions, the ackA gene in the microorganism is structurally and functionally intact such that the acetate kinase in the cells is fully expressed and fully functional.

Pyruvate oxidases convert pyruvate, phosphate, and O₂ to acetyl phosphate, CO₂, and H₂O₂. Pyruvate oxidases include enzymes classified under EC 1.2.3.3. An exemplary pyruvate oxidase is the pyruvate oxidase of *E. coli* (SEQ ID NO:16), which is encoded by poxB (SEQ ID NO:15). Other pyruvate oxidases include homologs of the *E. coli* pyruvate oxidase.

Lactate dehydrogenases convert pyruvate to lactate and vice versa. Lactate dehydrogenases include enzymes classified under any or all of EC 1.1.1.27 and EC 1.1.1.28. An exemplary lactate dehydrogenase is the LdhA of *E. coli* (SEQ ID NO:18), which is encoded by ldhA (SEQ ID NO:17). Other lactate dehydrogenases include homologs of the *E. coli* LdhA.

Cytochrome oxidases transfer electrons in the respiratory chain from donors to an acceptor. Cytochrome oxidases include enzymes classified under any or all of EC 1.9.3.1 and EC 1.10.3.-. Exemplary cytochrome oxidases suitable for functionally deleting in the present invention include cytochrome terminal oxidases, such as Family A cytochrome terminal oxidases. An exemplary Family A cytochrome terminal oxidase in *E. coli* is the cytochrome bo terminal oxidase, which is a multi-subunit complex comprising subunit I (SEQ ID NO:22) encoded by cyoB (SEQ ID NO:21), subunit II (SEQ ID NO:20) encoded by cyoA (SEQ ID NO:19), subunit III (SEQ ID NO:24) encoded by cyoC (SEQ ID NO:23), and subunit IV (SEQ ID NO:26) encoded by cyoD (SEQ ID NO:25). Subunits I-IV have activity classified under EC 1.10.3.-. A fifth gene of the cyo operon, cyoE (SEQ ID NO:27), encodes a heme O synthase (SEQ ID NO:28) that is essential for correct assembly of the complex and can be functionally deleted to effectively functionally delete the cytochrome bo terminal oxidase itself. Other cytochrome oxidases include homologs of the *E. coli* cytochrome bo terminal oxidase.

Succinate dehydrogenases catalyze the oxidation of succinate to fumarate with the reduction of ubiquinone to ubiquinol. Succinate dehydrogenases include enzymes classified under EC 1.3.5.1. An exemplary succinate dehydrogenase is the succinate dehydrogenase of *E. coli*, which is a multi-subunit complex comprising SdhA (SEQ ID NO:30) encoded by sdhA (SEQ ID NO:29), SdhB (SEQ ID NO:32) encoded by sdhB (SEQ ID NO:31), SdhC (SEQ ID NO:34) encoded by sdhC (SEQ ID NO:33), and SdhD (SEQ ID NO:36) encoded by sdhD (SEQ ID NO:35). Other succinate dehydrogenases include homologs of the *E. coli* succinate dehydrogenases.

6-Phosphogluconate dehydrogenases catalyze the decarboxylating reduction of 6-phosphogluconate into ribulose 5-phosphate in the presence of NADP⁺. Phosphogluconate dehydrogenases include enzymes classified under EC 1.1.1.44. An exemplary 6-phosphogluconate dehydrogenase is the Gnd of *E. coli* (SEQ ID NO:38), which is encoded by gnd (SEQ ID NO:37). Other 6-phosphogluconate dehydrogenases include homologs of the *E. coli* Gnd.

Glutamate dehydrogenases convert glutamate to α -ketoglutarate and vice versa. Glutamate dehydrogenases include enzymes classified under EC 1.4.1.4. An exemplary glutamate dehydrogenase is the GdhA of *E. coli* (SEQ ID NO:40), which is encoded by gdhA (SEQ ID NO:39). Other glutamate dehydrogenases include homologs of the *E. coli* GdhA.

In some versions of the invention, the microorganisms having the above-referenced sets of enzymes functionally deleted are evolved for enhanced production of pyruvate. The microorganisms are evolved by sequentially culturing microorganisms in media comprising decreasing concentrations of acetate. This process preferably involves sequentially culturing the microorganisms in aliquots of media, with sequential aliquots comprising decreasing concentrations of acetate. The concentrations of acetate in the media are preferably within a range of from about 0 mg/L to about 80 g/L, such as from about 0.001 mg/L to about 80 g/L, about 0.01 mg/L to about 50 g/L, about 0.1 mg/L to about 10 g/L, or about 0.1 mg/L to about 3 g/L. In some versions, the starting acetate concentration in the medium is within a range of from about 90 mg/L to about 80 g/L and sequentially reduces to a concentration with a range of from about 0 mg/L to about 90 mg/L. In some versions, the starting acetate concentration in the medium is within a range of from about 90 mg/L to about 80 g/L and sequentially reduces to a concentration with a range of from about 0.001 mg/L to about 90 mg/L. In some versions, the starting acetate concentration in the medium is within a range of from about 90 mg/L to about 1 g/L and sequentially reduces to a concentration with a range of from about 0.1 mg/L to about 90 mg/L. In some versions, the starting acetate concentration in the medium is within a range of from about 90 mg/L to about 500 g/L and sequentially reduces to a concentration with a range of from about 1 mg/L to about 90 mg/L.

The initial amount of total consumable carbon in the various media used in the sequential culturing is preferably approximately the same among the media. The initial amount of total consumable carbon preferably ranges from about 1 g/L to about 100 g/L, but may be higher or lower. Beyond the acetate, the balance of consumable carbon preferably comprises a sugar such as glucose or other carbohydrates or carbon sources known in the art. The sequential culturing may comprise passing the microorganism through the media in at least about 2, 3, 4, 5, 7, 10, 15, or 20 passages and/or up to about 5, 10, 15, 20, 30, 50 or more passages.

Some versions of the invention comprise microorganisms configured for increased production of ethanol. These microorganisms have the enzymes described above for producing pyruvate functionally deleted but additionally have pyruvate formate lyase functionally deleted.

Pyruvate formate lyases catalyze the reversible conversion of pyruvate and coenzyme-A into formate and acetyl-CoA. Pyruvate formate lyases include enzymes classified under EC 2.3.1.54. An exemplary pyruvate formate lyase is the PFL of *E. coli* (SEQ ID NO:42), which is encoded by pflB (SEQ ID NO:41). Other pyruvate formate lyases include homologs of the *E. coli* PFL.

In some versions of the invention, a pyruvate formate lyase activating enzyme in the recombinant microorganism is functionally deleted. Pyruvate formate lyase activating enzymes include enzymes classified under EC 1.97.1.4. Pyruvate formate lyase activating enzymes activate pyruvate formate lyases. Functionally deleting a pyruvate formate lyase activating enzyme constitutes a way to functionally delete a pyruvate formate lyase. An exemplary pyruvate formate lyase activating enzyme is the PFL activase of *E.*

coli (SEQ ID NO:44), which is encoded by pflA (SEQ ID NO:43). Other pyruvate formate lyase activating enzymes include homologs of the *E. coli* PFL activase.

The enzymes described herein can be functionally deleted by mutating or disrupting expression of any one or all of the genes encoding the enzyme or its substituent subunits. Accordingly, the pyruvate dehydrogenase can be functionally deleted by mutating or disrupting expression of any one or more of aceE, aceF, and lpdA or homologs thereof. The 2-oxoglutarate dehydrogenase can be functionally deleted by mutating or disrupting expression of any one or more of lpdA, sucA, and sucB or homologs thereof. The phosphate acetyltransferase can be functionally deleted by mutating or disrupting expression of pta or homologs thereof. The acetate kinase can be functionally deleted by mutating or disrupting expression of ackA or homologs thereof. The pyruvate oxidase can be functionally deleted by mutating or disrupting expression of poxB or homologs thereof. The lactate dehydrogenase can be functionally deleted by mutating or disrupting expression of ldhA or homologs thereof. The cytochrome oxidase can be functionally deleted by mutating or disrupting expression of any one or more of cyoA, cyoB, cyoC, cyoD and cyoE or homologs thereof. The succinate dehydrogenase can be functionally deleted by mutating or disrupting expression of any one or more of sdhA, sdhB, sdhC, and sdhD or homologs thereof. The 6-phosphogluconate dehydrogenase can be functionally deleted by mutating or disrupting expression of gnd or homologs thereof. The glutamate dehydrogenase can be functionally deleted by mutating or disrupting expression of gdhA or homologs thereof. The pyruvate formate lyase can be functionally deleted by mutating or disrupting expression of pflB and pflA or homologs thereof.

The microorganisms of the invention may also be modified to increase expression of one or more enzymes. Modifying the microorganism to increase expression of an enzyme can be performed using any methods currently known in the art or discovered in the future. Examples include genetically modifying the microorganism and culturing the microorganism in the presence of factors that increase expression of the enzyme. Suitable methods for genetic modification include but are not limited to placing the coding sequence under the control of a more active promoter, increasing the copy number of the gene, introducing a translational enhancer on the gene (see, e.g., Ollins et al. *Journal of Biological Chemistry*, 1989, 264(29):16973-16976), and/or increasing expression of transactivators. Increasing the copy number of the gene can be performed by introducing additional copies of the gene to the microorganism, i.e., by incorporating one or more exogenous copies of the native gene or a heterologous homolog thereof into the microbial genome, by introducing such copies to the microorganism on a plasmid or other vector, or by other means. "Exogenous" used in reference to a genetic element means the genetic element is introduced to a microorganism by genetic modification. "Heterologous" used in reference to a genetic element means that the genetic element is derived from a different species. A promoter that controls a particular coding sequence is herein described as being "operationally connected" to the coding sequence.

The microorganisms of the invention may include at least one recombinant nucleic acid configured to express or overexpress a particular enzyme. "Recombinant" as used herein with reference to a nucleic acid molecule or polypeptide is one that has a sequence that is not naturally occurring, has a sequence that is made by an artificial combination of two otherwise separated segments of

11

sequence, or both. This artificial combination can be achieved, for example, by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acid molecules or polypeptides, such as genetic engineering techniques. "Recombinant" is also used to describe nucleic acid molecules that have been artificially modified but contain the same regulatory sequences and coding regions that are found in the organism from which the nucleic acid was isolated. A recombinant cell or microorganism is one that contains a recombinant nucleic acid molecule or polypeptide. "Overexpress" as used herein means that a particular gene product is produced at a higher level in one cell, such as a recombinant cell, than in a corresponding cell. For example, a microorganism that includes a recombinant nucleic acid configured to overexpress an enzyme produces the enzyme at a greater amount than a microorganism that does not include the recombinant nucleic acid.

Exogenous, heterologous nucleic acids encoding enzymes to be expressed in the microorganism are preferably codon-optimized for the particular microorganism in which they are introduced. Codon optimization can be performed for any nucleic acid by a number of programs, including "GENEGPS"-brand expression optimization algorithm by DNA 2.0 (Menlo Park, Calif.), "GENEOPTIMIZER"-brand gene optimization software by Life Technologies (Grand Island, N.Y.), and "OPTIMUMGENE"-brand gene design system by GenScript (Piscataway, N.J.). Other codon optimization programs or services are well known and commercially available.

Microorganisms of the invention configured to increase production of ethanol may be modified to increase expression of pyruvate decarboxylase and alcohol dehydrogenase.

Pyruvate decarboxylases catalyze the decarboxylation of pyruvic acid to acetaldehyde and carbon dioxide. Pyruvate decarboxylases include enzymes classified under EC 4.1.1.1. An exemplary pyruvate decarboxylase is the PDC of *Zymomonas mobilis* (SEQ ID NO:46), which is encoded by pdc (SEQ ID NO:45). Other pyruvate decarboxylases include homologs of the *Z. mobilis* PDC.

Alcohol dehydrogenases catalyze the interconversion between alcohols and aldehydes or ketones with the reduction of nicotinamide adenine dinucleotide (NAD^+ to NADH). Alcohol dehydrogenases include enzymes classified under EC 1.1.1.1. An exemplary alcohol dehydrogenase is the ADH2 of *Zymomonas mobilis* (SEQ ID NO:48), which is encoded by adhB (SEQ ID NO:47). Other alcohol dehydrogenases include homologs of the *Z. mobilis* ADH2.

Increased expression of the pyruvate decarboxylase and/or the alcohol dehydrogenase can be included in a microorganism comprising a functional deletion of any of the genes or gene products, or combinations thereof, described herein.

Isocitrate lyase, encoded by aceA in *E. coli* or homologs thereof, can also be functionally deleted in any of the microorganisms described herein.

Homologs include genes or gene products (including enzymes) that are derived, naturally or artificially, from a common ancestral gene or gene product. Homology is generally inferred from sequence similarity between two or more genes or gene products. Homology between genes may be inferred from sequence similarity between the products of the genes. The precise percentage of similarity between sequences that is useful in establishing homology varies with the gene or gene product at issue, but as little as 25% sequence similarity (e.g., identity) over 50, 100, 150 or more residues (nucleotides or amino acids) is routinely used to establish homology (e.g., over the full length of the two

12

sequences to be compared). Higher levels of sequence similarity (e.g., identity), e.g., 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or more, can also be used to establish homology. Accordingly, homologs of the coding sequences, genes, or gene products described herein include coding sequences, genes, or gene products, respectively, having at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to the coding sequences, genes, or gene products, respectively, described herein. In some versions, homologs of the genes described herein include genes that have gene products at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical to the gene products of the genes described herein. Methods for determining sequence similarity percentages (e.g., BLASTP and BLASTN using default parameters) are described herein and are generally available. The homologous gene products should demonstrate comparable activities and, if an enzyme, participate in the same or analogous pathways. "Orthologs" are genes or coding sequences thereof in different species that evolved from a common ancestral gene by speciation. Normally, orthologs retain the same or similar function in the course of evolution. As used herein "orthologs" are included in the term "homologs." Homologs also include paralogs.

For sequence comparison and homology determination, one sequence typically acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence based on the designated program parameters. A typical reference sequence of the invention is a nucleic acid or amino acid sequence corresponding to coding sequences, genes, or gene products described herein.

Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2008)).

One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity for purposes of defining homologs is the BLAST algorithm, which is described in Altschul et al., *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in

both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. The above-described techniques are useful in identifying homologous sequences for use in the methods described herein.

The terms "identical" or "percent identity", in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described above (or other algorithms available to persons of skill) or by visual inspection.

The phrase "substantially identical", in the context of two nucleic acids or polypeptides refers to two or more sequences or subsequences that have at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90, about 95%, about 98%, or about 99% or more nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. Such "substantially identical" sequences are typically considered to be "homologous" without reference to actual ancestry. Preferably, the "substantial identity" exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably, the sequences are substantially identical over at least about 150 residues, at least about 250 residues, or over the full length of the two sequences to be compared.

Accordingly, homologs of the genes described herein include genes with gene products at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or more identical to the gene products of the genes described herein.

The microorganisms of the invention may be prokaryotic, such as bacteria or archaea, or eukaryotic, such as yeast. Among bacteria, any bacterium in the domain Bacteria, the kingdom Eubacteria, the phylum Proteobacteria, the class Gammaproteobacteria, the order Enterobacterales, and the family Enterobacteriaceae are suitable. Gram-positive, gram-negative, and ungrouped bacteria are suitable. Phototrophs, lithotrophs, and organotrophs are also suitable. In exemplary versions of the invention, the microorganism is *E. coli*. In some versions of the invention, the microorganism is a cyanobacterium. Suitable cyanobacteria include those from the genera *Agmenellum*, *Anabaena*, *Aphanocapsa*, *Arthrosphaera*, *Gloeocapsa*, *Haplosiphon*, *Mastigocladus*, *Nostoc*, *Oscillatoria*, *Prochlorococcus*, *Scytonema*, *Synechococcus*, and *Synechocystis*. Preferred cyanobacteria include those selected from the group consisting of *Synechococcus* spp., spp., *Synechocystis* spp., and *Nostoc* spp.

An aspect of the present invention includes methods of producing commodity chemicals, such as pyruvate and/or ethanol, with the microorganisms of the invention. The methods involve culturing the microorganism in conditions suitable for growth of the microorganism. Such conditions include providing suitable carbon sources for the particular microorganism along with suitable micronutrients. For eukaryotic microorganisms and heterotrophic bacteria, suitable carbon sources include various carbohydrates. Such carbohydrates may include biomass or other suitable carbon sources known in the art. For phototrophic bacteria, suitable carbon sources include CO₂, which is provided together with light energy. The commodity chemical can be purified or isolated with methods known in the art.

In some versions of the invention, the microorganism may be cultured in a medium comprising a biomass hydrolysate. The biomass hydrolysate can be produced from any biomass feedstock. Exemplary types of biomass feedstocks include sucrose-rich feedstocks such as sugar cane; starchy materials, such as corn grain; and lignocellulosic biomass, such as coastal Bermuda grass, corn cobs, corn stover, cotton seed hairs, grasses, hardwood stems, leaves, newspaper, nut shells, paper, primary wastewater solids, softwood stems, solid cattle manure, sorted refuse, swine waste, switchgrass, waste papers from chemical pulps, wheat straw, wood, and woody residues.

Prior to hydrolysis, the biomass feedstock may be pretreated or non-pretreated. Pretreatment of biomass feedstock removes a large proportion of the lignin and other materials and enhances the porosity of the biomass prior to hydrolysis. The biomass feedstock may be pretreated by any method. Exemplary pretreatments include chipping, grinding, milling, steam pretreatment, ammonia fiber expansion (AFEX, also referred to as ammonia fiber explosion), ammonia recycle percolation (ARP), CO₂ explosion, steam explosion, ozonolysis, wet oxidation, acid hydrolysis, dilute-acid hydrolysis, alkaline hydrolysis, organosolv, and pulsed electrical field treatment, among others. See, e.g., Kumar, P.; Barrett, D. M.; Delwiche, M. J.; Stroeve, P., Methods for Pretreatment of Lignocellulosic Biomass for Efficient Hydrolysis and Biofuel Production. *Industrial & Engineering Chemistry Research* 2009, 48, (8), 3713-3729.

The pretreated or non-pretreated biomass may be hydrolyzed by any suitable method. Hydrolysis converts biomass polymers to fermentable sugars, such as glucose and xylose, and other monomeric or oligomeric components. Exemplary hydrolysis methods include enzymatic hydrolysis (e.g., with cellulases or other enzymes) and acid hydrolysis (e.g., with sulfuric, sulfuric, hydrochloric, hydrofluoric, phosphoric, nitric, and/or formic acids), among other methods.

15

Exemplary biomass hydrolysates include AFEX-pre-treated corn stover hydrolysate (ACSH) (Schwalbach et al. *Appl. Environ. Microbiol.* 2012, 78, (9), 3442-3457) and AFEX-pretreated switchgrass hydrolysate (ASGH).

The medium comprising the biomass hydrolysate may comprise at least about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 99% biomass hydrolysate by volume or by mass.

The term "increase," whether used to refer to an increase in production of an organic acid, an increase in expression of an enzyme, etc., generally refers to an increase from a baseline amount, whether the baseline amount is a positive amount or none at all.

The elements and method steps described herein can be used in any combination whether explicitly described or not.

The singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.

Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

All patents, patent publications, and peer-reviewed publications (i.e., "references") cited herein are expressly incorporated by reference to the same extent as if each individual reference were specifically and individually indicated as being incorporated by reference. In case of conflict between the present disclosure and the incorporated references, the present disclosure controls.

It is understood that the invention is not confined to the particular construction and arrangement of parts herein illustrated and described, but embraces such modified forms thereof as come within the scope of the following claims.

EXAMPLES

Overview

Microbes produce a variety of useful chemicals. However, most strains have not evolved to produce compounds at industrially-relevant levels. Metabolic engineering develops biocatalysts to produce desired chemicals at high rates, yields, and titers. Strains have been engineered to produce a broad range of products, including transportation fuels (e.g. ethanol, butanol and biodiesel) [1-5], pharmaceuticals (e.g. alkaloids, polyketides, nonribosomal peptides and isoprenoids) [6-11] and bulk and fine chemicals (e.g. amino acids, organic acids, industrial solvents and polymer precursors) [12-16]. Metabolic engineering strategies involve increasing production of pathway precursors, recycling redox carriers, improving flux through biosynthesis pathways, reducing toxic intermediate concentrations, and/or increasing tolerance to intermediates and products. Increasing precursor(s) supply is often needed to generate more of a desired downstream product. For example, strains with elevated malonyl-CoA levels were engineered to produce phloroglucinol (a polyketide derived from malonyl-CoA) [17], and strains with higher oxaloacetate levels produced more succinate, threonine and lysine, which are all derived from oxaloacetate[18].

Pyruvate is a central metabolite and precursor to acetyl-CoA and several amino acids (including alanine, lysine, valine, isoleucine and leucine). Commodity chemicals (e.g.

16

ethanol, acetic acid, lactic acid and acrylic acid), as well as active pharmaceutical ingredients (e.g. polyketides and isoprenoids) can also be derived from pyruvate. Pyruvate can be converted into >60 commercial chemicals within five reaction steps. Furthermore, pyruvate itself can be used as a food additive, weight loss agent, and anti-aging skin treatment. Microbial production of pyruvate is an attractive alternative to current chemical processes, which are expensive and toxic [21].

10 *Escherichia coli*, *Corynebacterium glutamicum*, and *Saccharomyces cerevisiae* strains have been genetically engineered to produce pyruvate [19-24]. However, most strains have low yields and use expensive medium components. Previous *E. coli* metabolic engineering strategies focused on 15 blocking pyruvate consumption pathways to phosphoenolpyruvate (PEP), acetyl-CoA, ethanol, acetate, lactate and formate. Other strategies prevented conversion of PEP to oxaloacetate by deleting PEP synthase, increasing glycolytic flux by deleting F1-ATPase deletion mutant or reducing 20 NADH availability [19-21], and reducing TCA cycle fluxes by deleting α -ketoglutarate dehydrogenase [21]. The highest reported yield is 0.75 g pyruvate/g glucose (78% of the theoretical maximum yield) using a thiamin supplemented salts minimal medium. Pyruvate overproducing strains have 25 been further altered to produce other chemicals, including alanine and diacetyl [25].

The present examples design and construct pyruvate strains using a genome-scale metabolic model of *E. coli*. OptORF [26] was used to search for gene deletions that 30 would have high pyruvate yields at their maximal growth rate. Four mutant strains were constructed and characterized for growth and pyruvate production, and two of the four strains were adaptively evolved to increase growth rates and further improve pyruvate production. The pyruvate strains 35 were further engineered to produce ethanol, which is derived from pyruvate. The examples show strains achieving up to 95% of the maximum theoretic yields for pyruvate. The examples also show growth and production of chemicals in bioreactors and with media containing biomass hydrolysate.

40 Materials and Methods
Strains and Plasmids

E. coli BW25113 and the pCP20 plasmid were obtained from the *E. coli* genetic stock center (CGSC, Yale University). Single *E. coli* gene deletion strains were obtained from 45 the Keio collection (Open Biosystems) and used to construct multiple gene deletion strains (listed in Table 1). To generate mutants with multiple gene deletions, the kanamycin resistance gene (kan) was removed using the pCP20 plasmid [39]. An additional gene was deleted (and kan re-inserted) using P1 transduction from a donor Keio mutant and selection on LB agar plates with 50 μ g/mL kanamycin. This process was repeated for each additional knockout and the gene deletions were verified by PCR. The GLBRCE1 strain, pJGG2 plasmid, and its corresponding empty vector (pBBR-DSC5) were obtained from Robert Landick (University of 55 Wisconsin-Madison). The pJGG2 plasmid is a low copy number plasmid with a lac promoter that controls expression of the *Zymomonas mobilis* PET cassette genes (pdc and adhB) that encode enzymes to produce ethanol from pyruvate. GLBRCE1 lacks ldhA, pflB and ackA and contains pJGG2 and a chromosomal copy of the PET cassette inserted 60 in the pflB locus [36].

Media and Culture Conditions

For shake flask and hungate tube experiments, M9 minimal media [44] supplemented with glucose and acetate (at varying concentrations) was used. Gentamicin was added to the media (at 15 μ g/mL) for strains containing pJGG2 or

pBBR-DSC5 plasmids. All strains were precultured overnight in Luria Broth (LB), pelleted and washed twice in M9 media, and then resuspended in M9 media with an initial OD₆₀₀ of 0.01. For aerobic flask experiments, cultures were grown aerobically in 250 mL flasks containing 100 mL of media.

For anaerobic hungate tube experiments, cultures were grown in hungate culture tubes with 10 mL of media and IPTG was added (at 200 μ M) to induce the expression of PET cassette. Hungate tubes were vacuumed and flushed with argon three times. All experiments were carried out in triplicate at 37° C. in a shaking incubator. Samples were periodically taken for further analysis and cells were removed using 0.2 μ m nylon filter.

For aerobic bioreactor experiments, a minimal salts medium (adapted from [40]) was used that included 3.5 g/L KH₂PO₄, 5 g/L K₂HPO₄, 3.5 g/L (NH₄)₂HPO₄, 2 mM MgSO₄, 0.1 mM CaCl₂, 0.01 mM FeCl₃ and 0.5 mL per L trace metal solution (described previously [40]). Glucose (30 g/L) and acetate (at reported concentrations) were added to the minimal salts medium. AFEX-pretreated switchgrass hydrolysate (ASGH) was provided by the Great Lakes Bioenergy Research Center. The initial concentrations of glucose, xylose and acetate in ASGH hydrolysate were quantified by HPLC. Bioreactor seed cultures were prepared by inoculating 100 mL of minimal salts medium (with 30 g/L glucose and 0.9 g/L acetate) from a 5 mL overnight LB culture such that the initial OD₆₀₀ was 0.01. Cells were grown at 37° C. for 14 hours in a 250-mL shake flask and then transferred into three 250-mL flasks containing 100 mL of same medium. The cultures were grown at 37° C. for another 8 hours and used to inoculate the bioreactors. The starting OD₆₀₀ in the bioreactors was 0.05.

Bioreactors

Batch and fed-batch experiments were conducted in a 3 L bioreactor (Applikon Biotechnology, Inc., Shiedam, Netherlands) using a 1 L working volume with the following parameters 37° C., 0.5 L/min air inflow and pH 7.0±0.1. Acid (0.5 M H₂SO₄) and base (2 M KOH) buffers were added to adjust the pH as needed. The stirring speed was set to 500-800 rpm by a single Rushton impeller to ensure the dissolved oxygen level was above 40% of saturation. Each bioreactor experiment was conducted in duplicate. Samples were taken periodically for sugar and end-product analysis after cells were removed by centrifugation. For fed-batch experiments, a 200 g/L acetate solution was added to the reactor when growth slowed. For PYR020, the fed-batch started with 30 g/L glucose and 0.6 g/L acetate, and an additional 0.3 g/L acetate was added (1.5 mL of 200 g/L solution). For PYR004, the fed-batch started with 30 g/L glucose and 1.5 g/L acetate, and an additional 1.5 g/L acetate was added (7.5 mL of 200 g/L solution).

Chemical Analyses

Glucose concentrations were determined using an enzyme assay from Sigma (GAGO20). Pyruvate, lactate, acetate, succinate, and formate concentrations in the medium were measured by HPLC using an Aminex HPX-87H with Cation-H guard column (Bio-Rad, cat#125-0140). The mobile phase contained 0.02 N H₂SO₄ (for samples from minimal medium) or 0.05 N H₂SO₄ (for samples from ammonia fiber expansion (AFEX)-pretreated switchgrass hydrolysate (ASGH)) and was run at a flow rate of 0.5 mL/min at 50° C. The end-products were quantified (from standard curves) based on their refractive index. The reported yields were all adjusted by taking into account evaporation and buffer addition to bioreactors. The uptake and secretion rates were determined from the metabolite and biomass concentration

data during exponential growth. Biomass concentrations (gram of cell dry weight per liter, gDW/L) were calculated from OD₆₀₀ values using a conversion factor 1 OD₆₀₀=0.415 gDW/L [41].

Adaptive Evolution

PYR001 and PYR002 were adaptively evolved independently for 20 passages. The initial cultures were grown in M9 minimal medium with 1.6 g/L glucose and 0.4 g/L acetate. At an OD₆₀₀~0.2, cells were transferred to fresh medium (such that starting OD₆₀₀ was 0.01). During adaptive evolution, the amount of acetate in the medium was gradually reduced, while the glucose concentration increased so that the total carbon source was 2 g/L. After 15 passages, the medium contained 1.98 g/L glucose and 0.02 g/L acetate. Cultures from each passage were frozen and stored at -80° C.

Strain Design

OptORF was used to identify gene deletions that couple growth and pyruvate production [26]. This method finds mutants that would produce pyruvate at their highest biomass yield. OptORF was run using a tilted inner objective function (growth rate—0.001•pyruvate production rate) [42] and a gene deletion penalty equal to 1 in the outer objective function. All simulations were done for glucose aerobic conditions using the iJR904 *E. coli* genome-scale metabolic network [43], with a maximum glucose uptake rate of 10 mmol/gDW/hour and an unlimited oxygen uptake.

Results

In Silico Strain Design for Pyruvate Production

To improve pyruvate production, OptORF suggested four strategies which delete: (1) aceE, cyoA, cydB, pta, eutI, ldhA and dld; (2) lpdA, gnd, sdhA, poxB, pflB, pflD, tdcE and purU; (3) aceE, gdhA, poxB, ldhA, dld, atpE, pflB, pflD and tdcE; or (4) aceE, gnd, poxB, ldhA, dld, atpE, pflB, pflD and tdcE (FIGS. 2A-2D). Given the large numbers of deletions, the identified genes were further evaluated and prioritized for deletion. Enzymes that are inactive under glucose aerobic conditions (e.g. due to regulation) were first excluded, including pyruvate formate lyases (PflB and PflD) [27, 28]. In addition, eutI, dld and tdcE encode minor isozymes for Pta, LdhA and PflB, respectively [29-32]. Deleting purU also had little impact on cell growth in glucose minimal media [33, 34]. Based on these considerations, pflB, pflD, eutI, dld, tdcE and purU were not deleted since they are likely to have low (if any) activity anyway. Additionally, the cydB and atpE deletions were experimentally lethal in combination with other suggested gene deletions (data not shown) and were not included in the constructed strains. The remaining genes identified by OptORF were deleted to create four engineered strains (PYR001-PYR004, Table 1).

The engineered strains each involved deletions that impacted metabolism and pyruvate production differently. Deleting aceE, lpdA, pta, poxB, and/or ldhA reduces the conversion of pyruvate into acetyl-CoA, acetate, and lactate. Deletion of cyoA, sdhA, and/or lpdA slows down the citric acid (TCA) cycle which would decrease ATP production, and thus biomass yields. With regard to gdhA and gnd, *E. coli* has two primary pathways for glutamate synthesis using NADPH, ammonia and α -ketoglutarate. The glutamate dehydrogenase (GDH) pathway (via gdhA) does not require ATP, while the other glutamine synthetase-glutamine oxo-glutarate aminotransferase (GS-GOGAT) pathway consumes one ATP per glutamate formed. Deleting gdhA forces cells to use the GS-GOGAT pathway, increasing ATP consumption and decreasing biomass yields. Similarly, deleting gnd prevents NADPH production via the pentose phosphate

pathway, and cells produce NADPH from NADH via pyridine nucleotide transhydrogenase. The transhydrogenase consumes energy, thereby lowering the maximum biomass yield. In both cases, lowering the maximum biomass yield (via *gdhA* or *gnd* deletions) will increase pyruvate yields, since pyruvate and biomass formation compete for carbon. The gene deletions either prevent pyruvate consumption or reduce growth, and synergistically enhance pyruvate production. Based on the computational results, four strains (PYR001-PYR004) were constructed and tested experimentally (see Table 1). The *aceA* deletion in PYR001 is not required.

TABLE 1

Strains and plasmids.		
Strains/Plasmid	Genotype/Relevant characteristics	Reference
<i>E. coli</i> strains		
BW25113	<i>lacI</i> ^Q <i>rrnBT14</i> <i>ΔlacZWJ16</i> <i>hsdR514</i> ΔaraBADH33 ΔrhaBADLD78	[39]
PYR001	BW25113 <i>aceE::kan</i> <i>AcyoA</i> Apta Δ <i>ldhA</i> Δ <i>aceA</i>	This study
PYR002	BW25113 <i>lpdA::kan</i> <i>Agnd</i> <i>ApoxB</i> Δ <i>sdhA</i>	This study
PYR003	BW25113 <i>aceE::kan</i> <i>AgdhA</i> <i>ApoxB</i> Δ <i>ldhA</i>	This study
PYR004	BW25113 <i>aceE::kan</i> <i>Agnd</i> <i>ApoxB</i> Δ <i>ldhA</i>	This study
PYR010	Adaptively evolved strain of PYR001 (single isolate)	This study
PYR020	Adaptively evolved strain of PYR002 (single isolate)	This study
GLBRCE1	MG1655 Δ <i>ackA</i> Δ <i>ldhA</i> Δ <i>pflB</i> ::PET <i>crl</i> (<i>70insIS1</i>) <i>yibE</i> (<i>253insG</i>) <i>gltB</i> (<i>G3384A</i>) <i>yodD</i> (<i>A85T</i>) <i>glpR</i> (<i>150delG</i>) <i>gatC</i> (<i>916insCC</i>), pJGG2	[36]
EH010-pfLB	PYR010 Δ <i>aceE</i> <i>pflB::kan</i> pJGG2	This study
EH020-pfLB	PYR020 Δ <i>pdaA</i> <i>pflB::kan</i> pJGG2	This study
EH030-pfLB	PYR003 Δ <i>aceE</i> <i>pflB::kan</i> pJGG2	This study
EH040-pfLB	PYR004 Δ <i>aceE</i> <i>pflB::kan</i> pJGG2	This study

TABLE 1-continued

Strains and plasmids.		
Strains/Plasmid	Genotype/Relevant characteristics	Reference
Plasmids		
pBBR1-MSC5	pBBR oriT; P _{lac} ; Gent ^R	[36]
pJGG2	pBBR1-MSC5 with adhB and pdc (PET cassette) from pLOI295; Gent ^R	[36]

Abbreviations:
kan, kanamycin resistance gene;
Gent^R, gentamicin resistance.

Characterization of Engineered Pyruvate Strains

Pyruvate production was characterized in the parent *E. coli* (BW25113) and four mutant strains PYR001, PYR002, PYR003 and PYR004 in M9 minimal medium supplemented with glucose (FIGS. 3A-3C). All mutant strains contain either an *aceE* or *lpdA* deletion, which prevents synthesis of acetyl-CoA from pyruvate via pyruvate dehydrogenase. As a result, acetate was added to the media for all four mutant strains to allow for acetyl-CoA synthesis and growth (Table 2). The four mutants grew slower than the parent strain, but produced pyruvate as predicted by the model (FIGS. 3A-3C), whereas the parent strain did not secrete any pyruvate. Strain PYR001 grew the slowest and only consumed ~40% of glucose (~4.0 mM) within 60 hours. However, PYR001 converted most of the glucose consumed to pyruvate (79% of the theoretical maximum yield, Table 2). Strains PYR003 and PYR004 both completed growth within 20 hours and produced 17.0 and 19.4 mM pyruvate, respectively (79% and 87% of theoretical maximum yield). Among the four mutants, PYR002 had the lowest pyruvate yield (43%) and also exhibited a slower growth rate.

The secretion of metabolic by-products, such as succinate, formate, acetate, lactate and ethanol, was analyzed using HPLC (FIG. 4). Acetate was the main byproduct of the parent strain (BW25113). PYR001 and PYR002 each produced ~1 to 2 mM acetate (which was surprising since they required exogenous acetate for growth), while PYR003 and PYR004 consumed acetate, presumably for acetyl-CoA production. PYR002 was the only strain that produced lactate (~9.8 mM), which explains its relatively low pyruvate yield. Succinate, formate, and ethanol were below the limits of detection by HPLC.

TABLE 2

Production of pyruvate from the parent and mutant strains in shake flasks.								
Strains	M9 Medium with			Growth	Pyruvate Yield		Pyruvate Production Rate	
	Glucose (g/L)	Acetate (g/L)	Rate (hour ⁻¹)		% of max. theoretical yield [†]	Conversion [‡] (g pyruvate/g substrate)	Pyruvate Titer (g/L) [§]	Volumetric (g/L/hour)
BW25113	2	0	0.59 ± 0.01	0	0	0	0	0
PYR001	1.9	0.1	0.02 ± 0.00	79.15 ± 4.63	0.78 ± 0.05	0.62 ± 0.04	0.01 ± 0.00	6.04 ± 0.24
PYR002	1.8	0.2*	0.12 ± 0.01	43.24 ± 2.89	0.43 ± 0.03	0.91 ± 0.06	0.02 ± 0.00	5.47 ± 0.04
PYR003	1.9	0.1	0.45 ± 0.03	79.05 ± 0.63	0.75 ± 0.00	1.50 ± 0.01	0.08 ± 0.00	20.36 ± 0.47
PYR004	1.9	0.1	0.30 ± 0.00	86.60 ± 4.12	0.82 ± 0.04	1.71 ± 0.08	0.07 ± 0.01	19.11 ± 0.25
PYR010	1.98	0.02	0.20 ± 0.04	68.33 ± 7.81	0.67 ± 0.08	1.39 ± 0.16	0.06 ± 0.00	14.91 ± 1.68
PYR020	1.98	0.02	0.34 ± 0.00	95.23 ± 3.12	0.92 ± 0.03	1.95 ± 0.06	0.05 ± 0.00	23.73 ± 0.88

*PYR002 required more acetate than other strains to start growth within 48 hour.

[†]Percent of theoretical yield is calculated as the pyruvate concentration divided by the theoretical maximum production of pyruvate (2 mmol of pyruvate per mmol of glucose). Acetate was also taken account for calculating the theoretical maximum production (0.5 mmol of pyruvate per mmol of acetate). The yield was adjusted by the culture volume loss due to the liquid evaporation in shake flasks under aerobic conditions.

[‡]Conversion is expressed as the gram of pyruvate produced per gram of total carbon source (including glucose and acetate). It was adjusted by the culture volume loss due to the liquid evaporation in shake flasks under aerobic conditions.

[§]The reported titer is the concentration determined by HPLC (and does not account for evaporative loss).

[¶]The specific production rate is the pyruvate production rate per gram of cell dry weight (gDW) during exponential growth.

The numbers that follow the ± sign are standard deviations (SD) from triplicate experiments.

Adaptive Evolution to Improve Pyruvate Productivity

Strains PYR003 and PYR004 showed high pyruvate productivity, while strains PYR001 and PYR002 exhibited low pyruvate yields and/or production rates. All four pyruvate producing strains were designed such that at their maximum growth rate pyruvate production would be high. Therefore, an adaptive evolution approach was used to evolve PYR001 and PYR002 and select for faster growth, which should also select for higher pyruvate rates. Adaptive evolution was conducted under aerobic conditions for 20 passages at 37° C. in glucose+acetate M9 minimal medium. Acetate was added to the medium to enable cell growth, but the concentration was reduced over adaptive evolution (Table 2). Single colonies of the evolved populations, containing progenies of PYR001 and PYR002, were isolated from the last passage and are referred to as PYR010 and PYR020, respectively. The evolved isolates' growth and pyruvate production were characterized (Table 2 and FIGS. 3D-F). The evolved strains had a 10-fold (PYR010) and 3-fold (PYR020) increase in growth rate and ~2-fold increase in pyruvate titers (PYR010 and PYR020). In terms of pyruvate yield, PYR010 had a 10% lower yield than its unevolved strain (PYR001) while PYR020 had ~2-fold increase (PYR020). Interestingly, both evolved strains needed less acetate (5-fold and 10-fold decrease) in the medium to support their growth. Among the four unevolved strains and two evolved strains, PYR020 performed best with respect to yield and titer, followed by PYR004. Both strains were selected for further characterization in bioreactors (Table 3).

Culture in High Concentration of Carbon Source and Lignocellulosic Biomass

Strains with high yields, titers and volumetric production rates are desired for industrial application. While our engineered strains achieved high yields in shake flasks, their titers and volumetric production rate were low due to the low glucose concentrations in the medium. Therefore, a minimal salts medium with higher glucose concentrations (30 g/L) was used to evaluate production by two of the higher yielding pyruvate strains (PYR020 and PYR004). Acetate was the limiting nutrient for both mutants, and thus two different concentrations were used in different experiments (0.9 g/L and 1.5 g/L for PYR020, and 1.5 g/L and 3 g/L for PYR004). Experiments were conducted in 1 L volume, pH-controlled bioreactors, and the dissolved oxygen level was kept above 40% of saturation to maintain an aerobic environment.

PYR020 and PYR004 were first grown in batch bioreactors in minimal salts media with 30 g/L glucose plus acetate. Both PYR004 and PYR020 had slightly higher growth rates, pyruvate yields and titers in media containing less acetate (1.5 g/L for PYR004 and 0.9 g/L for PYR020) (Table 3). For PYR004, higher acetate concentrations significantly reduced the time required to complete conversion of glucose to

pyruvate (from ~33 hours to ~20 hours, FIG. 5). However, at the same acetate concentration (1.5 g/L) PYR020 was faster than PYR004 (FIG. 5, Panel (A), and FIG. 6, Panel (B)), presumably because PYR020 was evolved to grow at lower acetate concentrations. In batch conditions, both strains exhibited higher volumetric productivities when grown with higher acetate levels (Table 3). The two strains produce pyruvate at varying amounts during different stages of batch growth. PYR004 produced a large amount of pyruvate after growth stopped (~27% and ~63% of total pyruvate produced for 3 and 1.5 g/L acetate, respectively) (FIG. 5), while PYR020 produced most of the pyruvate during growth (~91% and 71% for 1.5 and 0.9 g/L acetate, respectively) (FIG. 6). In addition, PYR020 had ~33% higher specific pyruvate production rates (measured in mmol pyruvate/gDW/h) during exponential growth than PYR004 (Table 3).

Both strains were also grown in fed-batch bioreactors, where additional acetate was added once growth slowed. Compared to the batch results with the same total amount of acetate (0.9 g/L for PYR020 and 3 g/L for PYR004), both strains produced less pyruvate (~1.9 and ~2.2% lower yields for PYR020 and PYR004, respectively) in fed-batch experiments (Table 3, FIG. 5 and FIG. 6). However, both strains had higher volumetric pyruvate production rates when grown in fed-batch compared to batch growth with the same total amount of acetate. In both batch and fed-batch operation, tradeoffs appear to exist between volumetric productivities and pyruvate yields, with PYR004 tending to have higher volumetric productivities and PYR020 tending to have higher yields in the conditions tested (Table 3).

Since PYR020 had slightly higher pyruvate yields in minimal salts media than PYR004, PYR020 was further characterized in media derived from lignocellulosic biomass. AFEX-pretreated switchgrass hydrolysate (ASGH) was used in batch bioreactor experiments, and contained 48 g/L glucose and 2.6 g/L acetate. The natural presence of acetate in ASGH (and other plant hydrolysates) meant no acetate supplementation was required. Compared to glucose minimal salts media, PYR020 had a similar exponential growth rate in ASGH (~0.22 hour⁻¹), but entered into a slower linear growth phase after ~20 hours (FIG. 7). Growth stopped at ~80 hours, after all the glucose and most of the acetate (1.8 g/L) were utilized. However, xylose, another sugar present in ASGH, was hardly used. While pyruvate titers (40.7 g/L) and pyruvate yields (85.6%) were still high, the volumetric production rate was substantially lower in ASGH than minimal salts media due to slower growth (Table 3). Hydrolysates derived from lignocellulosic biomass contain microbial inhibitors (e.g., feruloyl amide) [35], whose presence reduces growth and xylose conversion. To further increase pyruvate production from lignocellulosic biomass, improvements in xylose conversion and inhibitor tolerance are likely needed.

TABLE 3

Production of pyruvate from the mutant strains in bioreactors.										
Strains	Bioreactor Mode	Medium [#]			Growth Rate (hour ⁻¹)	Pyruvate yield		Pyruvate Production Rate		
		Glucose (g/L)	Acetate (g/L)	theoretical yield [†]		% of max.	Conversion [‡] (g pyruvate/g substrate)	Titer (g/L) [§]	Volumetric (g/L/hour)	Specific [¶] (mmol/gDW/hour)
PYR020	Batch	30	0.9	0.25 ± 0.02	92.35 ± 0.41	0.89 ± 0.01	27.38 ± 0.16	1.01 ± 0.01	20.91 ± 1.60	
PYR020	Batch	30	1.5	0.23 ± 0.00	89.95 ± 4.72	0.85 ± 0.05	26.85 ± 1.60	1.10 ± 0.07	20.06 ± 2.08	
PYR020	Fed-batch	30	0.9	0.27 ± 0.02	90.61 ± 1.46	0.86 ± 0.02	26.73 ± 0.58	1.14 ± 0.02	24.17 ± 2.05	

TABLE 3-continued

Production of pyruvate from the mutant strains in bioreactors.										
Strains	Bioreactor Mode	Medium [#]		Growth	Pyruvate yield		Pyruvate Production Rate			
		Glucose (g/L)	Acetate (g/L)		% of max.	Theoretical yield [†]	(g pyruvate/g substrate)	Titer (g/L) [§]	Volumetric (g/L/hour)	Specific [¶] (mmol/gDW/hour)
PYR004	Batch	30	1.5	0.56 ± 0.03	91.17 ± 0.02	0.87 ± 0.00	27.35 ± 0.01	0.88 ± 0.00	15.11 ± 4.61	
PYR004	Batch	30	3.0	0.52 ± 0.01	86.63 ± 0.40	0.80 ± 0.01	26.36 ± 0.41	1.17 ± 0.02	11.45 ± 3.55	
PYR004	Fed-batch	30	3.0	0.53 ± 0.03	84.70 ± 2.70	0.77 ± 0.01	25.32 ± 0.43	1.37 ± 0.02	17.09 ± 6.71	
PYR020	Batch*	48	2.6	0.22 ± 0.02	85.63 ± 3.54	0.82 ± 0.04	40.74 ± 2.09	0.51 ± 0.04	26.36 ± 3.10	

[#]The first six experiments were done in a minimal salts medium (not M9) supplemented with glucose and acetate (see methods for details). In the last experiment, the medium was ASGH hydrolysate which contained 48 g/L glucose, 27 g/L xylose and 2.6 g/L acetate (as determined by HPLC).

[†]Percent of theoretical yield is calculated as the pyruvate concentration divided by the theoretical maximum production of pyruvate (2 mmol of pyruvate per mmol of glucose). Acetate was also taken account for calculating the theoretical maximum production (0.5 mmol of pyruvate per mmol of acetate). The yield was adjusted by the culture volume loss due to the liquid evaporation in shake flasks under aerobic conditions.

[‡]Conversion is expressed as the gram of pyruvate produced per gram of total carbon source (including glucose and acetate). It was adjusted to account for the volume of added buffer to maintain the bioreactor at pH 7.

[§]The reported titer is the concentration determined by HPLC (and does not account for the volume of added buffer).

[¶]The specific production rate is the pyruvate production rate per gram of cell dry weight (gDW) during exponential growth.

The numbers that follow the ± sign are standard deviations (SD) from duplicate bioreactor experiments.

Production of Ethanol by PYR-Derived Strains

Pyruvate is a precursor to many metabolites, fuels, and chemicals. To test whether the engineered pyruvate strains could produce other chemicals, we further engineered the strains to convert pyruvate into ethanol. The pJGG2 plasmid was added which contains the PET cassette—pyruvate decarboxylase (pdc) and alcohol dehydrogenase (adhB)—from *Zymomonas mobilis* under the control of an IPTG inducible lac promoter. Ethanol production was measured under anaerobic conditions since producing ethanol recycles NADH generated by glycolysis. However, under anaerobic conditions pyruvate formate lyase (PflAB) converts pyruvate into acetyl-CoA and formate, and so pflB was additionally deleted from the pyruvate strains to create four ethanol strains: EH010-pflB, EH020-pflB, EH030-pflB and EH040-pflB.

Anaerobic fermentations in M9 minimal media supplemented with glucose (1.98 g/L) and acetate (0.02 g/L) were carried out in hungate tubes. Three control strains were included: the parent strain (BW25113) with empty vector (pBBR1-MSC5), parent strain with pJGG2 plasmid, and an

ethanol production strain, GLBRCE1 (which lacks ackA, NW, and ldhA and expresses the PET cassette from the chromosome and pJGG2 plasmid [36]). In the parent strain, expressing the PET cassette using pJGG2 increased the growth rate, ethanol yield (by ~66%), and ethanol production rate compared to the empty vector (Table 4). The improved growth and ethanol production is likely a result of enhanced NADH recycling. Compared to the parent strain with pJGG2, all strains engineered to produce ethanol (GLBRCE1, EH010-pflB, EH020-pflB, EH030-pflB and EH040-pflB) had lower growth rates (Table 4). Three mutants (EH020-pflB, EH030-pflB and EH040-pflB) had between ~16% and ~21% higher ethanol yields compared to the parent strain with pJGG2, and had similar yields to GLBRCE1 (FIG. 8A). Two of these mutants (EH020-pflB and EH040-pflB) had higher volumetric productivity than both GLBRCE1 and the parent strain with pJGG2 (Table 4). Additional fermentations were performed using medium with more acetate (0.1 g/L with 1.9 g/L glucose) and/or reduced sampling frequency, and the ethanol yields and byproduct concentrations did not appear to change when more acetate was supplemented (FIGS. 8A and 8B).

TABLE 4

Production of ethanol from the parent and mutant strains.										
Strains [§]	Growth Rate (hour ⁻¹)	M9 Medium with		% of max.	Ethanol yield		Ethanol Production Rate			
		Glucose (g/L)	Acetate (g/L)		Theoretical yield [†]	(g pyruvate/g substrate)	Ethanol Titer (g/L)	Volumetric (g/L/hour)	Specific [¶] (mmol/gDW/hour)	
BW25113 + pBBR1-MSC5	0.28 ± 0.00	2	0	38.04 ± 1.70	0.19 ± 0.01	0.39 ± 0.02	0.02 ± 0.00	6.26 ± 0.10		
BW25113 + pJGG2	0.37 ± 0.02	2	0	63.06 ± 2.59	0.32 ± 0.01	0.64 ± 0.03	0.04 ± 0.00	11.71 ± 1.09		
GLBRCE1	0.16 ± 0.02	2	0	82.21 ± 0.91	0.42 ± 0.01	0.83 ± 0.01	0.03 ± 0.00	16.08 ± 0.78		
EH010-pflB	0.18 ± 0.01	1.98	0.02	61.81 ± 6.77	0.31 ± 0.03	0.62 ± 0.07	0.02 ± 0.00	16.61 ± 1.15		
EH020-pflB	0.25 ± 0.02	1.98	0.02	80.23 ± 4.84	0.41 ± 0.02	0.81 ± 0.05	0.04 ± 0.00	23.10 ± 1.48		
EH030-pflB	0.19 ± 0.05	1.98	0.02	79.47 ± 7.12	0.40 ± 0.04	0.80 ± 0.07	0.02 ± 0.00	19.29 ± 1.12		
EH040-pflB	0.22 ± 0.03	1.98	0.02	84.59 ± 7.03	0.43 ± 0.04	0.85 ± 0.07	0.04 ± 0.00	22.37 ± 2.28		

[§]Strains GLBRCE1, EH010-pflB, EH020-pflB, EH030-pflB, and EH040-pflB all contain pJGG2.

[†]Percent of theoretical yield is calculated as the ethanol concentration divided by the theoretical maximum production of ethanol (2 mmol of ethanol per mmol of glucose). Acetate is also taken account for calculating the theoretical maximum production (0.67 mmol of ethanol per mmol of glucose).

[‡]The conversion is expressed as the gram of ethanol produced per gram of carbon.

[¶]The specific production rate is the pyruvate production rate per gram of cell dry weight (gDW) during exponential growth. The numbers that follow the ± sign are standard deviations (SD) from triplicate experiments.

Discussion

Optimizing production of a specific metabolite usually involves increasing synthesis of its precursors. Pyruvate is a starting compound for synthesizing a variety of biofuels (e.g., ethanol, 1-butanol and isobutanol) and chemicals. A high-yield pyruvate producing strain has great potential for creating strains to produce valuable chemicals. In this study, a genome-scale metabolic model of *E. coli* and OptORF were used to identify gene deletion targets to improve pyruvate production. Strains constructed based on the computational predictions produced high levels of pyruvate and adaptive evolution of two strains increased pyruvate yields, titers and volumetric production rates. Further engineering of these platform pyruvate strains resulted in strains with high ethanol production.

All the designed strains over-produced pyruvate. The gene targets prevented pyruvate consumption by removing competing pathways and reduced growth by eliminating more energetically efficient routes for NADPH and glutamate production. The mutations involved shutting down the pentose phosphate pathway, reducing TCA cycle flux, and lowering biomass production (FIGS. 2A-2D). All of the mutants were predicted to have increased glycolytic fluxes and coupling between growth and pyruvate production. Two of the strains immediately exhibited high pyruvate yields, while two other strains were adaptively evolved to improve production rates and/or yields.

All the pyruvate strains have pyruvate dehydrogenase subunits deleted (either aceE or lpdA). The model predicted that other pathways (besides pyruvate-formate lyase) could be used to produce acetyl-CoA. Acetyl-CoA could be made from acetaldehyde via acetaldehyde dehydrogenase (MhpF), where acetaldehyde is produced by threonine degradation and other reactions. Acetyl-CoA could also be produced by 2-amino-3-ketobutyrate CoA ligase (Kbl) from threonine degradation. However, all of the mutants were unable to grow in the absence of acetate, suggesting that these other pathways are not active at high enough levels. Acetate was consumed by all the pyruvate strains, except PYR001, presumably to generate acetyl-CoA by acetyl-CoA synthetase. The amount of acetate available (0.34-3.4 mM) was greater than or close to the amount acetyl-CoA needed for biomass (estimated as the product of the biomass concentration and acetyl-CoA biomass requirement, which is 3.7 mmol acetyl-CoA per gDW) [37]. In the ethanol production study, the mutants with increased fluxes of ethanol synthesis were observed to grow faster, which is also probably caused by the generation of acetaldehyde and then converted to acetyl-CoA, while another possibility is the balancing of NADH.

When the resulting pyruvate strains were re-engineered for ethanol production, three of the resulting strains achieved high ethanol yields (EH020-pflB, EH030-pflB and EH040-pflB) under anaerobic conditions. Deleting pflB and expressing the PET cassette increased ethanol as expected, except for EH010-pflB. EH010-pflB (derived from PYR010), had the lowest yield of the mutants with pflB deletion and PET addition. Among all the strains tested, EH010-pflB is closest genetically to GLBRCE1. Both EH010-pflB and GLBRCE1 have ldhA, pta and pflB deletions. Even though EH010-pflB has two additional deletions, aceE and cyoA, neither gene would be expected to be expressed anaerobically [38]. Thus, the significantly lower ethanol yield in EH010-pflB compared with GLBRCE1 was unexpected. GLBRCE1 was derived from a closely-related background strain (MG1655, compared to BW25113) and has an extra chromosomal copy of the PET cassette. This

additional copy of the PET cassette could lead to higher PET expression levels and ethanol production in GLBRCE1. When compared to EH010, EH010-pflB should have reduced formate production (which it does, see FIG. 8A) and increased availability of pyruvate. However, EH010-pflB and EH010 exhibited similar ethanol yields (FIG. 8A). For the EH010-pflB strain, only 80% of the carbon was recovered in the biomass and measured products (which is lower than the other strains) and so it is possible that some other metabolite (not detected by HPLC) was secreted by EH010-pflB.

Yeast and bacterial strains have previously been engineered for pyruvate production [20, 22-24]. The strains usually require additional nutrients besides glucose (e.g., yeast extract, tryptone, thiamine) which will increase the cost for commercial production. An *E. coli* strain TC44 was previously reported to show the highest pyruvate production with 78% of theoretical yield and 1.2 g/L/hour production rate, when supplemented with thiamine. Our strain, PYR020, uses only mineral salt medium and reaches significantly higher yield (92% of theoretical yield) and a high production rate of 1.01 g/L/hour. This strain also could utilize cheaper hydrolysate feedstock to produce pyruvate with a high yield and titer. While PYR020 requires acetate for growth, acetate is commonly found in lignocellulosic hydrolysates. The PYR020 and PYR004 strains have the highest pyruvate production yield reported so far, and will be an ideal platform to create new strains to produce other important chemicals derived from pyruvate.

REFERENCES

- Ingram L O, Conway T, Clark D P, Sewell G W, Preston J F. Genetic-Engineering of Ethanol-Production in *Escherichia-Coli*. *Appl Environ Microb*. 1987; 53(10): 2420-5. PubMed PMID: WOS:A1987K354800024.
- Atsumi S, Hanai T, Liao J C. Non-fermentative pathways for synthesis of branched-chain higher alcohols as biofuels. *Nature*. 2008; 451(7174):86-U13. doi: Doi 10.1038/Nature06450. PubMed PMID: WOS:000252079300039.
- Steen E J, Kang Y S, Bokinsky G, Hu Z H, Schirmer A, McClure A, et al. Microbial production of fatty-acid-derived fuels and chemicals from plant biomass. *Nature*. 2010; 463(7280):559-U182. doi: Doi 10.1038/Nature08721. PubMed PMID: WOS:000273981100055.
- Beller H R, Goh E B, Keasling J D. Genes Involved in Long-Chain Alkene Biosynthesis in *Micrococcus luteus*. *Appl Environ Microb*. 2010; 76(4):1212-23. doi: Doi 10.1128/Aem.02312-09. PubMed PMID: WOS:000274328900029.
- Schirmer A, Rude M A, Li X Z, Popova E, del Cardayre S B. Microbial Biosynthesis of Alkanes. *Science*. 2010; 329(5991):559-62. doi: DOI 10.1126/science.1187936. PubMed PMID: WOS:000280483500035.
- Hawkins K M, Smolke C D. Production of benzylisoquinoline alkaloids in *Saccharomyces cerevisiae*. *Nat Chem Biol*. 2008; 4(9):564-73. doi: Doi 10.1038/Nchembio.105. PubMed PMID: WOS:000258597700015.
- Pfeifer B A, Admirala S J, Gramajo H, Cane D E, Khosla C. Biosynthesis of complex polyketides in a metabolically engineered strain of *E.coli*. *Science*. 2001; 291(5509): 1790-2. doi: DOI 10.1126/science.1058092. PubMed PMID: WOS:000167320600060.
- Siewers V, San-Bento R, Nielsen J. Implementation of Communication-Mediating Domains for Non-Ribosomal Peptide Production in *Saccharomyces cerevisiae*. *Bio-*

- technol Bioeng. 2010; 106(5):841-4. doi: Doi 10.1002/Bit.22739. PubMed PMID: WOS:000280058800014.
9. Ro D K, Paradise E M, Ouellet M, Fisher K J, Newman K L, Ndungu J M, et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. *Nature*. 2006; 440(7086):940-3. doi: Doi 10.1038/Nature04640. PubMed PMID: WOS:000236736700042.
10. Leonard E, Ajikumar P K, Thayer K, Xiao W H, Mo J D, Tidor B, et al. Combining metabolic and protein engineering of a terpenoid biosynthetic pathway for over-production and selectivity control. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107(31):13654-9. doi: DOI 10.1073/pnas.1006138107. PubMed PMID: WOS: 000280605900021.
11. Asadollahi M A, Maury J, Patil K R, Schalk M, Clark A, Nielsen J. Enhancing sesquiterpene production in *Saccharomyces cerevisiae* through in silico driven metabolic engineering. *Metab Eng*. 2009; 11(6):328-34. doi: DOI 10.1016/j.ymben.2009.07.001. PubMed PMID: WOS: 000272036700002.
12. Park J H, Lee K H, Kim T Y, Lee S Y. Metabolic engineering of *Escherichia coli* for the production of L-valine based on transcriptome analysis and in silico gene knockout simulation. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104(19):7797-802. doi: DOI 10.1073/pnas.0702609104. PubMed PMID: WOS: 000246461500015.
13. Fong S S, Burgard A P, Herring C D, Knight E M, Blattner F R, Maranas C D, et al. In silico design and adaptive evolution of *Escherichia coli* for production of lactic acid. *Biotechnol Bioeng*. 2005; 91(5):643-8. doi: Doi 10.1002/bit.20542. PubMed PMID: WOS: 000231523600012.
14. Zhang X L, Jantama K, Moore J C, Jarboe L R, Shanmugam K T, Ingram L O. Metabolic evolution of energy-conserving pathways for succinate production in *Escherichia coli*. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106(48): 20180-5. doi: DOI 10.1073/pnas.0905396106. PubMed PMID: WOS:000272254400012.
15. Nakamura C E, Whited G M. Metabolic engineering for the microbial production of 1,3-propanediol. *Curr Opin Biotech*. 2003; 14(5):454-9. doi: DOI 10.1016/j.copbio.2003.08.005. PubMed PMID: WOS: 000186448200002.
16. Wierckx N J P, Ballerstedt H, de Bont J A M, Wery J. Engineering of solvent-tolerant *Pseudomonas putida* S12 for bioproduction of phenol from glucose. *Appl Environ Microb*. 2005; 71(12):8221-7. doi: Doi 10.1128/Aem.71.12.8221-8227.2005. PubMed PMID: WOS: 000234417600072.
17. Zha W J, Rubin-Pitel S B, Shao Z Y, Zhao H M. Improving cellular malonyl-CoA level in *Escherichia coli* via metabolic engineering. *Metab Eng*. 2009; 11(3):192-8. doi: DOI 10.1016/j.ymben.2009.01.005. PubMed PMID: WOS:000265565300008.
18. Ravi R, Gokarn M A E, Elliot Altman, inventor Pyruvate carboxylase overexpression for enhanced production of oxaloacetate-derived biochemicals in microbial cells 1999.
19. Zhu Y H, Eiteman M A, Altman R, Altman E. High Glycolytic Flux Improves Pyruvate Production by a Metabolically Engineered *Escherichia coli* Strain. *Appl Envi-*

- ron Microb. 2008; 74(21):6649-55. doi: Doi 10.1128/Aem.01610-08. PubMed PMID: WOS: 000260429600020.
20. Tomar A, Eiteman M A, Altman E. The effect of acetate pathway mutations on the production of pyruvate in *Escherichia coli*. *Applied Microbiology and Biotechnology*. 2003; 62(1):76-82. doi: DOI 10.1007/s00253-003-1234-6. PubMed PMID: WOS:000184014000010.
21. Causey T B, Shanmugam K T, Yomano L P, Ingram L O. Engineering *Escherichia coli* for efficient conversion of glucose to pyruvate. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101(8):2235-40. doi: DOI 10.1073/pnas.0308171100. PubMed PMID: WOS:000220140400004.
22. Xu G Q, Hua Q, Duan N J, Liu L M, Chen J. Regulation of thiamine synthesis in *Saccharomyces cerevisiae* for improved pyruvate production. *Yeast*. 2012; 29(6):209-17. doi: Doi 10.1002/yea.2902. PubMed PMID: WOS: 000305078900002.
23. Wang Z K, Gao C J, Wang Q, Liang Q F, Qi Q S. Production of pyruvate in *Saccharomyces cerevisiae* through adaptive evolution and rational cofactor metabolic engineering. *Biochem Eng J*. 2012; 67:126-31. doi: DOI 10.1016/j.bej.2012.06.006. PubMed PMID: WOS: 000310945100017.
24. Wieschalka S, Blombach B, Eikmanns B J. Engineering *Corynebacterium glutamicum* for the production of pyruvate. *Applied Microbiology and Biotechnology*. 2012; 94(2):449-59. doi: DOI 10.1007/s00253-011-3843-9. PubMed PMID: WOS:000302035500014.
25. Mark A, Eiteman E A, inventor Microbial production of pyruvate and pyruvate derivatives patent US 20,100,304, 450. 2012.
26. Kim J, Reed J L. OptORF: Optimal metabolic and regulatory perturbations for metabolic engineering of microbial strains. *Bmc Syst Biol*. 2010; 4. doi: Artn 53 Doi 10.1186/1752-0509-4-53. PubMed PMID: WOS: 000278257700002.
27. Peng L, Shimizu K. Global metabolic regulation analysis for *Escherichia coli* K12 based on protein expression by 2-dimensional electrophoresis and enzyme activity measurement. *Applied Microbiology and Biotechnology*. 2003; 61(2):163-78. doi: DOI 10.1007/s00253-002-1202-6. PubMed PMID: WOS:000182702800011.
28. Sawers G, Watson G. A glycyl radical solution: oxygen-dependent interconversion of pyruvate formate-lyase. *Molecular Microbiology*. 1998; 29(4):945-54. doi: DOI 10.1046/j.1365-2958.1998.00941.x. PubMed PMID: WOS:000075451700002.
29. Bologna F P, Campos-Bermudez V A, Saavedra D D, Andreo C S, Drincovich M F. Characterization of *Escherichia coli* EutD: a Phosphotransacetylase of the Ethanolamine Operon. *J Microbiol*. 2010; 48(5):629-36. doi: DOI 10.1007/s12275-010-0091-0. PubMed PMID: WOS:000283630100012.
30. Zhou L, Zuo Z R, Chen X Z, Niu D D, Tian K M, Prior B A, et al. Evaluation of Genetic Manipulation Strategies on d-Lactate Production by *Escherichia coli*. *Curr Microbiol*. 2011; 62(3):981-9. doi: DOI 10.1007/s00284-010-9817-9. PubMed PMID: WOS:000287754500044.
31. Tarmy E M, Kaplan N O. Kinetics of *Escherichia Coli* B D-Lactate Dehydrogenase and Evidence for Pyruvate-Controlled Change in Conformation. *Journal of Biological Chemistry*. 1968; 243(10):2587-&. PubMed PMID: WOS:A1968B201700019.
32. Sawers G, Hesslinger C, Muller N, Kaiser M. The glycyl radical enzyme TdcE can replace pyruvate formate-lyase

- in glucose fermentation. *Journal of Bacteriology*. 1998; 180(14):3509-16. PubMed PMID: WOS: 000074720100003.
33. Nagy P L, Marolewski A, Benkovic S J, Zalkin H. Formyltetrahydrofolate Hydrolase, a Regulatory Enzyme That Functions to Balance Pools of Tetrahydrofolate and One-Carbon Tetrahydrofolate Adducts in *Escherichia Coli*. *Journal of Bacteriology*. 1995; 177(5):1292-8. PubMed PMID: WOS:A1995QJ43900023.
34. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, et al. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst Biol*. 2006; 2. doi: Artn 2006.0008 Doi 10.1038/Msb4100050. PubMed PMID: WOS:000243245400009.
35. Mills T Y, Sandoval N R, Gill R T. Cellulosic hydrolysate toxicity and tolerance mechanisms in *Escherichia coli*. *Biotechnol Biofuels*. 2009; 2. doi: Artn 26 10.1186/1754-6834-2-26. PubMed PMID: WOS: 000272095400002.
36. Schwalbach M S, Keating D H, Tremaine M, Marner W D, Zhang Y P, Bothfeld W, et al. Complex Physiology and Compound Stress Responses during Fermentation of Alkali-Pretreated Corn Stover Hydrolysate by an *Escherichia coli* Ethanologen. *Appl Environ Microb*. 2012; 78(9):3442-57. doi: Doi 10.1128/Aem.07329-11. PubMed PMID: WOS:000302807500047.
37. Neidhardt F C, John L. Ingraham, and Moselio Schaeffer. *Physiology of the bacterial cell: a molecular approach*. Sunderland, Mass.: Sinauer Associates; 1990.
38. Toya Y, Nakahigashi K, Tomita M, Shimizu K. Metabolic regulation analysis of wild-type and arcA mutant *Escherichia coli* under nitrate conditions using different levels of omics data. *Molecular bioSystems*. 2012; 8(10): 2593-604. Epub 2012/07/14. doi: 10.1039/c2mb25069a. PubMed PMID: 22790675.

39. Datsenko K A, Wanner B L. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97(12): 6640-5. doi: DOI 10.1073/pnas.120163297. PubMed PMID: WOS:000087526300074.
40. Causey T B, Zhou S, Shanmugam K T, Ingram L O. Engineering the metabolism of *Escherichia coli* W3110 for the conversion of sugar to redox-neutral and oxidized products: Homoacetate production. *Proceedings of the National Academy of Sciences of the United States of America*. 2003; 100(3):825-32. doi: 10.1073/pnas.0337684100. PubMed PMID: WOS: 000180838100014.
41. Baumler D J, Peplinski R G, Reed J L, Glasner J D, Perna N T. The evolution of metabolic networks of *E. coli*. *Bmc Syst Biol*. 2011; 5:182. doi: Artn 182 Doi 10.1186/1752-0509-5-182. PubMed PMID: WOS: 000297698400001.
42. Feist A M, Zielinski D C, Orth J D, Schellenberger J, Herrgard M J, Palsson B O. Model-driven evaluation of the production potential for growth-coupled products of *Escherichia coli*. *Metab Eng*. 2010; 12(3):173-86. doi: DOI 10.1016/j.ymben.2009.10.003. PubMed PMID: WOS:000276821400001.
43. Reed J L, Vo T D, Schilling C H, Palsson B O. An expanded genome-scale model of *Escherichia coli* K-12 (iJR904 GSM/GPR). *Genome Biol*. 2003; 4(9). doi: Artn R54 Doi 10.1186/Gb-2003-4-9-R54. PubMed PMID: WOS:000185048100007.
44. Miller, J. H. *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory, (1972), 433.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 48

```

<210> SEQ ID NO 1
<211> LENGTH: 2664
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 1

atgtcagaac gtttccaaa tgacgtggat ccgatcgaaa ctcgcgactg gctccaggcg   60
atcgaatcg tcatccgtga agaaagggtt gagcgtgctc agtatctgtat cgaccaactg  120
cttgctgaag cccgcaaagg cggtgtaaac gtagccgcag gcacaggtat cagcaactac  180
atcaacacca tccccgttga agaacaacccg gagtatccgg gtaatctgga actggAACGC 240
cgtattcgtt cagctatccg ctggaacgcc atcatgacgg tgctgegtgc gtcgaaaaaaaa 300
gacctcgaac tggggggcca tatggcgtcc ttccagtctt ccgcaaccat ttatgtatgtg 360
tgctttaacc acttcttccg tgcacgcAACAC gaggcaggatg gggggcacct ggtttacttc 420
cagggccaca tctccccggg cgtgtacgct cgtgcttcc tggaaaggctg tctgactcag 480
gagcagctgg ataacttccg tcaggaagtt cacggcaatg gctctcttc ctatccgcac 540
ccgaaaactga tgccgaaatt ctggcagttc ccgaccgtat ctatgggtct gggccgatt 600
ggtgcttattt accaggctaa attcctgaaa tatctggaa accgtggcct gaaagataacc 660
tctaaacaaa ccgtttacgc gttcctcggt gacggtaaaa tggacgaacc ggaatccaaa 720
ggtgcgatca ccatcgctac ccgtgaaaaa ctggataacc tggatcttcgt tatcaactgt 780

```

-continued

aacctgcagc gtcttgcacgg cccggtcacc ggtaacggca agatcatcaa cgaactggaa	840
ggcatcttcg aagggtctgg ctggAACGTG atcaaagtga tgggggttag cggtggat	900
gaactgctgc gtaaggatac cagcggtaaa ctgatccagc tgatgaacga aaccgttgc	960
ggcgactacc agacctaatac ggtgcgtacg ttctgtaca cttcttcgt	1020
aaatatctg aaaccgcagc actgggtgcgactggactg acgagcagat ctgggcactg	1080
aaccgttgtg gtcacgatcc gaagaaaatc tacgctgc tcaagaaacgc gcaggaaacc	1140
aaaggcaaag cgacagtaat cttgtctcat accattaaag gttacggcat gggcgacg	1200
gctgaaggta aaaacatcgc gcaccaggta aagaaaatc acatggacgg tttgcgtcat	1260
atccgcgacc gtttcaatgt gccgggtgtct gatgcagata tcgaaaaact gccgtacatc	1320
acttcccg aagggtctga agagcatacc tatctgcacg ctcagcgtca gaaactgcac	1380
ggttatctgc caagccgtca gccgaacttc accgagaagc ttgagctgcc gagcctgca	1440
gacttcggcg cgctgttgg aagcagagac aaagagatct ctaccactat cgcttcgtt	1500
cgtgcttgca acgtgtatgcgaaacaagatcgtatgcgtt accgtatc	1560
gccgacgaaagcgactttt cggtatggaa ggtctgttcc gtcagattgg tatttacagc	1620
ccgaacggtc acgactacac cccgcaggac cgccggcagg ttgttactataaagaagac	1680
gagaaaggta agattctgca ggaagggtac aacgagctgg ggcgggtt ttcctggctg	1740
gcagcggcga cctcttacag caccaacaat ctgcccgtatgc tccctgttca catctattac	1800
tgcgtatgtcg gttccagcg tattggcgat ctgtgttgg cggctggcga ccagcaagcg	1860
cgtggcttcc tgatcggcgg tacttccgtt cgtaccaccc tgaacggcga aggtctgcag	1920
cacgaagatg gtcacagcca cattcagtcg ctgactatcc cgaactgtat ctcttacac	1980
ccggcttacg cttacgaatg tgctgtcatac atgcgtacgc gtctggagcg tatgtacgg	2040
gaaaaacaag agaacgttta ctactacatc actacgctga acgaaaacta ccacatgcc	2100
gcaatgcgg aagggtctga ggaagggtatc cgtaaaggta tctacaaact cgaaactatt	2160
gaaggttagca aaggtaaatgc tgcgtgtcgg tctacgtcg tgcgttgcgttgcgt	2220
gaagcagctg agatcctggc gaaagattac ggcgttaggtt ctgacgttta tagcgtgacc	2280
tccttcaccg agctggcgcg tgatggcgat gattgtgaaac gctggaaacat gtcaccccg	2340
ctggaaactc cgccgttcc gtatatcgat caggtgtatgc acgacgctcc ggcgtggca	2400
tctaccgact atatgaaact gttcgctgag caggtccgtt cttacgtacc ggctgacgac	2460
taccgcgtac tgggtactga tggcttcgtt cggtccgaca gcccgtggaa cctgcgtcac	2520
cacttcgaag ttgtatgttcc ttatgtcgat gttgcggcgc tggggcgaact ggctaaacgt	2580
ggcgaaatcg ataagaaaatgc ggttgcgtac gcaatgcaca aattcaacat cgatgcagat	2640
aaagtttaacc cgctgttggc gtaa	2664

<210> SEQ ID NO 2

<211> LENGTH: 887

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 2

Met Ser Glu Arg Phe Pro Asn Asp Val Asp Pro Ile Glu Thr Arg Asp			
1	5	10	15

Trp Leu Gln Ala Ile Glu Ser Val Ile Arg Glu Glu Gly Val Glu Arg		
20	25	30

Ala Gln Tyr Leu Ile Asp Gln Leu Leu Ala Glu Ala Arg Lys Gly Gly

US 9,850,505 B2

33

34

-continued

35	40	45
Val Asn Val Ala Ala Gly Thr Gly Ile Ser Asn Tyr Ile Asn Thr Ile		
50	55	60
Pro Val Glu Glu Gln Pro Glu Tyr Pro Gly Asn Leu Glu Leu Glu Arg		
65	70	75 80
Arg Ile Arg Ser Ala Ile Arg Trp Asn Ala Ile Met Thr Val Leu Arg		
85	90	95
Ala Ser Lys Lys Asp Leu Glu Leu Gly Gly His Met Ala Ser Phe Gln		
100	105	110
Ser Ser Ala Thr Ile Tyr Asp Val Cys Phe Asn His Phe Phe Arg Ala		
115	120	125
Arg Asn Glu Gln Asp Gly Gly Asp Leu Val Tyr Phe Gln Gly His Ile		
130	135	140
Ser Pro Gly Val Tyr Ala Arg Ala Phe Leu Glu Gly Arg Leu Thr Gln		
145	150	155 160
Glu Gln Leu Asp Asn Phe Arg Gln Glu Val His Gly Asn Gly Leu Ser		
165	170	175
Ser Tyr Pro His Pro Lys Leu Met Pro Glu Phe Trp Gln Phe Pro Thr		
180	185	190
Val Ser Met Gly Leu Gly Pro Ile Gly Ala Ile Tyr Gln Ala Lys Phe		
195	200	205
Leu Lys Tyr Leu Glu His Arg Gly Leu Lys Asp Thr Ser Lys Gln Thr		
210	215	220
Val Tyr Ala Phe Leu Gly Asp Gly Glu Met Asp Glu Pro Glu Ser Lys		
225	230	235 240
Gly Ala Ile Thr Ile Ala Thr Arg Glu Lys Leu Asp Asn Leu Val Phe		
245	250	255
Val Ile Asn Cys Asn Leu Gln Arg Leu Asp Gly Pro Val Thr Gly Asn		
260	265	270
Gly Lys Ile Ile Asn Glu Leu Glu Gly Ile Phe Glu Gly Ala Gly Trp		
275	280	285
Asn Val Ile Lys Val Met Trp Gly Ser Arg Trp Asp Glu Leu Leu Arg		
290	295	300
Lys Asp Thr Ser Gly Lys Leu Ile Gln Leu Met Asn Glu Thr Val Asp		
305	310	315 320
Gly Asp Tyr Gln Thr Phe Lys Ser Lys Asp Gly Ala Tyr Val Arg Glu		
325	330	335
His Phe Phe Gly Lys Tyr Pro Glu Thr Ala Ala Leu Val Ala Asp Trp		
340	345	350
Thr Asp Glu Gln Ile Trp Ala Leu Asn Arg Gly Gly His Asp Pro Lys		
355	360	365
Lys Ile Tyr Ala Ala Phe Lys Lys Ala Gln Glu Thr Lys Gly Lys Ala		
370	375	380
Thr Val Ile Leu Ala His Thr Ile Lys Gly Tyr Gly Met Gly Asp Ala		
385	390	395 400
Ala Glu Gly Lys Asn Ile Ala His Gln Val Lys Lys Met Asn Met Asp		
405	410	415
Gly Val Arg His Ile Arg Asp Arg Phe Asn Val Pro Val Ser Asp Ala		
420	425	430
Asp Ile Glu Lys Leu Pro Tyr Ile Thr Phe Pro Glu Gly Ser Glu Glu		
435	440	445
His Thr Tyr Leu His Ala Gln Arg Gln Lys Leu His Gly Tyr Leu Pro		
450	455	460

-continued

Ser Arg Gln Pro Asn Phe Thr Glu Lys Leu Glu Leu Pro Ser Leu Gln
 465 470 475 480

Asp Phe Gly Ala Leu Leu Glu Glu Gln Ser Lys Glu Ile Ser Thr Thr
 485 490 495

Ile Ala Phe Val Arg Ala Leu Asn Val Met Leu Lys Asn Lys Ser Ile
 500 505 510

Lys Asp Arg Leu Val Pro Ile Ile Ala Asp Glu Ala Arg Thr Phe Gly
 515 520 525

Met Glu Gly Leu Phe Arg Gln Ile Gly Ile Tyr Ser Pro Asn Gly Gln
 530 535 540

Gln Tyr Thr Pro Gln Asp Arg Glu Gln Val Ala Tyr Tyr Lys Glu Asp
 545 550 555 560

Glu Lys Gly Gln Ile Leu Gln Glu Gly Ile Asn Glu Leu Gly Ala Gly
 565 570 575

Cys Ser Trp Leu Ala Ala Ala Thr Ser Tyr Ser Thr Asn Asn Leu Pro
 580 585 590

Met Ile Pro Phe Tyr Ile Tyr Tyr Ser Met Phe Gly Phe Gln Arg Ile
 595 600 605

Gly Asp Leu Cys Trp Ala Ala Gly Asp Gln Gln Ala Arg Gly Phe Leu
 610 615 620

Ile Gly Gly Thr Ser Gly Arg Thr Thr Leu Asn Gly Glu Gly Leu Gln
 625 630 635 640

His Glu Asp Gly His Ser His Ile Gln Ser Leu Thr Ile Pro Asn Cys
 645 650 655

Ile Ser Tyr Asp Pro Ala Tyr Ala Tyr Glu Val Ala Val Ile Met His
 660 665 670

Asp Gly Leu Glu Arg Met Tyr Gly Glu Lys Gln Glu Asn Val Tyr Tyr
 675 680 685

Tyr Ile Thr Thr Leu Asn Glu Asn Tyr His Met Pro Ala Met Pro Glu
 690 695 700

Gly Ala Glu Glu Gly Ile Arg Lys Gly Ile Tyr Lys Leu Glu Thr Ile
 705 710 715 720

Glu Gly Ser Lys Gly Lys Val Gln Leu Leu Gly Ser Gly Ser Ile Leu
 725 730 735

Arg His Val Arg Glu Ala Ala Glu Ile Leu Ala Lys Asp Tyr Gly Val
 740 745 750

Gly Ser Asp Val Tyr Ser Val Thr Ser Phe Thr Glu Leu Ala Arg Asp
 755 760 765

Gly Gln Asp Cys Glu Arg Trp Asn Met Leu His Pro Leu Glu Thr Pro
 770 775 780

Arg Val Pro Tyr Ile Ala Gln Val Met Asn Asp Ala Pro Ala Val Ala
 785 790 795 800

Ser Thr Asp Tyr Met Lys Leu Phe Ala Glu Gln Val Arg Thr Tyr Val
 805 810 815

Pro Ala Asp Asp Tyr Arg Val Leu Gly Thr Asp Gly Phe Gly Arg Ser
 820 825 830

Asp Ser Arg Glu Asn Leu Arg His His Phe Glu Val Asp Ala Ser Tyr
 835 840 845

Val Val Val Ala Ala Leu Gly Glu Leu Ala Lys Arg Gly Glu Ile Asp
 850 855 860

Lys Lys Val Val Ala Asp Ala Ile Ala Lys Phe Asn Ile Asp Ala Asp
 865 870 875 880

-continued

Lys Val Asn Pro Arg Leu Ala
885

<210> SEQ ID NO 3
<211> LENGTH: 1893
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<400> SEQUENCE: 3

atggctatcg	aatcaaagt	accggacatc	ggggctgatg	aagttgaaat	caccgagatc	60
ctggtcaaag	tgggcacaa	agttgaagcc	gaacagtgc	tgatcacccgt	agaaggcgac	120
aaaggctcta	tggaagttcc	gtctccgcag	gcgggtatcg	ttaaagagat	caaagtctct	180
gttggcgata	aaacccagac	cggcgcactg	attatgattt	tcgattccgc	cgacgggtgca	240
gcagacgctg	cacctgctca	ggcagaagag	aagaagaag	cagctccggc	agcagcacca	300
gcggctgccc	cggcaaaaga	cgttaacgtt	ccggatatcg	gcagcgcacga	agttgaagtg	360
accgaaaatcc	tggtggaaat	tggcgataaa	gttgaagctg	aacagtgcgt	gatcacccgt	420
gaaggcgaca	aggcttotat	ggaagttccg	gctccgtttt	ctggcacccgt	gaaagagatc	480
aaagtgaacg	tgggtgacaa	agtgtctacc	ggctcgctga	ttatggtctt	cgaagtgcgc	540
ggtgaagcag	gcgcggcagc	tccggccgt	aaacaggaag	cagctccggc	agcggccct	600
gcaccagcgg	ctggcgtgaa	agaagttaac	gttccggata	tcggcggtga	cgaagttgaa	660
gtgactgaag	tgttgtgaa	agtgggcac	aaagttccg	ctgaacagtc	actgatcacc	720
gtagaaggcg	acaaagcttc	tatggaaattt	ccggcgcgt	ttgcaggcgt	cgtgaaggaa	780
ctgaaaagtca	acgttggcga	taaagtgaaa	actggctcg	tgattatgtat	cttcgaagtt	840
gaaggcgac	cgcctcgccg	agctcctcg	aaacaggaag	cggcagcgc	ggcacccggca	900
gcaaaagctg	aagccccggc	agcagcacca	gctgcgaaag	cggaggc	atctgaattt	960
gctaaaaacg	acgttatgt	tcacgcgact	ccgtgtatcc	gccgtctggc	acgcgagtt	1020
ggtgttaacc	ttgcgaaatg	gaaggcact	ggcgttaaag	gtcgatctt	gcgcgaagac	1080
gttcaggctt	acgtgaaaga	agctatcaaa	cgtgcagaag	cagctccggc	agcgaactggc	1140
ggtgttatcc	ctggcatgt	gccgtggccg	aagggtggact	tcaagcaattt	tggtaatcc	1200
gaagaagttgg	aactggcccg	catccagaaa	atctctggt	cgaacctgag	ccgttaactgg	1260
gtaatgatcc	cgcatttac	tcacttcgac	aaaaccgata	tcaccgagtt	ggaagegttc	1320
cgttaaacagc	agaacgaaga	agcggcggaa	cgtaaagctg	atgtgaagat	cacccgggt	1380
gttccatca	tgaaagccgt	tgctgcagct	cttgagcaga	tgccctcgctt	caatagttcg	1440
ctgtcggaaag	acggtcagcg	tctgaccctg	aagaaataca	tcaacatcg	tgtggcggt	1500
gatacccgca	acggctcggt	ttgttccgt	ttcaaaagac	tcaacaagaa	aggcatcatc	1560
gagctgtctc	gcgcgcgtat	gactatttct	aagaaagcgc	gtgacggtaa	gctgactgcg	1620
ggcgaaatgc	agggcggttg	cttcaccatc	tccagcatcg	gcggcctgg	tactaccac	1680
ttcgcgcgcg	ttgtgaacgc	gccggaaatg	gctatccctg	gcgtttccaa	gtccgcgt	1740
gagccgggtgt	ggaatggtaa	agatgtcg	ccgcgtctg	tgctgcgt	ttctctotcc	1800
ttcgaccacc	gcgtgatcga	cggtgctgat	ggtgcccg	tcattaccat	cattaacaac	1860
acgctgtctg	acattcgccg	tctggtgatg	taa			1893

<210> SEQ ID NO 4
<211> LENGTH: 630
<212> TYPE: PRT

-continued

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 4

```

Met Ala Ile Glu Ile Lys Val Pro Asp Ile Gly Ala Asp Glu Val Glu
1          5          10          15

Ile Thr Glu Ile Leu Val Lys Val Gly Asp Lys Val Glu Ala Glu Gln
20         25          30

Ser Leu Ile Thr Val Glu Gly Asp Lys Ala Ser Met Glu Val Pro Ser
35         40          45

Pro Gln Ala Gly Ile Val Lys Glu Ile Lys Val Ser Val Gly Asp Lys
50         55          60

Thr Gln Thr Gly Ala Leu Ile Met Ile Phe Asp Ser Ala Asp Gly Ala
65         70          75          80

Ala Asp Ala Ala Pro Ala Gln Ala Glu Glu Lys Lys Glu Ala Ala Pro
85         90          95

Ala Ala Ala Pro Ala Ala Ala Ala Lys Asp Val Asn Val Pro Asp
100        105         110

Ile Gly Ser Asp Glu Val Glu Val Thr Glu Ile Leu Val Lys Val Gly
115        120         125

Asp Lys Val Glu Ala Glu Gln Ser Leu Ile Thr Val Glu Gly Asp Lys
130        135         140

Ala Ser Met Glu Val Pro Ala Pro Phe Ala Gly Thr Val Lys Glu Ile
145        150         155         160

Lys Val Asn Val Gly Asp Lys Val Ser Thr Gly Ser Leu Ile Met Val
165        170         175

Phe Glu Val Ala Gly Glu Ala Gly Ala Ala Ala Pro Ala Ala Lys Gln
180        185         190

Glu Ala Ala Pro Ala Ala Ala Pro Ala Pro Ala Ala Gly Val Lys Glu
195        200         205

Val Asn Val Pro Asp Ile Gly Gly Asp Glu Val Glu Val Thr Glu Val
210        215         220

Met Val Lys Val Gly Asp Lys Val Ala Ala Glu Gln Ser Leu Ile Thr
225        230         235         240

Val Glu Gly Asp Lys Ala Ser Met Glu Val Pro Ala Pro Phe Ala Gly
245        250         255

Val Val Lys Glu Leu Lys Val Asn Val Gly Asp Lys Val Lys Thr Gly
260        265         270

Ser Leu Ile Met Ile Phe Glu Val Glu Gly Ala Ala Pro Ala Ala Ala
275        280         285

Pro Ala Lys Gln Glu Ala Ala Ala Pro Ala Pro Ala Ala Lys Ala Glu
290        295         300

Ala Pro Ala Ala Ala Pro Ala Ala Lys Ala Glu Gly Lys Ser Glu Phe
305        310         315         320

Ala Glu Asn Asp Ala Tyr Val His Ala Thr Pro Leu Ile Arg Arg Leu
325        330         335

Ala Arg Glu Phe Gly Val Asn Leu Ala Lys Val Lys Gly Thr Gly Arg
340        345         350

Lys Gly Arg Ile Leu Arg Glu Asp Val Gln Ala Tyr Val Lys Glu Ala
355        360         365

Ile Lys Arg Ala Glu Ala Ala Pro Ala Ala Thr Gly Gly Ile Pro
370        375         380

Gly Met Leu Pro Trp Pro Lys Val Asp Phe Ser Lys Phe Gly Glu Ile
385        390         395         400

```

US 9,850,505 B2

41**42**

-continued

Glu Glu Val Glu Leu Gly Arg Ile Gln Lys Ile Ser Gly Ala Asn Leu
 405 410 415
 Ser Arg Asn Trp Val Met Ile Pro His Val Thr His Phe Asp Lys Thr
 420 425 430
 Asp Ile Thr Glu Leu Glu Ala Phe Arg Lys Gln Gln Asn Glu Glu Ala
 435 440 445
 Ala Lys Arg Lys Leu Asp Val Lys Ile Thr Pro Val Val Phe Ile Met
 450 455 460
 Lys Ala Val Ala Ala Leu Glu Gln Met Pro Arg Phe Asn Ser Ser
 465 470 475 480
 Leu Ser Glu Asp Gly Gln Arg Leu Thr Leu Lys Lys Tyr Ile Asn Ile
 485 490 495
 Gly Val Ala Val Asp Thr Pro Asn Gly Leu Val Val Pro Val Phe Lys
 500 505 510
 Asp Val Asn Lys Lys Gly Ile Ile Glu Leu Ser Arg Glu Leu Met Thr
 515 520 525
 Ile Ser Lys Lys Ala Arg Asp Gly Lys Leu Thr Ala Gly Glu Met Gln
 530 535 540
 Gly Gly Cys Phe Thr Ile Ser Ser Ile Gly Gly Leu Gly Thr Thr His
 545 550 555 560
 Phe Ala Pro Ile Val Asn Ala Pro Glu Val Ala Ile Leu Gly Val Ser
 565 570 575
 Lys Ser Ala Met Glu Pro Val Trp Asn Gly Lys Glu Phe Val Pro Arg
 580 585 590
 Leu Met Leu Pro Ile Ser Leu Ser Phe Asp His Arg Val Ile Asp Gly
 595 600 605
 Ala Asp Gly Ala Arg Phe Ile Thr Ile Ile Asn Asn Thr Leu Ser Asp
 610 615 620
 Ile Arg Arg Leu Val Met
 625 630

<210> SEQ ID NO 5
 <211> LENGTH: 1488
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 5

```

gtggataatg ggcgtcataa aaaaaacgtc agaccgcgc gagataaata tataagggtc     60
atgatgagta ctgaaatcaa aactcagggtc gtggtacttg gggcaggccc cgcaggttac   120
tccgctgcct tccgttgcgc tgatttaggt ctggaaaccg taatcgtaga acgttacaac   180
actcttggcg gtgtttgcct gaacgtcggc tgtatccctt ctaaaggact gtcgacgta   240
gcaaaagtta tcgaagaagc caaaggcgctg gctgaacacg gtatcgctt cggcgaaaccg   300
aaaaccgata tcgacaagat tcgtacctgg aaagagaaaag taatcaatca gtcgaccggt   360
ggtctggctg gatatggcgaa aggccgc当地 gtc当地ggctc gggtaaattt   420
accggggcta acaccctgga agttgaaggt gagaacggta aaaccgtgat caacttcgac   480
aacgcgatca ttgcagcggg ttctcgcccg attcaactgc cggttattcc goatgaagat   540
cccgctatct gggactccac tgacgcgtc gaactgaaag aagtaccaga acgcctgctg   600
gtaatgggtg cggttatcat cggtctggaa atgggcaccc tataaccacgc gtc当地ggctc   660
cagattgacg tgggtgaaat gttcgaccag gtc当地ccgg cagctgataa agacatcgtt   720
aaagtcttta ccaaggctat cagcaagaaa ttcaacctga tgctggaaac caaagttacc   780
  
```

-continued

gccgttgaag	cgaaagaaga	cggcatttat	gtgacgatgg	aaggcaaaaa	agcacccgct	840
gaaccgcage	gttacgacgc	cgtgctggta	gcgattggtc	gtgtgccgaa	cgttaaaaac	900
ctcgacgcag	gcaaagctgg	cgtggaagtt	gacgaccgtg	gtttcatccg	cgttgacaaa	960
cagctgcgtt	ccaacgtacc	gcacatctt	gctatcgccg	atatcgctgg	tcagccatgt	1020
ctggcacaca	aagggtttca	cgaagggtcac	gttgcgcgt	aagttatcgc	cggtaagaaa	1080
cactactcg	atccgaaagt	tatcccgatc	atcgctata	ccgaaccaga	agttgcgtgg	1140
gtaggtctga	ctgagaaaga	agcgaagag	aaaggcatca	gctatgaaac	cggccaccc	1200
ccgtgggctg	cttctggctg	tgctatcgct	tccgactgcg	cagacggtat	gaccaagctg	1260
attttcgaca	aagaatctca	ccgtgtgatc	ggtggtgc	ttgtcggtac	taacgggtgg	1320
gagctgtcg	gtgaaatcg	cctggcaatc	gaaatgggtt	gtgacgctga	agacatcgca	1380
ctgaccatcc	atgcgcaccc	gactctgcac	gagtctgtgg	gcctggggc	agaagtgttc	1440
gaaggtagca	ttaccgacct	gccgaaccc	aaagcgaaga	agaagtaa		1488

<210> SEQ ID NO 6

<211> LENGTH: 495

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 6

Met	Asp	Asn	Gly	Arg	His	Lys	Lys	Asn	Val	Arg	Pro	Ala	Gly	Asp	Lys
1						5			10				15		

Tyr	Ile	Glu	Val	Met	Met	Ser	Thr	Glu	Ile	Lys	Thr	Gln	Val	Val	Val
								20		25			30		

Leu	Gly	Ala	Gly	Pro	Ala	Gly	Tyr	Ser	Ala	Ala	Phe	Arg	Cys	Ala	Asp
								35		40			45		

Leu	Gly	Leu	Glu	Thr	Val	Ile	Val	Glu	Arg	Tyr	Asn	Thr	Leu	Gly	Gly
						50		55			60				

Val	Cys	Leu	Asn	Val	Gly	Cys	Ile	Pro	Ser	Lys	Ala	Leu	Leu	His	Val
						65		70			75			80	

Ala	Lys	Val	Ile	Glu	Glu	Ala	Lys	Ala	Leu	Ala	Glu	His	Gly	Ile	Val
						85		90			95				

Phe	Gly	Glu	Pro	Lys	Thr	Asp	Ile	Asp	Lys	Ile	Arg	Thr	Trp	Lys	Glu
						100		105			110				

Lys	Val	Ile	Asn	Gln	Leu	Thr	Gly	Gly	Leu	Ala	Gly	Met	Ala	Lys	Gly
						115		120			125				

Arg	Lys	Val	Lys	Val	Val	Asn	Gly	Leu	Gly	Lys	Phe	Thr	Gly	Ala	Asn
						130		135			140				

Thr	Leu	Glu	Val	Glu	Glu	Asn	Gly	Lys	Thr	Val	Ile	Asn	Phe	Asp	
						145		150			155			160	

Asn	Ala	Ile	Ile	Ala	Ala	Gly	Ser	Arg	Pro	Ile	Gln	Leu	Pro	Phe	Ile
						165		170			175				

Pro	His	Glu	Asp	Pro	Arg	Ile	Trp	Asp	Ser	Thr	Asp	Ala	Leu	Glu	Leu
						180		185			190				

Lys	Glu	Val	Pro	Glu	Arg	Leu	Leu	Val	Met	Gly	Gly	Ile	Ile	Gly	
						195		200			205				

Leu	Glu	Met	Gly	Thr	Val	Tyr	His	Ala	Leu	Gly	Ser	Gln	Ile	Asp	Val
						210		215			220				

Val	Glu	Met	Phe	Asp	Gln	Val	Ile	Pro	Ala	Ala	Asp	Lys	Asp	Ile	Val
						225		230			235			240	

Lys	Val	Phe	Thr	Lys	Arg	Ile	Ser	Lys	Lys	Phe	Asn	Leu	Met	Leu	Glu
						245		250			255				

US 9,850,505 B2

45**46**

-continued

Thr Lys Val Thr Ala Val Glu Ala Lys Glu Asp Gly Ile Tyr Val Thr
 260 265 270
 Met Glu Gly Lys Lys Ala Pro Ala Glu Pro Gln Arg Tyr Asp Ala Val
 275 280 285
 Leu Val Ala Ile Gly Arg Val Pro Asn Gly Lys Asn Leu Asp Ala Gly
 290 295 300
 Lys Ala Gly Val Glu Val Asp Asp Arg Gly Phe Ile Arg Val Asp Lys
 305 310 315 320
 Gln Leu Arg Thr Asn Val Pro His Ile Phe Ala Ile Gly Asp Ile Val
 325 330 335
 Gly Gln Pro Met Leu Ala His Lys Gly Val His Glu Gly His Val Ala
 340 345 350
 Ala Glu Val Ile Ala Gly Lys Lys His Tyr Phe Asp Pro Lys Val Ile
 355 360 365
 Pro Ser Ile Ala Tyr Thr Glu Pro Glu Val Ala Trp Val Gly Leu Thr
 370 375 380
 Glu Lys Glu Ala Lys Glu Lys Gly Ile Ser Tyr Glu Thr Ala Thr Phe
 385 390 395 400
 Pro Trp Ala Ala Ser Gly Arg Ala Ile Ala Ser Asp Cys Ala Asp Gly
 405 410 415
 Met Thr Lys Leu Ile Phe Asp Lys Glu Ser His Arg Val Ile Gly Gly
 420 425 430
 Ala Ile Val Gly Thr Asn Gly Gly Glu Leu Leu Gly Glu Ile Gly Leu
 435 440 445
 Ala Ile Glu Met Gly Cys Asp Ala Glu Asp Ile Ala Leu Thr Ile His
 450 455 460
 Ala His Pro Thr Leu His Glu Ser Val Gly Leu Ala Ala Glu Val Phe
 465 470 475 480
 Glu Gly Ser Ile Thr Asp Leu Pro Asn Pro Lys Ala Lys Lys Lys
 485 490 495

<210> SEQ ID NO 7

<211> LENGTH: 2802

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 7

```

atgcagaaca gcgcttgaa agcctggttg gactttctt acctctctgg cgcaaaccag   60
agctggatag aacagctcta tgaagacttc ttaccgatc ctgactcggt tgacgctaac  120
tggcggtcga cgttccagca gttacctggt acgggagtc aaccggatca attccactct 180
caaacgcgtg aataattccg ccgcctggcg aaagacgctt cacgttactc ttcaacgatc 240
tccgaccctg acaccaatgt gaagcagggt aaagtccctgc agtcattaa cgcataccgc 300
ttccgtggtc accagcatgc gaatctcgat ccgcgtggac tgtggcagca agataaagtg 360
ggcgatctgg atccgtctt ccacgatctg accgaagcag acttccagga gaccttcaac 420
gtcggttcat ttgccagccg caaagaaacc atgaaaactcg gcgagctgct ggaagccctc 480
aagcaaacct actgcggccc gattggtgcc gagtatatgc acattaccag caccgaagaa 540
aaacgctgga tccaacagcg tatcgagtct ggtcgcgcga cttcaatag cgaagagaaa 600
aaacgcttct taagcgact gaccgcgcgt gaaggtctt aacggttacct cggcgaaaa 660
ttccctggcg caaaacgctt ctcgcgtggaa ggcggtgacg cgtaatccc gatgcttaaa 720
gagatgtatcc gccacgctgg caacagcggc acccgcaag tggttctcggt gatggcgac 780

```

-continued

cgtggcgcg tgaacgtgt ggtgaacgtg ctgggtaaaa aaccgcaga cttgttcgac 840
gagttcgccg gttaaacataa agaacacctc ggcacgggtg acgtaaaata ccacatggc 900
ttctcgctg acttccagac cgatggccgc ctggtgacc tggcgtggc gtttaaccg 960
tctcacctt agattgttaag cccggtagtt atcggtctg ttcgtccccg tctggacaga 1020
cttgatgagc cgagcagcaa caaatgtgt ccaatcacca tccacgggtga cgccgcagtg 1080
accgggcagg gcgtggttca ggaacccctg aacatgtcgaa aagcgcgtgg ttatgaagtt 1140
ggcggtacgg tacgtatcg tataacaac caggtgggt tcaccaccc taatccgctg 1200
gatgcccgtt ctacgcccgtt ctgtactgtat atcggtaaaga tggttcaggc cccgattttc 1260
cacgttaacg cggacgatcc ggaagccgtt gcctttgtga cccgtctggc gctcgatttc 1320
cgtaacacctt taaaacgtga tgttccatc gacctgggtg gctaccggc tcacggccac 1380
aacgaagccg acgagccgag cgcaacccag cgcgtatgt atcagaaaat caaaaaacat 1440
ccgacaccgc gaaaaatcta cgctgacaag ctggagcagg aaaaagtggc gacgctggaa 1500
gatgccaccg agatggtaa cctgtaccgc gatgcgttgcg atgctggcga ttgcgtatgt 1560
gcagagtggc gtccgtatgaa catgcactt ttcacctggt cggcgtaccc caaccacgaa 1620
tgggacgaag agtacccgaa caaagtttagt atgaagccgc tgcaggagct ggcgaaacgc 1680
atcagcacgg tgccggaagc agttgaaatg cagtctcgat tgcgttgcgat ttatggcgt 1740
cgccaggcga tggctgcccgg tgagaaactg ttcgactggg ggggtgcggaa aaacctcgct 1800
tacgcccacgc tgggtatgaa aggcatccg gttccgttgcg cgggtgaaga ctccggcgc 1860
ggtaccttct tccaccgcg cggcgtatc cacaaccatg ctaacgggtt cacttacacg 1920
ccgctgcaac atatccataa cggcaggccg ggttccgtg tctggactc cgtactgtct 1980
gaagaagcag tgcgtggcgtt tgaatatgtt tatgccaccg cagaaccacg cactctgacc 2040
atctggaaag cgcagttcg tgcacttcgc aacgggtgcg agggtggttat cgaccaggc 2100
atctccctcg gcaacagaaa atggggccgg atgtgtggc tgggtatgtt gtcggccac 2160
ggttacgaag ggcaggggcc ggacgactcc tccggcgtc tggaaacgtt tctgaactt 2220
tgtgtgagc aaaacatgca ggtttcgta cggcttaccc cggcacaggc ttaccacatg 2280
ctgcgtcgatc aggccgtcg cgggtatgcgt cgtccgttgc tgcgtatgtc gccgaaatcc 2340
ctgcgtcgatc atcccgctggc ggtttccagg ctcgaagaac tggcgaacgg caccttcgt 2400
ccagccatcg gtgaatacgaa cgagcttgcgat cggaaaggccg tgaagccgtg agtgcgtgt 2460
tctggtaagg tttattacga cctgtggaa cagcgtcgta agaacaatca acacgtgtc 2520
gcacattgtgc gtatcgagca actctaccgg ttcggccata aagcgtatgc ggaagtgttg 2580
cagcagtttg ctcacgtcaa ggattttgtc tggtgcagg aagagccgt caaccaggcc 2640
gcatggtaact gcaacccagca tcatttcgtt gaaatgttgc cgtttggggc ttctcgctg 2700
tatgcaggcc gcccggccctc cgcctctccg cggtagggat atatgtccgt tcaccagaaa 2760
caqcaacaaq atctqqttaa tqacqccqctq aacqtcqaat aa 2802

<210> SEQ ID NO 8

<211> LENGTH: 933

<212> TYPE: PRT

<212> FILE: TRI

<400> SEQUENCE: 8

Met	Gln	Asn	Ser	Ala	Leu	Lys	Ala	Trp	Leu	Asp	Ser	Ser	Tyr	Leu	Ser
1					5				10						15

US 9,850,505 B2

49**50**

-continued

Gly Ala Asn Gln Ser Trp Ile Glu Gln Leu Tyr Glu Asp Phe Leu Thr
20 25 30

Asp Pro Asp Ser Val Asp Ala Asn Trp Arg Ser Thr Phe Gln Gln Leu
35 40 45

Pro Gly Thr Gly Val Lys Pro Asp Gln Phe His Ser Gln Thr Arg Glu
50 55 60

Tyr Phe Arg Arg Leu Ala Lys Asp Ala Ser Arg Tyr Ser Ser Thr Ile
65 70 75 80

Ser Asp Pro Asp Thr Asn Val Lys Gln Val Lys Val Leu Gln Leu Ile
85 90 95

Asn Ala Tyr Arg Phe Arg Gly His Gln His Ala Asn Leu Asp Pro Leu
100 105 110

Gly Leu Trp Gln Gln Asp Lys Val Ala Asp Leu Asp Pro Ser Phe His
115 120 125

Asp Leu Thr Glu Ala Asp Phe Gln Glu Thr Phe Asn Val Gly Ser Phe
130 135 140

Ala Ser Gly Lys Glu Thr Met Lys Leu Gly Glu Leu Leu Glu Ala Leu
145 150 155 160

Lys Gln Thr Tyr Cys Gly Pro Ile Gly Ala Glu Tyr Met His Ile Thr
165 170 175

Ser Thr Glu Glu Lys Arg Trp Ile Gln Gln Arg Ile Glu Ser Gly Arg
180 185 190

Ala Thr Phe Asn Ser Glu Glu Lys Arg Phe Leu Ser Glu Leu Thr
195 200 205

Ala Ala Glu Gly Leu Glu Arg Tyr Leu Gly Ala Lys Phe Pro Gly Ala
210 215 220

Lys Arg Phe Ser Leu Glu Gly Asp Ala Leu Ile Pro Met Leu Lys
225 230 235 240

Glu Met Ile Arg His Ala Gly Asn Ser Gly Thr Arg Glu Val Val Leu
245 250 255

Gly Met Ala His Arg Gly Arg Leu Asn Val Leu Val Asn Val Leu Gly
260 265 270

Lys Lys Pro Gln Asp Leu Phe Asp Glu Phe Ala Gly Lys His Lys Glu
275 280 285

His Leu Gly Thr Gly Asp Val Lys Tyr His Met Gly Phe Ser Ser Asp
290 295 300

Phe Gln Thr Asp Gly Gly Leu Val His Leu Ala Leu Ala Phe Asn Pro
305 310 315 320

Ser His Leu Glu Ile Val Ser Pro Val Val Ile Gly Ser Val Arg Ala
325 330 335

Arg Leu Asp Arg Leu Asp Glu Pro Ser Ser Asn Lys Val Leu Pro Ile
340 345 350

Thr Ile His Gly Asp Ala Ala Val Thr Gly Gln Gly Val Val Gln Glu
355 360 365

Thr Leu Asn Met Ser Lys Ala Arg Gly Tyr Glu Val Gly Gly Thr Val
370 375 380

Arg Ile Val Ile Asn Asn Gln Val Gly Phe Thr Thr Ser Asn Pro Leu
385 390 395 400

Asp Ala Arg Ser Thr Pro Tyr Cys Thr Asp Ile Gly Lys Met Val Gln
405 410 415

Ala Pro Ile Phe His Val Asn Ala Asp Asp Pro Glu Ala Val Ala Phe
420 425 430

US 9,850,505 B2

51

-continued

Val Thr Arg Leu Ala Leu Asp Phe Arg Asn Thr Phe Lys Arg Asp Val		
435	440	445

Phe Ile Asp Leu Val Cys Tyr Arg Arg His Gly His Asn Glu Ala Asp		
450	455	460

Glu Pro Ser Ala Thr Gln Pro Leu Met Tyr Gln Lys Ile Lys Lys His		
465	470	475

Pro Thr Pro Arg Lys Ile Tyr Ala Asp Lys Leu Glu Gln Glu Lys Val		
485	490	495

Ala Thr Leu Glu Asp Ala Thr Glu Met Val Asn Leu Tyr Arg Asp Ala		
500	505	510

Leu Asp Ala Gly Asp Cys Val Val Ala Glu Trp Arg Pro Met Asn Met		
515	520	525

His Ser Phe Thr Trp Ser Pro Tyr Leu Asn His Glu Trp Asp Glu Glu		
530	535	540

Tyr Pro Asn Lys Val Glu Met Lys Arg Leu Gln Glu Leu Ala Lys Arg		
545	550	555

Ile Ser Thr Val Pro Glu Ala Val Glu Met Gln Ser Arg Val Ala Lys		
565	570	575

Ile Tyr Gly Asp Arg Gln Ala Met Ala Ala Gly Glu Lys Leu Phe Asp		
580	585	590

Trp Gly Gly Ala Glu Asn Leu Ala Tyr Ala Thr Leu Val Asp Glu Gly		
595	600	605

Ile Pro Val Arg Leu Ser Gly Glu Asp Ser Gly Arg Gly Thr Phe Phe		
610	615	620

His Arg His Ala Val Ile His Asn Gln Ser Asn Gly Ser Thr Tyr Thr		
625	630	635

Pro Leu Gln His Ile His Asn Gly Gln Gly Ala Phe Arg Val Trp Asp		
645	650	655

Ser Val Leu Ser Glu Glu Ala Val Leu Ala Phe Glu Tyr Gly Tyr Ala		
660	665	670

Thr Ala Glu Pro Arg Thr Leu Thr Ile Trp Glu Ala Gln Phe Gly Asp		
675	680	685

Phe Ala Asn Gly Ala Gln Val Val Ile Asp Gln Phe Ile Ser Ser Gly		
690	695	700

Glu Gln Lys Trp Gly Arg Met Cys Gly Leu Val Met Leu Leu Pro His		
705	710	715

Gly Tyr Glu Gly Gln Gly Pro Glu His Ser Ser Ala Arg Leu Glu Arg		
725	730	735

Tyr Leu Gln Leu Cys Ala Glu Gln Asn Met Gln Val Cys Val Pro Ser		
740	745	750

Thr Pro Ala Gln Val Tyr His Met Leu Arg Arg Gln Ala Leu Arg Gly		
755	760	765

Met Arg Arg Pro Leu Val Val Met Ser Pro Lys Ser Leu Leu Arg His		
770	775	780

Pro Leu Ala Val Ser Ser Leu Glu Glu Leu Ala Asn Gly Thr Phe Leu		
785	790	795

Pro Ala Ile Gly Glu Ile Asp Glu Leu Asp Pro Lys Gly Val Lys Arg		
805	810	815

Val Val Met Cys Ser Gly Lys Val Tyr Tyr Asp Leu Leu Glu Gln Arg		
820	825	830

Arg Lys Asn Asn Gln His Asp Val Ala Ile Val Arg Ile Glu Gln Leu		
835	840	845

Tyr Pro Phe Pro His Lys Ala Met Gln Glu Val Leu Gln Gln Phe Ala		
---	--	--

52

US 9,850,505 B2

53

54

-continued

His Val Lys Asp Phe Val Trp Cys Gln Glu Pro Leu Asn Gln Gly	850	855	860	
	865	870	875	880
Ala Trp Tyr Cys Ser Gln His His Phe Arg Glu Val Ile Pro Phe Gly				
	885	890		895
Ala Ser Leu Arg Tyr Ala Gly Arg Pro Ala Ser Ala Ser Pro Ala Val				
	900	905		910
Gly Tyr Met Ser Val His Gln Lys Gln Gln Gln Asp Leu Val Asn Asp				
	915	920		925
Ala Leu Asn Val Glu				
	930			

<210> SEQ ID NO 9
<211> LENGTH: 1218
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 9
atgagtagcgttagatattct ggtccctgac ctgcctgaat ccgtagccga tgccaccgtc 60
gcaacacctggc ataaaaaaacc cggcgacgca gtcgtacgtg atgaagtgtct ggtagaatac 120
gaaactgaca aagtggtaact ggaagtacccg gcatcagcag acggcattctt ggatgcggtt 180
cttggaaatgtt aaggtaacaac ggttaacgtct cgtcagatcc ttgggtcgctt gcgtgaaggc 240
aacagcgccg gtaaaagaaaac cagcgccaaa tctgaagaga aagcgtccac tccggcgcaa 300
cgccagcagg cgtctcttggaa agagcaaaac aacgatcgct taagccccgc gatccgtcg 360
ctgttgttgcgtt aacacaatctt cgacgcccagc gccattaaag gcacccggtgtt gggtggtctgtt 420
ctgtactcggtt aagatgttggaa aaaacatctt gcttggaaagccc cggcgaaaaga gtctgtcccg 480
gcagcggtctt ctccggcggtt gcaaccggctt ctggctgcac gtatgtaaaa acgtgtcccg 540
atgactcgcc ttgtgttggaaatggc tggtaagggcgtt tggatgttggaaatggc tggatgttggc 600
atgctgacca cgttcaacgaa agtcaacatgtt aagccgattttt tggatgttggaaatggc tggatgttggc 660
ggtaagcgttt ttgtttttttt ccacggcatc cgtctgggtt ttatgttggaaatggc tggatgttggc 720
ggcggtgttggaaatggc tggatgttggc tggatgttggc tggatgttggc tggatgttggc 780
gtggtttacc acaactatattt cgttccatgtt atggcggtttt ctacggccggc cggccgttgggtt 840
acggccgggttcc tggatgttggc tggatgttggc tggatgttggc tggatgttggc tggatgttggc 900
gagctggcgttcc tggatgttggc tggatgttggc tggatgttggc tggatgttggc tggatgttggc 960
tttccatca ccaacgggttcc tggatgttggc tggatgttggc tggatgttggc tggatgttggc 1020
ccgcggccgttcc tggatgttggc tggatgttggc tggatgttggc tggatgttggc tggatgttggc 1080
cagggttggatgttcc tggatgttggc tggatgttggc tggatgttggc tggatgttggc tggatgttggc 1140
ggtcgcgttcc tggatgttggc tggatgttggc tggatgttggc tggatgttggc tggatgttggc 1200
ctgtgtgtttcc tggatgttggc tggatgttggc tggatgttggc tggatgttggc tggatgttggc 1260

<210> SEQ ID NO 10
<211> LENGTH: 405
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 10

Met	Ser	Ser	Val	Asp	Ile	Leu	Val	Pro	Asp	Leu	Pro	Glu	Ser	Val	Ala
1				5				10						15	

Asp Ala Thr Val Ala Thr Trp His Lys Lys Pro Gly Asp Ala Val Val

US 9,850,505 B2

55**56**

-continued

20	25	30
Arg Asp Glu Val Leu Val Glu Ile Glu Thr Asp Lys Val Val Leu Glu		
35	40	45
Val Pro Ala Ser Ala Asp Gly Ile Leu Asp Ala Val Leu Glu Asp Glu		
50	55	60
Gly Thr Thr Val Thr Ser Arg Gln Ile Leu Gly Arg Leu Arg Glu Gly		
65	70	75
80		
Asn Ser Ala Gly Lys Glu Thr Ser Ala Lys Ser Glu Glu Lys Ala Ser		
85	90	95
Thr Pro Ala Gln Arg Gln Gln Ala Ser Leu Glu Glu Gln Asn Asn Asp		
100	105	110
Ala Leu Ser Pro Ala Ile Arg Arg Leu Leu Ala Glu His Asn Leu Asp		
115	120	125
Ala Ser Ala Ile Lys Gly Thr Gly Val Gly Arg Leu Thr Arg Glu		
130	135	140
Asp Val Glu Lys His Leu Ala Lys Ala Pro Ala Lys Glu Ser Ala Pro		
145	150	155
160		
Ala Ala Ala Pro Ala Ala Gln Pro Ala Leu Ala Ala Arg Ser Glu		
165	170	175
Lys Arg Val Pro Met Thr Arg Leu Arg Lys Arg Val Ala Glu Arg Leu		
180	185	190
Leu Glu Ala Lys Asn Ser Thr Ala Met Leu Thr Thr Phe Asn Glu Val		
195	200	205
Asn Met Lys Pro Ile Met Asp Leu Arg Lys Gln Tyr Gly Glu Ala Phe		
210	215	220
Glu Lys Arg His Gly Ile Arg Leu Gly Phe Met Ser Phe Tyr Val Lys		
225	230	235
240		
Ala Val Val Glu Ala Leu Lys Arg Tyr Pro Glu Val Asn Ala Ser Ile		
245	250	255
Asp Gly Asp Asp Val Val Tyr His Asn Tyr Phe Asp Val Ser Met Ala		
260	265	270
Val Ser Thr Pro Arg Gly Leu Val Thr Pro Val Leu Arg Asp Val Asp		
275	280	285
Thr Leu Gly Met Ala Asp Ile Glu Lys Lys Ile Lys Glu Leu Ala Val		
290	295	300
Lys Gly Arg Asp Gly Lys Leu Thr Val Glu Asp Leu Thr Gly Gly Asn		
305	310	315
320		
Phe Thr Ile Thr Asn Gly Gly Val Phe Gly Ser Leu Met Ser Thr Pro		
325	330	335
Ile Ile Asn Pro Pro Gln Ser Ala Ile Leu Gly Met His Ala Ile Lys		
340	345	350
Asp Arg Pro Met Ala Val Asn Gly Gln Val Glu Ile Leu Pro Met Met		
355	360	365
Tyr Leu Ala Leu Ser Tyr Asp His Arg Leu Ile Asp Gly Arg Glu Ser		
370	375	380
Val Gly Phe Leu Val Thr Ile Lys Glu Leu Leu Glu Asp Pro Thr Arg		
385	390	395
400		
Leu Leu Leu Asp Val		
405		

<210> SEQ ID NO 11
<211> LENGTH: 2145
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

-continued

<400> SEQUENCE: 11

gtgtccccgtta	tattatgtcttaccc	ggaaccagcg	tcggctctgac	cagcgtcagc	60		
cttggcgtgat	tccgtgcataat	ggaacgc当地	ggcggtcgctc	tgagcggttt	caaacctatc	120	
gctcagccgc	gtaccgggtgg	cgatgc当地	gatcagacta	cgactatcgt	gctgtc当地	180	
tcttccacca	cgacggccgc	tgaaccgctg	aaaatgagct	acgttgaagg	tctgtttcc	240	
agcaatcaga	aagatgtgt	gatgaaagag	atcatcgca	actaccacgc	taacacccaaa	300	
gacgctgaag	tcgttctgg	ggaaggctctg	gtccc当地	gtaaggcacca	gtttgccc当地	360	
tctctgaact	acgaaatcgc	caaaaacgctg	aacgc当地	tcgttctcg	tatgtctc当地	420	
ggcactgata	ctccggaaaca	gttggaaagag	cgtatcgaac	tgactcgeaa	cagcttc当地	480	
gggtgc当地	aaaaacaccaat	taccggcgtt	atcgtaaca	aactgaacgc	tccggttgat	540	
gagcagggtc	gtacccgtcc	ggatctgtcc	gagatffff	acgactccac	caaaggccaaa	600	
gtgaacaacg	ttgatccggc	gaagctgcaaa	aatccagcc	cgtgtccggt	tctcggc当地	660	
gtgccgtgga	gttttgc当地	gatcgcgact	cgtgc当地	atatggctcg	ccacccgtaa	720	
gcgaccatca	tcaacgc当地	cgacatcaat	actcgccg	ttaaatccgt	cactttctgc	780	
gcacgc当地	tccgc当地	gctggagcac	tccgtgc当地	gttctctg	gttgacttcc	840	
gcagacccgc	ctgacgtgct	gggtgc当地	tgc当地	ccatgaacgg	cgttagaaatc	900	
ggtgccctgc	tgctgactgg	cggctacgaa	atggacgc当地	gcatttctaa	actgtgc当地	960	
cgtgtttcg	ctactggcct	gccgttattt	atggtgc当地	ccaacccctg	gcagacttct	1020	
cttagcctgc	agagcttcaa	cctggaaagtt	ccgggtgc当地	atcatgc当地	tatcgaaaaa	1080	
gttcaggaat	acgtggctaa	ctacatcaac	gctgactgg	tcgattctct	gactgc当地	1140	
tctgagcgca	gcccgtgtct	gtctccgcca	gcttgc当地	atcagctgac	tgaacttgc当地	1200	
cgc当地	caaaacgtat	cgttgc当地	gaaggtgc当地	aaccgc当地	cgttaaagca	1260	
gccc当地	gtgctgaa	acttgc当地	tgctggtaa	tccggc当地	1320		
atcaacccgt	ttgc当地	tcagggtgt	gaactgggt	caggcattga	aatcggtt当地	1380	
ccagaagtgg	ttcgc当地	ctatgtgg	cgtctgg	aactgc当地	gaacaaaggc	1440	
atgaccgaaa	ccgttgc当地	cgaacagctg	gaagacaacg	tggttctgg	tacgc当地	1500	
ctggaaacaag	atgaagttga	tggctgg	tccgg	gtctgg	tacccggat	1560	
atccgc当地	cgtgc当地	gatcaaaact	gcacccggca	gctccctgg	atctccgt	1620	
ttcttc当地	tgttgc当地	acaggtttac	gttacgg	actgtgc当地	caacccggat	1680	
ccgaccgc当地	aacagctggc	agaaatcgca	attcagtc当地	ctgatccgc当地	tgccgc当地	1740	
ggtatcgaa	cgcgcggtc	tatgtctcc	tactccaccg	gtacttctgg	tgctgg	1800	
gacgtgaa	aagtgc当地	agcaactcg	ctggcg	cagg	aaaaacgtcc	tgatctgat	1860
atcgacggc	cgctgc当地	cgacgc当地	gtaatgg	ctgg	gaa	atccaaagca	1920
ccgaactctc	cggttgc当地	tcgc当地	gtgttcatct	tccggatct	gaacaccgg	1980	
aacaccac	acaaaggc当地	acagegttct	gctgacctg	tctctatcg	accgtatcg	2040	
cagggtatgc	gcaaggccg	taacgacctg	tccgtgg	cactgg	tgatatcg	2100	
tacaccatcg	cgctgc当地	gattcactt	gcacagc当地	agtaa		2145	

<210> SEQ ID NO 12

<211> LENGTH: 714

<212> TYPE: PRT

US 9,850,505 B2

59**60**

-continued

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 12

Met Ser Arg Ile Ile Met Leu Ile Pro Thr Gly Thr Ser Val Gly Leu			
1	5	10	15

Thr Ser Val Ser Leu Gly Val Ile Arg Ala Met Glu Arg Lys Gly Val		
20	25	30

Arg Leu Ser Val Phe Lys Pro Ile Ala Gln Pro Arg Thr Gly Gly Asp		
35	40	45

Ala Pro Asp Gln Thr Thr Ile Val Arg Ala Asn Ser Ser Thr Thr		
50	55	60

Thr Ala Ala Glu Pro Leu Lys Met Ser Tyr Val Glu Gly Leu Leu Ser			
65	70	75	80

Ser Asn Gln Lys Asp Val Leu Met Glu Glu Ile Ile Ala Asn Tyr His		
85	90	95

Ala Asn Thr Lys Asp Ala Glu Val Val Leu Val Glu Gly Leu Val Pro		
100	105	110

Thr Arg Lys His Gln Phe Ala Gln Ser Leu Asn Tyr Glu Ile Ala Lys		
115	120	125

Thr Leu Asn Ala Glu Ile Val Phe Val Met Ser Gln Gly Thr Asp Thr		
130	135	140

Pro Glu Gln Leu Lys Glu Arg Ile Glu Leu Thr Arg Asn Ser Phe Gly			
145	150	155	160

Gly Ala Lys Asn Thr Asn Ile Thr Gly Val Ile Val Asn Lys Leu Asn		
165	170	175

Ala Pro Val Asp Glu Gln Gly Arg Thr Arg Pro Asp Leu Ser Glu Ile		
180	185	190

Phe Asp Asp Ser Thr Lys Ala Lys Val Asn Asn Val Asp Pro Ala Lys		
195	200	205

Leu Gln Glu Ser Ser Pro Leu Pro Val Leu Gly Ala Val Pro Trp Ser		
210	215	220

Phe Asp Leu Ile Ala Thr Arg Ala Ile Asp Met Ala Arg His Leu Asn			
225	230	235	240

Ala Thr Ile Ile Asn Glu Gly Asp Ile Asn Thr Arg Arg Val Lys Ser		
245	250	255

Val Thr Phe Cys Ala Arg Ser Ile Pro His Met Leu Glu His Phe Arg		
260	265	270

Ala Gly Ser Leu Leu Val Thr Ser Ala Asp Arg Pro Asp Val Leu Val		
275	280	285

Ala Ala Cys Leu Ala Ala Met Asn Gly Val Glu Ile Gly Ala Leu Leu		
290	295	300

Leu Thr Gly Gly Tyr Glu Met Asp Ala Arg Ile Ser Lys Leu Cys Glu			
305	310	315	320

Arg Ala Phe Ala Thr Gly Leu Pro Val Phe Met Val Asn Thr Asn Thr		
325	330	335

Trp Gln Thr Ser Leu Ser Leu Gln Ser Phe Asn Leu Glu Val Pro Val		
340	345	350

Asp Asp His Glu Arg Ile Glu Lys Val Gln Glu Tyr Val Ala Asn Tyr		
355	360	365

Ile Asn Ala Asp Trp Ile Asp Ser Leu Thr Ala Thr Ser Glu Arg Ser		
370	375	380

Arg Arg Leu Ser Pro Pro Ala Phe Arg Tyr Gln Leu Thr Glu Leu Ala			
385	390	395	400

US 9,850,505 B2

61**62**

-continued

Arg Lys Ala Gly Lys Arg Ile Val Leu Pro Glu Gly Asp Glu Pro Arg
405 410 415

Thr Val Lys Ala Ala Ala Ile Cys Ala Glu Arg Gly Ile Ala Thr Cys
420 425 430

Val Leu Leu Gly Asn Pro Ala Glu Ile Asn Arg Val Ala Ala Ser Gln
435 440 445

Gly Val Glu Leu Gly Ala Gly Ile Glu Ile Val Asp Pro Glu Val Val
450 455 460

Arg Glu Asn Tyr Val Gly Arg Leu Val Glu Leu Arg Lys Asn Lys Gly
465 470 475 480

Met Thr Glu Thr Val Ala Arg Glu Gln Leu Glu Asp Asn Val Val Leu
485 490 495

Gly Thr Leu Met Leu Glu Gln Asp Glu Val Asp Gly Leu Val Ser Gly
500 505 510

Ala Val His Thr Thr Ala Asn Thr Ile Arg Pro Pro Leu Gln Leu Ile
515 520 525

Lys Thr Ala Pro Gly Ser Ser Leu Val Ser Ser Val Phe Phe Met Leu
530 535 540

Leu Pro Glu Gln Val Tyr Val Tyr Gly Asp Cys Ala Ile Asn Pro Asp
545 550 555 560

Pro Thr Ala Glu Gln Leu Ala Glu Ile Ala Ile Gln Ser Ala Asp Ser
565 570 575

Ala Ala Ala Phe Gly Ile Glu Pro Arg Val Ala Met Leu Ser Tyr Ser
580 585 590

Thr Gly Thr Ser Gly Ala Gly Ser Asp Val Glu Lys Val Arg Glu Ala
595 600 605

Thr Arg Leu Ala Gln Glu Lys Arg Pro Asp Leu Met Ile Asp Gly Pro
610 615 620

Leu Gln Tyr Asp Ala Ala Val Met Ala Asp Val Ala Lys Ser Lys Ala
625 630 635 640

Pro Asn Ser Pro Val Ala Gly Arg Ala Thr Val Phe Ile Phe Pro Asp
645 650 655

Leu Asn Thr Gly Asn Thr Thr Tyr Lys Ala Val Gln Arg Ser Ala Asp
660 665 670

Leu Ile Ser Ile Gly Pro Met Leu Gln Gly Met Arg Lys Pro Val Asn
675 680 685

Asp Leu Ser Arg Gly Ala Leu Val Asp Asp Ile Val Tyr Thr Ile Ala
690 695 700

Leu Thr Ala Ile Gln Ser Ala Gln Gln Gln
705 710

<210> SEQ ID NO 13

<211> LENGTH: 1203

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 13

atgtcgagta agtttagtact gggtctgaac tgcggtagt ctcaactgaa atttgccatc	60
---	----

atcgatgcag taaatggtga agagtacctt tctggtttag ccgaatgttt ccacctgccc	120
---	-----

gaagcacgta tcaaattggaa aatggacggc aataaacagg aagcggctt aggtgcaggc	180
---	-----

gccgctcaca gcgaagcgct caactttatc gttaatacta ttctggcaca aaaaccagaa	240
---	-----

ctgtctgcgc agctgactgc tatcggtcac cgtatcgta acggcggcga aaagtatacc	300
--	-----

agctccgtag tgatcgatga gtctgttatt cagggtatca aagatgcagc ttctttgca	360
--	-----

-continued

ccgctgcaca acccggtca cctgatcggt atcgaagaag ctctgaaatc tttcccacag	420
ctgaaagaca aaaacgttgc tgtatttgac accgcgttcc accagactat gccggaagag	480
tcttacctct acgcctgcc ttacaacctg tacaaagagc acggcatccg tcgttacggc	540
gcmcacggca ccagccactt ctatgttaacc caggaagcgg caaaaatgtc gaacaaacccg	600
gtagaagaac tgaacatcat cacctgccac ctggcaacg gtgggtccgt ttctgtatc	660
cgcaacggta aatgcgttga cacctctatg ggccgtaccc cgctggagg tctggtcatg	720
ggtagccgtt ctgggtatcgatcgatccggc atcatcttc acctgcaega caccctgggc	780
atgagcgttg acgcaatcaa caaactgctg accaaagagt ctggcctgct gggtctgacc	840
gaagtgacca gggactgccc ctatgttga gacaactacg cgacgaaaga agacgagaag	900
cgcgcataatgg acgtttactg ccaccgcctg gccaatatac tcgggtcccta cactgcgtg	960
atggatggtc gtctggacgc tggtgtattc actgggtgta tcggtgaaaa tgccgcaatg	1020
gttcgtgaac tgtctctggg caaactgggc gtgtgggtt ttgaagttga tcatgaacgc	1080
aacctggctg cacgtttcgg caaatctgtt ttcatcaaca aagaaggtac cogtcctgcg	1140
gtgggttatcc caaccaacga agaactgggtt atcgcgcaga acgcgagccg cctgactgcc	1200
tga	1203

<210> SEQ ID NO 14

<211> LENGTH: 400

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 14

Met Ser Ser Lys Leu Val Leu Val Asn Cys Gly Ser Ser Ser Leu			
1	5	10	15

Lys Phe Ala Ile Ile Asp Ala Val Asn Gly Glu Glu Tyr Leu Ser Gly			
20	25	30	

Leu Ala Glu Cys Phe His Leu Pro Glu Ala Arg Ile Lys Trp Lys Met			
35	40	45	

Asp Gly Asn Lys Gln Glu Ala Ala Leu Gly Ala Gly Ala Ala His Ser			
50	55	60	

Glu Ala Leu Asn Phe Ile Val Asn Thr Ile Leu Ala Gln Lys Pro Glu			
65	70	75	80

Leu Ser Ala Gln Leu Thr Ala Ile Gly His Arg Ile Val His Gly Gly			
85	90	95	

Glu Lys Tyr Thr Ser Ser Val Val Ile Asp Glu Ser Val Ile Gln Gly			
100	105	110	

Ile Lys Asp Ala Ala Ser Phe Ala Pro Leu His Asn Pro Ala His Leu			
115	120	125	

Ile Gly Ile Glu Glu Ala Leu Lys Ser Phe Pro Gln Leu Lys Asp Lys			
130	135	140	

Asn Val Ala Val Phe Asp Thr Ala Phe His Gln Thr Met Pro Glu Glu			
145	150	155	160

Ser Tyr Leu Tyr Ala Leu Pro Tyr Asn Leu Tyr Lys Glu His Gly Ile			
165	170	175	

Arg Arg Tyr Gly Ala His Gly Thr Ser His Phe Tyr Val Thr Gln Glu			
180	185	190	

Ala Ala Lys Met Leu Asn Lys Pro Val Glu Glu Leu Asn Ile Ile Thr			
195	200	205	

Cys His Leu Gly Asn Gly Gly Ser Val Ser Ala Ile Arg Asn Gly Lys

US 9,850,505 B2

65**66**

-continued

210	215	220
Cys Val Asp Thr Ser Met Gly Leu Thr Pro Leu Glu Gly Leu Val Met		
225	230	235
Gly Thr Arg Ser Gly Asp Ile Asp Pro Ala Ile Ile Phe His Leu His		
245	250	255
Asp Thr Leu Gly Met Ser Val Asp Ala Ile Asn Lys Leu Leu Thr Lys		
260	265	270
Glu Ser Gly Leu Leu Gly Leu Thr Glu Val Thr Ser Asp Cys Arg Tyr		
275	280	285
Val Glu Asp Asn Tyr Ala Thr Lys Glu Asp Ala Lys Arg Ala Met Asp		
290	295	300
Val Tyr Cys His Arg Leu Ala Lys Tyr Ile Gly Ala Tyr Thr Ala Leu		
305	310	315
Met Asp Gly Arg Leu Asp Ala Val Val Phe Thr Gly Gly Ile Gly Glu		
325	330	335
Asn Ala Ala Met Val Arg Glu Leu Ser Leu Gly Lys Leu Gly Val Leu		
340	345	350
Gly Phe Glu Val Asp His Glu Arg Asn Leu Ala Ala Arg Phe Gly Lys		
355	360	365
Ser Gly Phe Ile Asn Lys Glu Gly Thr Arg Pro Ala Val Val Ile Pro		
370	375	380
Thr Asn Glu Glu Leu Val Ile Ala Gln Asp Ala Ser Arg Leu Thr Ala		
385	390	395
		400

<210> SEQ ID NO 15

<211> LENGTH: 1719

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 15

atgaaaacaaa cggttgcagc ttatatcgcc aaaacactcg aatcgccagg ggtgaaacgc	60
atctggggag tcacaggcga ctctctgaac ggtcttagtg acagtctta tcgcatggc	120
accatcgagt ggatgtccac ccgccacgaa gaagtggccg ccttgcgcgc tggcgctgaa	180
gcacaactta gcgagaact ggccgtctgc gccggatcgt gggccccgg caacctgcac	240
ttaatcaacg gcctgttcga ttgccaccgc aatcacgttc cggtactggc gattgecgct	300
catattccct ccagcgaat tggcagcggc tatttccagg aaacccaccc acaagagcta	360
ttccgcgaat gtatcacta ttgcgagctg gttccagcc cggagcagat cccacaagta	420
ctggcgattt ccatgcgcaa agcggtgctt aaccgtggcg tttcggttgt cgtgttacca	480
ggcgacgtgg cgtaaaacc tgccgcagaa gggcaacca tgcactggta tcatgcgcca	540
caaccagtcg tgacgcgga agaagaagag ttacgcacaa tggcgcaact gtcgcgttat	600
tccagcaata tcgcctgat gtgtggcagc ggctgcgcgg gggcgcataa agatgttagtt	660
gagtttgcgg gaaaaattaa agcgcttattt gttcatgccc tgccgcgtt aaacatgtc	720
gaatacgtata atccgtatga tggatggatg accgggtta tcggcttctc gtcaggttcc	780
cataccatgtatg tgaacgcgca cacgttagtg ctactcgcc cgcacatttcc ctaccgogcc	840
ttctacccga ccgatgcgaa aatcattcag attgatatac acccagccag catcgccgt	900
cacagcaagg tggatgtggc actggtcggc gatatcaagt cgactctgcg tgcattgttt	960
ccatgtggg aagaaaaagc cgatgcgaa tttctggata aagcgctgga agattaccgc	1020
gacgccccca aagggtggc cgatgttgcgaa aacccgagcg agaaagccat tcacccgca	1080

-continued

tatctggcgc agcaaattag tcatttgcc gccgatgacg ctatttcac ctgtgacgtt 1140
 ggtacgcca cggtgtggc ggcacggtt ctaaaaatga acggcaagcg tgcgcgttta 1200
 ggttcggtta accacggttc gatggctaac gccatgccgc aggccgtgg tgccgaggcg 1260
 acagagccag aacgtcaggt ggtcgcattg tgccgcgtg ggggttttag catgttcatg 1320
 ggcgattcc tctcagtgt gcagatgaaa ctgcgcgtg aaattgtcgt cttaacaac 1380
 agegtgtgg gctttgtggc gatggagatg aaagctggt gctatttgc tgacggcacc 1440
 gaactacacg acacaaactt tgccgcatt gccgaagcgt gcccattac gggtatccgt 1500
 gtagaaaaag cgtctgaagt ttagaaagcc ctgcacgcg ctttccat cgacggccg 1560
 gtgttgggtt atgtgggtt cggccaaagaa gagttagcca ttccaccgca gatcaaactc 1620
 gaacaggcga aaggtttcag cctgtatatg ctgcgcgcaaa tcatcagcgg acgcgggtat 1680
 gaaagtgtatcg aactggcgaa aacaaactgg ctaaggtaa 1719

<210> SEQ ID NO 16

<211> LENGTH: 572

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 16

Met	Lys	Gln	Thr	Val	Ala	Ala	Tyr	Ile	Ala	Lys	Thr	Leu	Glu	Ser	Ala
1				5				10				15			

Gly	Val	Lys	Arg	Ile	Trp	Gly	Val	Thr	Gly	Asp	Ser	Leu	Asn	Gly	Leu
				20				25				30			

Ser	Asp	Ser	Leu	Asn	Arg	Met	Gly	Thr	Ile	Glu	Trp	Met	Ser	Thr	Arg
			35			40			45						

His	Glu	Glu	Val	Ala	Ala	Phe	Ala	Ala	Gly	Ala	Glu	Ala	Gln	Leu	Ser
				50			55			60					

Gly	Glu	Leu	Ala	Val	Cys	Ala	Gly	Ser	Cys	Gly	Pro	Gly	Asn	Leu	His
				65			70		75			80			

Leu	Ile	Asn	Gly	Leu	Phe	Asp	Cys	His	Arg	Asn	His	Val	Pro	Val	Leu
				85			90					95			

Ala	Ile	Ala	Ala	His	Ile	Pro	Ser	Ser	Glu	Ile	Gly	Ser	Gly	Tyr	Phe
				100			105			110					

Gln	Glu	Thr	His	Pro	Gln	Glu	Leu	Phe	Arg	Glu	Cys	Ser	His	Tyr	Cys
				115			120			125					

Glu	Leu	Val	Ser	Ser	Pro	Glu	Gln	Ile	Pro	Gln	Val	Leu	Ala	Ile	Ala
				130			135			140					

Met	Arg	Lys	Ala	Val	Leu	Asn	Arg	Gly	Val	Ser	Val	Val	Val	Leu	Pro
	145				150			155			160				

Gly	Asp	Val	Ala	Leu	Lys	Pro	Ala	Pro	Glu	Gly	Ala	Thr	Met	His	Trp
				165			170			175					

Tyr	His	Ala	Pro	Gln	Pro	Val	Val	Thr	Pro	Glu	Glu	Glu	Leu	Arg
				180			185			190				

Lys	Leu	Ala	Gln	Leu	Leu	Arg	Tyr	Ser	Ser	Asn	Ile	Ala	Leu	Met	Cys
				195			200			205					

Gly	Ser	Gly	Cys	Ala	Gly	Ala	His	Lys	Glu	Leu	Val	Glu	Phe	Ala	Gly
				210			215			220					

Lys	Ile	Lys	Ala	Pro	Ile	Val	His	Ala	Leu	Arg	Gly	Lys	Glu	His	Val
	225				230			235			240				

Glu	Tyr	Asp	Asn	Pro	Tyr	Asp	Val	Gly	Met	Thr	Gly	Leu	Ile	Gly	Phe
				245			250			255					

Ser	Ser	Gly	Phe	His	Thr	Met	Met	Asn	Ala	Asp	Thr	Leu	Val	Leu	Leu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

US 9,850,505 B2

69**70**

-continued

260	265	270
Gly Thr Gln Phe Pro Tyr Arg Ala Phe Tyr Pro Thr Asp Ala Lys Ile		
275	280	285
Ile Gln Ile Asp Ile Asn Pro Ala Ser Ile Gly Ala His Ser Lys Val		
290	295	300
Asp Met Ala Leu Val Gly Asp Ile Lys Ser Thr Leu Arg Ala Leu Leu		
305	310	315
320		
Pro Leu Val Glu Glu Lys Ala Asp Arg Lys Phe Leu Asp Lys Ala Leu		
325	330	335
Glu Asp Tyr Arg Asp Ala Arg Lys Gly Leu Asp Asp Leu Ala Lys Pro		
340	345	350
Ser Glu Lys Ala Ile His Pro Gln Tyr Leu Ala Gln Gln Ile Ser His		
355	360	365
Phe Ala Ala Asp Asp Ala Ile Phe Thr Cys Asp Val Gly Thr Pro Thr		
370	375	380
Val Trp Ala Ala Arg Tyr Leu Lys Met Asn Gly Lys Arg Arg Leu Leu		
385	390	395
400		
Gly Ser Phe Asn His Gly Ser Met Ala Asn Ala Met Pro Gln Ala Leu		
405	410	415
Gly Ala Gln Ala Thr Glu Pro Glu Arg Gln Val Val Ala Met Cys Gly		
420	425	430
Asp Gly Gly Phe Ser Met Leu Met Gly Asp Phe Leu Ser Val Val Gln		
435	440	445
Met Lys Leu Pro Val Lys Ile Val Val Phe Asn Asn Ser Val Leu Gly		
450	455	460
Phe Val Ala Met Glu Met Lys Ala Gly Gly Tyr Leu Thr Asp Gly Thr		
465	470	475
480		
Glu Leu His Asp Thr Asn Phe Ala Arg Ile Ala Glu Ala Cys Gly Ile		
485	490	495
Thr Gly Ile Arg Val Glu Lys Ala Ser Glu Val Asp Glu Ala Leu Gln		
500	505	510
Arg Ala Phe Ser Ile Asp Gly Pro Val Leu Val Asp Val Val Ala		
515	520	525
Lys Glu Glu Leu Ala Ile Pro Pro Gln Ile Lys Leu Glu Gln Ala Lys		
530	535	540
Gly Phe Ser Leu Tyr Met Leu Arg Ala Ile Ile Ser Gly Arg Gly Asp		
545	550	555
560		
Glu Val Ile Glu Leu Ala Lys Thr Asn Trp Leu Arg		
565	570	

<210> SEQ ID NO 17

<211> LENGTH: 990

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 17

atgaaactcg ccgtttatag cacaacacag tacgacaaga agtacctgca acaggtaac	60
gagtccttg gcttgagct ggaattttt gacttctgc tgacggaaaa aaccgctaaa	120
actgccaatg gctgcgaagc ggtatgtatt ttctgtaaacg atgacggcag ccggccgtg	180
ctggaaagac tggaaaagca cggcgtaaa tatatcgct tgcgctgtgc cggttcaat	240
aacgtcgacc ttgacgcggc aaaagaactg gggctcaaag tagtccgtgt tccagcctat	300
gatccagagg ccgttgctga acacgccatc ggtatgtga tgacgctgaa ccggcgatt	360

-continued

caccgcgcac atcagcgatcc	420
actatgtatgc	480
cgcatctgaa	540
gcgcgtggaa	600
atctctctgc	660
gatcasatga	720
caggcggcaa	780
gagaacgaa	840
ttccgtcgct	900
cgagaagctc	960
ggcgaaacct	990

<210> SEQ ID NO 18
<211> LENGTH: 329
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli
<220> FEATURE:
<221> NAME/KBY: misc_feature
<222> LOCATION: (222)...(222)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 18

Met Lys Leu Ala Val Tyr Ser Thr Lys Gln Tyr Asp Lys Lys Tyr Leu			
1	5	10	15

Gln Gln Val Asn Glu Ser Phe Gly Phe Glu Leu Glu Phe Phe Asp Phe			
20	25	30	

Leu Leu Thr Glu Lys Thr Ala Lys Thr Ala Asn Gly Cys Glu Ala Val			
35	40	45	

Cys Ile Phe Val Asn Asp Asp Gly Ser Arg Pro Val Leu Glu Glu Leu			
50	55	60	

Lys Lys His Gly Val Lys Tyr Ile Ala Leu Arg Cys Ala Gly Phe Asn			
65	70	75	80

Asn Val Asp Leu Asp Ala Ala Lys Glu Leu Gly Leu Lys Val Val Arg			
85	90	95	

Val Pro Ala Tyr Asp Pro Glu Ala Val Ala Glu His Ala Ile Gly Met			
100	105	110	

Met Met Thr Leu Asn Arg Arg Ile His Arg Ala Tyr Gln Arg Thr Arg			
115	120	125	

Asp Ala Asn Phe Ser Leu Glu Gly Leu Thr Gly Phe Thr Met Tyr Gly			
130	135	140	

Lys Thr Ala Gly Val Ile Gly Thr Gly Lys Ile Gly Val Ala Met Leu			
145	150	155	160

Arg Ile Leu Lys Gly Phe Gly Met Arg Leu Leu Ala Phe Asp Pro Tyr			
165	170	175	

Pro Ser Ala Ala Ala Leu Glu Leu Gly Val Glu Tyr Val Asp Leu Pro			
180	185	190	

Thr Leu Phe Ser Glu Ser Asp Val Ile Ser Leu His Cys Pro Leu Thr			
195	200	205	

Pro Glu Asn Tyr His Leu Leu Asn Glu Ala Ala Phe Asp Xaa Met Lys			
210	215	220	

Asn Gly Val Met Ile Val Asn Thr Ser Arg Gly Ala Leu Ile Asp Ser			
225	230	235	240

-continued

Gln	Ala	Ala	Ile	Glu	Ala	Leu	Lys	Asn	Gln	Lys	Ile	Gly	Ser	Leu	Gly
245					250					255					

Met	Asp	Val	Tyr	Glu	Asn	Glu	Arg	Asp	Leu	Phe	Phe	Glu	Asp	Lys	Ser
260				265					270						

Asn	Asp	Val	Ile	Gln	Asp	Asp	Val	Phe	Arg	Arg	Leu	Ser	Ala	Cys	His
275				280					285						

Asn	Val	Leu	Phe	Thr	Gly	His	Gln	Ala	Phe	Leu	Thr	Ala	Glu	Ala	Leu
290				295					300						

Thr	Ser	Ile	Ser	Gln	Thr	Thr	Leu	Gln	Asn	Leu	Ser	Asn	Leu	Glu	Lys
305				310			315			320					

Gly	Glu	Thr	Cys	Pro	Asn	Glu	Leu	Val							
325															

<210> SEQ ID NO 19

<211> LENGTH: 948

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 19

atgagactca	ggaaatacaa	taaaaagg	tttg	ggatgg	tgt	cattatttgc	aggcactgta		60						
tttgtcagtg	gctgtat	tc	tgcgtgtt	aatccc	aaag	gacagattgg	tctggagcaa		120						
cgttcactga	tactgacggc	at	tttggcc	cctg	atgtt	gatttgc	tcgttattcc	cgcaatcttgc	180						
atggctgttgc	gtttcg	cctg	gaagtaccgt	g	gcg	gcaataa	aagatgctaa	gtacagccccg	240						
aactggtcac	actccaataa	ag	tggaa	agct	gt	gggtctgg	cggtacctat	cttaatcatc	300						
atcttccttgc	cag	tactgac	ctggaaa	acc	actc	acgc	cttc	ttgagcctag	caagccgctg	360					
gcacacgacg	agaagccat	tac	ccatcgaa	gtgg	tttcca	tggactggaa	atgg	tttcc	420						
atctacc	cc	acagg	ggat	tgctacc	tg	aatgaa	atcg	tttcc	cc	480					
gtgtacttca	aa	gtgac	ctc	caact	ccgt	atgaa	ctc	tctt	catttcc	540					
agccagattt	at	gcat	ggc	cggtat	gc	actc	gc	tc	tcgt	600					
ggcacttat	tg	cc	acgg	atctc	tc	agc	ggcc	tc	tcagg	660					
aaagctt	ca	acac	ccg	tc	gc	ttc	gacc	agt	ggt	720					
tcgccaaca	cc	atgt	ctg	ca	tg	ggaaa	aa	tc	cg	780					
aaccagg	tg	aa	at	tttctc	ca	acgt	gaaa	cc	agacttgc	840					
tttatgg	tc	acgg	ta	agag	catg	ggac	atc	cc	aa	900					
gaagg	tg	aa	gg	catg	ga	catg	gccc	cc	attaa	948					

<210> SEQ ID NO 20

<211> LENGTH: 315

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 20

Met	Arg	Leu	Arg	Lys	Tyr	Asn	Lys	Ser	Leu	Gly	Trp	Leu	Ser	Leu	Phe
1															

Ala	Gly	Thr	Val	Leu	Leu	Ser	Gly	Cys	Asn	Ser	Ala	Leu	Leu	Asp	Pro
20					25					30					

Lys	Gly	Gln	Ile	Gly	Leu	Glu	Gln	Arg	Ser	Leu	Ile	Leu	Thr	Ala	Phe
35					40					45					

Gly	Leu	Met	Leu	Ile	Val	Val	Ile	Pro	Ala	Ile	Leu	Met	Ala	Val	Gly
50					55					60					

Phe Ala Trp Lys Tyr Arg Ala Ser Asn Lys Asp Ala Lys Tyr Ser Pro

US 9,850,505 B2

75

76

-continued

65	70	75	80
Asn Trp Ser His Ser Asn Lys Val Glu Ala Val Val Trp Thr Val Pro			
85	90		95
Ile Leu Ile Ile Ile Phe Leu Ala Val Leu Thr Trp Lys Thr Thr His			
100	105		110
Ala Leu Glu Pro Ser Lys Pro Leu Ala His Asp Glu Lys Pro Ile Thr			
115	120		125
Ile Glu Val Val Ser Met Asp Trp Lys Trp Phe Phe Ile Tyr Pro Glu			
130	135		140
Gln Gly Ile Ala Thr Val Asn Glu Ile Ala Phe Pro Ala Asn Thr Pro			
145	150	155	160
Val Tyr Phe Lys Val Thr Ser Asn Ser Val Met Asn Ser Phe Phe Ile			
165	170		175
Pro Arg Leu Gly Ser Gln Ile Tyr Ala Met Ala Gly Met Gln Thr Arg			
180	185		190
Leu His Leu Ile Ala Asn Glu Pro Gly Thr Tyr Asp Gly Ile Ser Ala			
195	200		205
Ser Tyr Ser Gly Pro Gly Phe Ser Gly Met Lys Phe Lys Ala Ile Ala			
210	215		220
Thr Pro Asp Arg Ala Ala Phe Asp Gln Trp Val Ala Lys Ala Lys Gln			
225	230	235	240
Ser Pro Asn Thr Met Ser Asp Met Ala Ala Phe Glu Lys Leu Ala Ala			
245	250		255
Pro Ser Glu Tyr Asn Gln Val Glu Tyr Phe Ser Asn Val Lys Pro Asp			
260	265		270
Leu Phe Ala Asp Val Ile Asn Lys Phe Met Ala His Gly Lys Ser Met			
275	280		285
Asp Met Thr Gln Pro Glu Gly Glu His Ser Ala His Glu Gly Met Glu			
290	295	300	
Gly Met Asp Met Ser His Ala Glu Ser Ala His			
305	310		315

<210> SEQ ID NO 21

<211> LENGTH: 1992

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 21

atgttcggaa aattatacact tcatgcgttc ccgttccatg aacctatcgat catggttacg	60
atcgctggca ttatttgggg aggtctggcg ctcgttgccc tgatcactta cttcggtaag	120
tggacctacc tggggaaaga gtggctgacc tccgtcgacc ataaacgcct cggtatcatg	180
tatatacatcg tggcgattgt gatgtactg cgtggttttg ctgacgcatt tatgtatcg	240
agccagcagg ctcttgcctc ggccccgcaa gcgggtttcc tgccacacctca ccactacgat	300
cagatcttca cccgcgcacgg cgtgattatg atcttcttcg tggcgatgcc ttccgttac	360
ggctctgatga acctgggttgt tccgtgcag atcggcgccgc gtgacgttgc gttcccggtc	420
ctcaacaact taagcttctg gtttaccgtt gttgggtgtaa ttctggttaa cgtttctctc	480
ggcgctggcg aatttgcgca gaccggctgg ctggcctatc caccgcatac gggatagag	540
tacagtcggc gagtcggtgt cgattactgg atatggagtc tccagctatc cggtataggt	600
acgacgccta ccggatcaaa cttcttcgtt accattctga agatgcgcgc accggggatg	660
accatgttca agatgcgcagt atttacctgg gcatcactgt gcgcaaacgt actgattatt	720

-continued

<210> SEQ ID NO 22

<211> LENGTH: 663

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 22

Met	Phe	Gly	Lys	Leu	Ser	Leu	Asp	Ala	Val	Pro	Phe	His	Glu	Pro	Ile
1				5					10					15	

Val Met Val Thr Ile Ala Gly Ile Ile Leu Gly Gly Leu Ala Leu Val
20 25 30

Gly Leu Ile Thr Tyr Phe Gly Lys Trp Thr Tyr Leu Trp Lys Glu Trp
 35 40 45

Leu Thr Ser Val Asp His Lys Arg Leu Gly Ile Met Tyr Ile Ile Val
50 55 60

Ala Ile Val Met Leu Leu Arg Gly Phe Ala Asp Ala Ile Met Met Arg
65 70 75 80

Ser Gln Gln Ala Leu Ala Ser Ala Gly Glu Ala Gly Phe Leu Pro Pro
85 90 95

His	His	Tyr	Asp	Gln	Ile	Phe	Thr	Ala	His	Gly	Val	Ile	Met	Ile	Phe
100								105					110		

Phe Val Ala Met Pro Phe Val Ile Gly Leu Met Asn Leu Val Val Pro
115 120 125

Leu Gln Ile Gly Ala Arg Asp Val Ala Phe Pro Phe Leu Asn Asn Leu
 130 135 140

US 9,850,505 B2

79

80

-continued

Ser Phe Trp Phe Thr Val Val Gly Val Ile Leu Val Asn Val Ser Leu
 145 150 155 160
 Gly Val Gly Glu Phe Ala Gln Thr Gly Trp Leu Ala Tyr Pro Pro Leu
 165 170 175
 Ser Gly Ile Glu Tyr Ser Pro Gly Val Gly Val Asp Tyr Trp Ile Trp
 180 185 190
 Ser Leu Gln Leu Ser Gly Ile Gly Thr Thr Leu Thr Gly Ile Asn Phe
 195 200 205
 Phe Val Thr Ile Leu Lys Met Arg Ala Pro Gly Met Thr Met Phe Lys
 210 215 220
 Met Pro Val Phe Thr Trp Ala Ser Leu Cys Ala Asn Val Leu Ile Ile
 225 230 235 240
 Ala Ser Phe Pro Ile Leu Thr Val Thr Val Ala Leu Leu Thr Leu Asp
 245 250 255
 Arg Tyr Leu Gly Thr His Phe Phe Thr Asn Asp Met Gly Gly Asn Met
 260 265 270
 Met Met Tyr Ile Asn Leu Ile Trp Ala Trp Gly His Pro Glu Val Tyr
 275 280 285
 Ile Leu Ile Leu Pro Val Phe Gly Val Phe Ser Glu Ile Ala Ala Thr
 290 295 300
 Phe Ser Arg Lys Arg Leu Phe Gly Tyr Thr Ser Leu Val Trp Ala Thr
 305 310 315 320
 Val Cys Ile Thr Val Leu Ser Phe Ile Val Trp Leu His His Phe Phe
 325 330 335
 Thr Met Gly Ala Gly Ala Asn Val Asn Ala Phe Phe Gly Ile Thr Thr
 340 345 350
 Met Ile Ile Ala Ile Pro Thr Gly Val Lys Ile Phe Asn Trp Leu Phe
 355 360 365
 Thr Met Tyr Gln Gly Arg Ile Val Phe His Ser Ala Met Leu Trp Thr
 370 375 380
 Ile Gly Phe Ile Val Thr Phe Ser Val Gly Gly Met Thr Gly Val Leu
 385 390 395 400
 Leu Ala Val Pro Gly Ala Asp Phe Val Leu His Asn Ser Leu Phe Leu
 405 410 415
 Ile Ala His Phe His Asn Val Ile Ile Gly Gly Val Val Phe Gly Cys
 420 425 430
 Phe Ala Gly Met Thr Tyr Trp Trp Pro Lys Ala Phe Gly Phe Lys Leu
 435 440 445
 Asn Glu Thr Trp Gly Lys Arg Ala Phe Trp Phe Trp Ile Ile Gly Phe
 450 455 460
 Phe Val Ala Phe Met Pro Leu Tyr Ala Leu Gly Phe Met Gly Met Thr
 465 470 475 480
 Arg Arg Leu Ser Gln Gln Ile Asp Pro Gln Phe His Thr Met Leu Met
 485 490 495
 Ile Ala Ala Ser Gly Ala Val Leu Ile Ala Leu Gly Ile Leu Cys Leu
 500 505 510
 Val Ile Gln Met Tyr Val Ser Ile Arg Asp Arg Asp Gln Asn Arg Asp
 515 520 525
 Leu Thr Gly Asp Pro Trp Gly Gly Arg Thr Leu Glu Trp Ala Thr Ser
 530 535 540
 Ser Pro Pro Pro Phe Tyr Asn Phe Ala Val Val Pro His Val His Glu
 545 550 555 560
 Arg Asp Ala Phe Trp Glu Met Lys Glu Lys Gly Glu Ala Tyr Lys Lys

US 9,850,505 B2

81**82**

-continued

565	570	575
-----	-----	-----

Pro Asp His Tyr Glu Glu Ile His Met Pro Lys Asn Ser Gly Ala Gly 580	585	590
--	-----	-----

Ile Val Ile Ala Ala Phe Ser Thr Ile Phe Gly Phe Ala Met Ile Trp 595	600	605
--	-----	-----

His Ile Trp Trp Leu Ala Ile Val Gly Phe Ala Gly Met Ile Ile Thr 610	615	620
--	-----	-----

Trp Ile Val Lys Ser Phe Asp Glu Asp Val Asp Tyr Tyr Val Pro Val 625	630	635	640
--	-----	-----	-----

Ala Glu Ile Glu Lys Leu Glu Asn Gln His Phe Asp Glu Ile Thr Lys 645	650	655
--	-----	-----

Ala Gly Leu Lys Asn Gly Asn 660

<210> SEQ ID NO 23

<211> LENGTH: 615

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 23

atggcaactg atactttgac gcacgcgact gcccacgcgc acgaacacgg gcaccacgat 60
gcaggcggaa caaaaatttt cgatTTTgg atctaccta tgagcgactg cattctgttc 120
tctatcttgt ttgctacctta tgccgttctg gtgaacggca ccgcaggcgg cccgacaggt 180
aaggacattt tcgaactgcc gttcgTTCTG gttgaaactt tcttgctgtt gttcagctcc 240
atcacctatg gcatggcggc tatcgccatg tacaaaaaca acaaaggcca ggtgatctcc 300
tggctggcgt tgacatggtt gtttggtgcc ggatttatcg ggatggaaat ctatgaattc 360
catcacctga ttgttaacgg catgggtccg gatcgacgcg gttcctgtc agcgTTCTT 420
gcgttggcgt gcacgcacgg tctgcacgTC acttccggTC ttatctggat ggcggtgctg 480
atggtgcaaa tcgccccgtcg cggccgtgacc agcactaacc gtacccgcattatgtgtctg 540
agcctgttct ggcacttcct ggatgtggtt tggatctgtg tggatctgtt tgTTTatctg 600
atggggggcga tgtaa 615

<210> SEQ ID NO 24

<211> LENGTH: 204

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 24

Met Ala Thr Asp Thr Leu Thr His Ala Thr Ala His Ala His Glu His 1	5	10	15
--	---	----	----

Gly His His Asp Ala Gly Gly Thr Lys Ile Phe Gly Phe Trp Ile Tyr 20	25	30
---	----	----

Leu Met Ser Asp Cys Ile Leu Phe Ser Ile Leu Phe Ala Thr Tyr Ala 35	40	45
---	----	----

Val Leu Val Asn Gly Thr Ala Gly Gly Pro Thr Gly Lys Asp Ile Phe 50	55	60
---	----	----

Glu Leu Pro Phe Val Leu Val Glu Thr Phe Leu Leu Leu Phe Ser Ser 65	70	75	80
---	----	----	----

Ile Thr Tyr Gly Met Ala Ala Ile Ala Met Tyr Lys Asn Asn Lys Ser 85	90	95
---	----	----

Gln Val Ile Ser Trp Leu Ala Leu Thr Trp Leu Phe Gly Ala Gly Phe 100	105	110
--	-----	-----

-continued

Ile Gly Met Glu Ile Tyr Glu Phe His His Leu Ile Val Asn Gly Met
115 120 125

Gly Pro Asp Arg Ser Gly Phe Leu Ser Ala Phe Phe Ala Leu Val Gly
130 135 140

Thr His Gly Leu His Val Thr Ser Gly Leu Ile Trp Met Ala Val Leu
145 150 155 160

Met Val Gln Ile Ala Arg Arg Gly Leu Thr Ser Thr Asn Arg Thr Arg
165 170 175

Ile Met Cys Leu Ser Leu Phe Trp His Phe Leu Asp Val Val Trp Ile
180 185 190

Cys Val Phe Thr Val Val Tyr Leu Met Gly Ala Met
195 200

<210> SEQ ID NO 25

<211> LENGTH: 330

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 25

atgagtcatt ctaacgtgag cggcgccgcgc tccccatggca gcgtaaaaac ctacatgaca	60
ggcttttatcc tgtcgatcat tctgacggtg attccgttct ggatggtgat gacaggggct	120
gcctctccgg ccgtaattct gggacaatac ctggcaatgg cagtggtaca gattctggtg	180
catctggtgt gttccctgca catgaatacc aaatcagatg aaggctggaa tatgacggca	240
tttgtcttca ccgtgcta at catgccatc ctggttgtgg gctccatttg gattatgtgg	300
aacctcaact acaacatgtat gatgcactaa	330

<210> SEQ ID NO 26

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 26

Met Ser His Ser Asn Val Ser Gly Gly Ala Ser His Gly Ser Val Lys
1 5 10 15

Thr Tyr Met Thr Gly Phe Ile Leu Ser Ile Ile Leu Thr Val Ile Pro
20 25 30

Phe Trp Met Val Met Thr Gly Ala Ala Ser Pro Ala Val Ile Leu Gly
35 40 45

Thr Ile Leu Ala Met Ala Val Val Gln Ile Leu Val His Leu Val Cys
50 55 60

Phe Leu His Met Asn Thr Lys Ser Asp Glu Gly Trp Asn Met Thr Ala
65 70 75 80

Phe Val Phe Thr Val Leu Ile Ala Ile Leu Val Val Gly Ser Ile
85 90 95

Trp Ile Met Trp Asn Leu Asn Tyr Asn Met Met Met His
100 105

<210> SEQ ID NO 27

<211> LENGTH: 891

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 27

atgatgttta agcaataacct gcaagtaacg aaaccaggca tcatcttgg caacctgatc	60
---	----

tcgggtgattg ggggattcct gctggcctca aagggcagca ttgattatcc cctgtttatc	120
--	-----

US 9,850,505 B2

85**86**

-continued

tacacgctgg ttgggttgtc actgggtgtg gcgtcgggtt gtgtgtttaa caactacatc	180
gacagggata tcgacagaaa gatggaaagg acgaagaatc ggggtgctggt gaaaggctg	240
atctctctcg ctgtctcgct ggtgtacgcc acgttgctgg gtattgtctt ctttatgtcg	300
ctgtggtttgc gcgcaatcc gctggcctgc tggctgggg tgatgggctt tgtggtttat	360
gtcggcggtt atagcctgta catgaaacgc cactctgtc acggcacgtt gattgggtcg	420
ctctccggcg ctgcgecgcc ggtgtacggc tactgtgccc taaccgggtga gttcgatagc	480
ggcgccagcga tccgtctggc tatcttcagc ctgtggcaga tgcctcactc ctatgcac	540
gccatttcc gcttaagga ttaccaggcg gcaaacaattt ccgttattgcc agtggtaaaa	600
ggcatttcgg tggcgaagaa tcacatcagc ctgtatataca tgcgccttgc cggtgcac	660
ctgtatgtct ctcttggcg ttacgctggg tataaatatc tggtggtcgc cgccgggtt	720
agcgtctggt ggtaggtat ggctctgcgc ggtataaag ttgctgtatc cagaatctgg	780
gcccccaaggc tggcggctt ctctatcatc gccatcactg ccctctggat gatgtatcc	840
gttgattta tggtaaccggc ctcgcatacg ctgtggctg ctgtgtggta a	891

<210> SEQ ID NO: 28

<211> LENGTH: 296

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 28

Met Met Phe Lys Gln Tyr Leu Gln Val Thr Lys Pro Gly Ile Ile Phe			
1	5	10	15

Gly Asn Leu Ile Ser Val Ile Gly Gly Phe Leu Leu Ala Ser Lys Gly			
20	25	30	

Ser Ile Asp Tyr Pro Leu Phe Ile Tyr Thr Leu Val Gly Val Ser Leu			
35	40	45	

Val Val Ala Ser Gly Cys Val Phe Asn Asn Tyr Ile Asp Arg Asp Ile			
50	55	60	

Asp Arg Lys Met Glu Arg Thr Lys Asn Arg Val Leu Val Lys Gly Leu			
65	70	75	80

Ile Ser Pro Ala Val Ser Leu Val Tyr Ala Thr Leu Leu Gly Ile Ala			
85	90	95	

Gly Phe Met Leu Leu Trp Phe Gly Ala Asn Pro Leu Ala Cys Trp Leu			
100	105	110	

Gly Val Met Gly Phe Val Val Tyr Val Gly Val Tyr Ser Leu Tyr Met			
115	120	125	

Lys Arg His Ser Val Tyr Gly Thr Leu Ile Gly Ser Leu Ser Gly Ala			
130	135	140	

Ala Pro Pro Val Ile Gly Tyr Cys Ala Val Thr Gly Glu Phe Asp Ser			
145	150	155	160

Gly Ala Ala Ile Leu Leu Ala Ile Phe Ser Leu Trp Gln Met Pro His			
165	170	175	

Ser Tyr Ala Ile Ala Ile Phe Arg Phe Lys Asp Tyr Gln Ala Ala Asn			
180	185	190	

Ile Pro Val Leu Pro Val Val Lys Gly Ile Ser Val Ala Lys Asn His			
195	200	205	

Ile Thr Leu Tyr Ile Ile Ala Phe Ala Val Ala Thr Leu Met Leu Ser			
210	215	220	

Leu Gly Gly Tyr Ala Gly Tyr Lys Tyr Leu Val Val Ala Ala Ala Val			
225	230	235	240

-continued

Ser Val Trp Trp Leu Gly Met Ala Leu Arg Gly Tyr Lys Val Ala Asp
245 250 255

Asp Arg Ile Trp Ala Arg Lys Leu Phe Gly Phe Ser Ile Ile Ala Ile
260 265 270

Thr Ala Leu Ser Val Met Met Ser Val Asp Phe Met Val Pro Asp Ser
275 280 285

His Thr Leu Leu Ala Ala Val Trp
290 295

<210> SEQ ID NO 29

<211> LENGTH: 1779

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 29

gtggggtgtg tcatgaaatt gcccagtcaga gaatttgcgt cagttgtat tgggtctggc	60
ggcgccaggta tgcgcgcggc gctgcaaatt tccccatacc gtttctgcgc aagggttat taccgttgcg	120
tctaaagtct tccccggcc ttcccaatacc gtttctgcgc aagggttat taccgttgcg	180
ctgggtataa cccatgaaga taactggaa tggcatatgt acgacaccgt aaaagggtcg	240
gactataatcg gtgaccagga cgcgattgaa tatatgtata aaaccgggcc ggaagcgtt	300
ctggaaactgg aacatatggg cctgcccgttc tcgcgtcttg atgatggtcg tatctatcaa	360
cgtcccggtt gcgggtcagtc gaaaaacttc ggccggcgcgc agggccgcacg tactgcggcg	420
gctggccgacc gtaccggtaa cgcactgttg cacacgctt atcagcagaa cctgaaaaac	480
cacaccacca ttttctccga gtggatgcgc ctggatctgg tgaaaaacca ggtatggcgca	540
gtggtcgggtt gtaccgcact gtgcatacgaa actggtaag tggttactt taaagctcgc	600
gcgcacagtgc tggcgactgg cgccccaggc cgatatttac agtccaccac caacgcccc	660
attaacactg gcgcacgggtt cggcatggct atccgtgcag gcgtaccggt acaggatatg	720
gaaaatgtggc agttccaccc gaccggattt gccggcgccg gcgtactggt caccgaaggt	780
tgcgcgtggc aaggcggtt tctgtgtaaac aaacatggcg aacgcgttat ggaacgttat	840
gcgcgcgaaacg ccaaagaccc ggcggggccgt gacgtgggtt cgcgttccat catgtacgaa	900
atccgtgtaa gccgcggctg tcatgggtccg tggggggccac acgcggaaactt gaaacttgc	960
catctggggaa aagaagttct tgaatcccgt ctgcgggtt tccgtgtaaactt ctcggccacc	1020
ttcgcgtcact ttgtatccggt gaaagagccg attccggtaa tcccaacccgt tcactacatg	1080
atgggcggta ttccgcacca agtgcgggtt caggcgctg ctgtgtaaactt gaaaggcgaa	1140
gatgtgggtt ttccggggctt atttgcgtt ggtgaaatcg ctgtgtatc ggtacatggc	1200
gctaaccgtc tggggccgaa ctcgtgtcg gacctgggtcg tatttgggtcg tgcggcaggt	1260
ctgcgtctgc aagagtctat cggcgacgcg ggccgcactgc ggcgtccag cgagtctgtat	1320
gtagaaggcgt ctctggatcg cctgcgtccgc tggaaacaata accgtaaacgg tgaagatccg	1380
gtggcgatcc gtaaaagact gcaagaatgt atgcagcata acttctcggtt cttccgtgaa	1440
ggtgatgcga tggcgaaagg gcttgcgtt gttgaaatgtt tccgcgcgcg tttgaaaaat	1500
gcccgtctgg atgacacttc aagtggatcc aatacccgac ggcgttgcgtt cctggaaactg	1560
gataaccgtg tggaaacggc gatgcgttgc gctgtttctg ccaacttccg taccgaaac	1620
cgtggcgccgc atagccgtt cggacttcccg gatgcgtatc atgaaaactg gtcgtgcac	1680
tccctgtatc tgccagagtc ggaatccatg acgcggccgaa ggcgtcaacat ggaaccgaaa	1740
ctgcggccggc cattcccgcc gaagattcgt acttactaa	1779

-continued

<210> SEQ ID NO 30
<211> LENGTH: 592
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 30

Met	Gly	Cys	Val	Met	Lys	Leu	Pro	Val	Arg	Glu	Phe	Asp	Ala	Val	Val
1				5				10					15		

Ile	Gly	Ala	Gly	Gly	Ala	Gly	Met	Arg	Ala	Ala	Leu	Gln	Ile	Ser	Gln
				20			25					30			

Ser	Gly	Gln	Thr	Cys	Ala	Leu	Leu	Ser	Lys	Val	Phe	Pro	Thr	Arg	Ser
				35			40				45				

His	Thr	Val	Ser	Ala	Gln	Gly	Gly	Ile	Thr	Val	Ala	Leu	Gly	Asn	Thr
50					55				60						

His	Glu	Asp	Asn	Trp	Glu	Trp	His	Met	Tyr	Asp	Thr	Val	Lys	Gly	Ser
65					70			75			80				

Asp	Tyr	Ile	Gly	Asp	Gln	Asp	Ala	Ile	Glu	Tyr	Met	Cys	Lys	Thr	Gly
				85				90			95				

Pro	Glu	Ala	Ile	Leu	Glu	Leu	Glu	His	Met	Gly	Leu	Pro	Phe	Ser	Arg
				100			105			110					

Leu	Asp	Asp	Gly	Arg	Ile	Tyr	Gln	Arg	Pro	Phe	Gly	Gly	Gln	Ser	Lys
				115			120			125					

Asn	Phe	Gly	Gly	Glu	Gln	Ala	Ala	Arg	Thr	Ala	Ala	Ala	Asp	Arg
				130			135			140				

Thr	Gly	His	Ala	Leu	Leu	His	Thr	Leu	Tyr	Gln	Gln	Asn	Leu	Lys	Asn
145				150			155			160					

His	Thr	Thr	Ile	Phe	Ser	Glu	Trp	Tyr	Ala	Leu	Asp	Leu	Val	Lys	Asn
				165			170			175					

Gln	Asp	Gly	Ala	Val	Val	Gly	Cys	Thr	Ala	Leu	Cys	Ile	Glu	Thr	Gly
				180			185			190					

Glu	Val	Val	Tyr	Phe	Lys	Ala	Arg	Ala	Thr	Val	Leu	Ala	Thr	Gly	Gly
				195			200			205					

Ala	Gly	Arg	Ile	Tyr	Gln	Ser	Thr	Thr	Asn	Ala	His	Ile	Asn	Thr	Gly
				210			215			220					

Asp	Gly	Val	Gly	Met	Ala	Ile	Arg	Ala	Gly	Val	Pro	Val	Gln	Asp	Met
225				230			235			240					

Glu	Met	Trp	Gln	Phe	His	Pro	Thr	Gly	Ile	Ala	Gly	Ala	Gly	Val	Leu
				245			250			255					

Val	Thr	Glu	Gly	Cys	Arg	Gly	Glu	Gly	Tyr	Leu	Leu	Asn	Lys	His	
				260			265			270					

Gly	Glu	Arg	Phe	Met	Glu	Arg	Tyr	Ala	Pro	Asn	Ala	Lys	Asp	Leu	Ala
				275			280			285					

Gly	Arg	Asp	Val	Val	Ala	Arg	Ser	Ile	Met	Ile	Glu	Ile	Arg	Glu	Gly
				290			295			300					

Arg	Gly	Cys	Asp	Gly	Pro	Trp	Gly	Pro	His	Ala	Lys	Leu	Lys	Leu	Asp
305				310			315			320					

His	Leu	Gly	Lys	Glu	Val	Leu	Glu	Ser	Arg	Leu	Pro	Gly	Ile	Leu	Glu
				325			330			335					

Leu	Ser	Arg	Thr	Phe	Ala	His	Val	Asp	Pro	Val	Lys	Glu	Pro	Ile	Pro
				340			345			350					

Val	Ile	Pro	Thr	Cys	His	Tyr	Met	Met	Gly	Gly	Ile	Pro	Thr	Lys	Val
				355			360			365					

Thr Gly Gln Ala Leu Thr Val Asn Glu Lys Gly Glu Asp Val Val Val

US 9,850,505 B2

91**92**

-continued

370	375	380
Pro Gly Leu Phe Ala Val Gly Glu Ile Ala Cys Val Ser Val His Gly		
385	390	395
		400
Ala Asn Arg Leu Gly Gly Asn Ser Leu Leu Asp Leu Val Val Phe Gly		
405	410	415
Arg Ala Ala Gly Leu His Leu Gln Glu Ser Ile Ala Glu Gln Gly Ala		
420	425	430
Leu Arg Asp Ala Ser Glu Ser Asp Val Glu Ala Ser Leu Asp Arg Leu		
435	440	445
Asn Arg Trp Asn Asn Asn Arg Asn Gly Glu Asp Pro Val Ala Ile Arg		
450	455	460
Lys Ala Leu Gln Glu Cys Met Gln His Asn Phe Ser Val Phe Arg Glu		
465	470	475
		480
Gly Asp Ala Met Ala Lys Gly Leu Glu Gln Leu Lys Val Ile Arg Glu		
485	490	495
Arg Leu Lys Asn Ala Arg Leu Asp Asp Thr Ser Ser Glu Phe Asn Thr		
500	505	510
Gln Arg Val Glu Cys Leu Glu Leu Asp Asn Leu Met Glu Thr Ala Tyr		
515	520	525
Ala Thr Ala Val Ser Ala Asn Phe Arg Thr Glu Ser Arg Gly Ala His		
530	535	540
Ser Arg Phe Asp Phe Pro Asp Arg Asp Asp Glu Asn Trp Leu Cys His		
545	550	555
		560
Ser Leu Tyr Leu Pro Glu Ser Glu Ser Met Thr Arg Arg Ser Val Asn		
565	570	575
Met Glu Pro Lys Leu Arg Pro Ala Phe Pro Pro Lys Ile Arg Thr Tyr		
580	585	590

<210> SEQ ID NO 31

<211> LENGTH: 717

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 31

atgagactcg agtttcaat ttatcgctat aaccggatg ttgtatgtgc tccgcgtatg	60
caggattaca cccttggaaac ggaagaaggc cgccgacatcg tgctgcttgc tgccgttatt	120
cagctgaaag agaaagatcc cagcctgtcg ttccggcgct cctggcgatgc aggtgtgtgc	180
ggttccgacg gtctgaacat gaacggtaaq aatggcttgc cctgttattac cccgatttcg	240
gcactcaacc agccggcaa gaagattgtt attcgccccgc tgccaggttt accggtgatc	300
cgcgatttgg tggtagacat gggacaattc tatgcgcaat atgaaaaat taagccttac	360
ctgttgaata atggacaaaatccgcacgt cgccgacatt tacatgtcc agagcagcgc	420
aaaaaaactcg acgggttgc tgaatgtatt ctctgcgcatt gttgttcaac ctcttgcgc	480
tctttcttgc ggaatcccga taagtttgc ggcggcgac gcttgcgttgc ggcataatcg	540
ttccctgtatcg atagccgtca taccgagact gacagccgcc tcgacggttt gagcgatgca	600
ttcagtgtat tccgctgtca cagcatcatcg aactgcgtca gtgttatgtcc gaaggggtcg	660
aacccgacgc gcggccatcgccatcatcaag tcgatgttgt tgcaacgtaa tgcgtaa	717

<210> SEQ ID NO 32

<211> LENGTH: 238

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

-continued

<400> SEQUENCE: 32

Met	Arg	Leu	Glu	Phe	Ser	Ile	Tyr	Arg	Tyr	Asn	Pro	Asp	Val	Asp	Asp
1															15

Ala	Pro	Arg	Met	Gln	Asp	Tyr	Thr	Leu	Glu	Ala	Glu	Glu	Gly	Arg	Asp	
														20	25	30

Met	Met	Leu	Leu	Asp	Ala	Leu	Ile	Gln	Leu	Lys	Glu	Lys	Asp	Pro	Ser	
														35	40	45

Leu	Ser	Phe	Arg	Arg	Ser	Cys	Arg	Glu	Gly	Val	Cys	Gly	Ser	Asp	Gly	
														50	55	60

Leu	Asn	Met	Asn	Gly	Lys	Asn	Gly	Leu	Ala	Cys	Ile	Thr	Pro	Ile	Ser		
														65	70	75	80

Ala	Leu	Asn	Gln	Pro	Gly	Lys	Lys	Ile	Val	Ile	Arg	Pro	Leu	Pro	Gly	
														85	90	95

Leu	Pro	Val	Ile	Arg	Asp	Leu	Val	Val	Asp	Met	Gly	Gln	Phe	Tyr	Ala	
														100	105	110

Gln	Tyr	Glu	Lys	Ile	Lys	Pro	Tyr	Leu	Leu	Asn	Asn	Gly	Gln	Asn	Pro	
														115	120	125

Pro	Ala	Arg	Glu	His	Leu	Gln	Met	Pro	Glu	Gln	Arg	Glu	Lys	Leu	Asp	
														130	135	140

Gly	Leu	Tyr	Glu	Cys	Ile	Leu	Cys	Ala	Cys	Cys	Ser	Thr	Ser	Cys	Pro		
														145	150	155	160

Ser	Phe	Trp	Trp	Asn	Pro	Asp	Lys	Phe	Ile	Gly	Pro	Ala	Gly	Leu	Leu	
														165	170	175

Ala	Ala	Tyr	Arg	Phe	Leu	Ile	Asp	Ser	Arg	Asp	Thr	Glu	Thr	Asp	Ser	
														180	185	190

Arg	Leu	Asp	Gly	Leu	Ser	Asp	Ala	Phe	Ser	Val	Phe	Arg	Cys	His	Ser	
														195	200	205

Ile	Met	Asn	Cys	Val	Ser	Val	Cys	Pro	Lys	Gly	Leu	Asn	Pro	Thr	Arg	
														210	215	220

Ala	Ile	Gly	His	Ile	Lys	Ser	Met	Leu	Leu	Gln	Arg	Asn	Ala			
														225	230	235

<210> SEQ ID NO 33

<211> LENGTH: 405

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 33

atgtggcgct	tattcatgtat	aagaaatgtg	aaaaaaacaaa	gacctgttaa	tctggaccta	60
------------	-------------	------------	-------------	------------	------------	----

cagaccatcc	ggttccccgt	cacggcgata	gcgtccattc	tccatcgctg	ttccgggttg	120
------------	------------	------------	------------	------------	------------	-----

atcaccttgc	ttgcagtgccc	catcctgctg	tggcttctgg	gtaccagcct	ctcttccct	180
------------	-------------	------------	------------	------------	-----------	-----

gaagggttcg	agcaagcttc	cgcgattatg	ggcagctt	tgcgtcaatt	tatcatgtgg	240
------------	------------	------------	----------	------------	------------	-----

ggcattcctta	ccgctctggc	atatcacgtc	gtcgtaggtt	ttcgccacat	gatgtatggat	300
-------------	------------	------------	------------	------------	-------------	-----

tttggctatc	tggaaagaaac	attcgaagcg	ggtaaacgct	ccgcacaaat	ctcccttggtt	360
------------	-------------	------------	------------	------------	-------------	-----

attactgtcg	tgcgttcaact	tctcgacgga	gtcctcgat	ggtaa		405
------------	-------------	------------	-----------	-------	--	-----

<210> SEQ ID NO 34

<211> LENGTH: 134

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 34

Met	Trp	Ala	Leu	Phe	Met	Ile	Arg	Asn	Val	Lys	Lys	Gln	Arg	Pro	Val		
1															5	10	15

US 9,850,505 B2

95**96**

-continued

Asn Leu Asp Leu Gln Thr Ile Arg Phe Pro Val Thr Ala Ile Ala Ser
 20 25 30

Ile Leu His Arg Val Ser Gly Val Ile Thr Phe Val Ala Val Gly Ile
 35 40 45

Leu Leu Trp Leu Leu Gly Thr Ser Leu Ser Ser Pro Glu Gly Phe Glu
 50 55 60

Gln Ala Ser Ala Ile Met Gly Ser Phe Phe Val Lys Phe Ile Met Trp
 65 70 75 80

Gly Ile Leu Thr Ala Leu Ala Tyr His Val Val Val Gly Ile Arg His
 85 90 95

Met Met Met Asp Phe Gly Tyr Leu Glu Glu Thr Phe Glu Ala Gly Lys
 100 105 110

Arg Ser Ala Lys Ile Ser Phe Val Ile Thr Val Val Leu Ser Leu Leu
 115 120 125

Ala Gly Val Leu Val Trp
 130

<210> SEQ ID NO 35

<211> LENGTH: 348

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 35

```
atggtaagca acgcctccgc attaggacgc aatggcgta c atgatttcat ctcgttcgt 60
gctaccgcta tcgtcctgac gctctacata atttatatgg tccggttttt cgctaccagt 120
ggcgagctga catatgaagt ctggattggt ttcttcgcct ctgcgttcac caaagtgttc 180
accctgtgg cgctgttttca tatcttgatc catgcctggc tcggcatgtg gcagggtttg 240
accgactacg ttaaacccgct ggccttgccc ctgatgctgc aactggtgat tgtcgttgc 300
ctggtggtttt acgtgattta tggattcggtt gtgggtgtggg gtgtgtga 348
```

<210> SEQ ID NO 36

<211> LENGTH: 115

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 36

Met Val Ser Asn Ala Ser Ala Leu Gly Arg Asn Gly Val His Asp Phe
 1 5 10 15

Ile Leu Val Arg Ala Thr Ala Ile Val Leu Thr Leu Tyr Ile Ile Tyr
 20 25 30

Met Val Gly Phe Phe Ala Thr Ser Gly Glu Leu Thr Tyr Glu Val Trp
 35 40 45

Ile Gly Phe Phe Ala Ser Ala Phe Thr Lys Val Phe Thr Leu Leu Ala
 50 55 60

Leu Phe Ser Ile Leu Ile His Ala Trp Ile Gly Met Trp Gln Val Leu
 65 70 75 80

Thr Asp Tyr Val Lys Pro Leu Ala Leu Arg Leu Met Leu Gln Leu Val
 85 90 95

Ile Val Val Ala Leu Val Val Tyr Val Ile Tyr Gly Phe Val Val Val
 100 105 110

Trp Gly Val
 115

<210> SEQ ID NO 37

US 9,850,505 B2

97**98**

-continued

<211> LENGTH: 1407
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<400> SEQUENCE: 37

atgtcaaagc	aacagatcg	cgttagtcgg	atggcagtga	tggggcgca	ccttgcgctc	60
aacatcgaaa	gtcgtggta	taccgtctct	attttcaacc	gttcccgtga	aaagacggaa	120
gaagtgattg	ccgaaaatcc	aggcaaaaaa	ctgggttcctt	actatacgg	gaaagagttt	180
gttgaatctc	tggaaacgcc	tcgtcgcatc	ctgttaatgg	tgaaagcagg	tgcaggcacf	240
gatgctgcta	ttgattccct	caagccatac	ctcgataaag	gtgacatcat	cattgatgg	300
ggttaatacct	tcttccagga	caccattcgt	cgtaaccgtg	agctttctgc	cgaaggctt	360
aacttcattt	gtacccgtgt	ctccgggtgt	gaagaaggcg	cgctgaaagg	tccttccatt	420
atgcctggtg	ggcagaaaaga	agcctatgaa	cttggcgcgc	cgatcctgac	caaaatcgcc	480
gcagtggctg	aagacggtga	gccatgcgtt	acctatattt	gtgccgatgg	cgcaggcac	540
tatgtgaaga	tggttcacaa	cggttattgaa	tacggagata	tgcaactgat	tgctgaagcc	600
tattctctgc	ttaaagggtgg	cctgaacctc	accaacgaa	aactggcgc	gacccttacc	660
gagtggaata	acggtaact	gagcagctac	ctgatcgaca	tcaccaaaga	tatcttacc	720
aaaaaaagatg	aagatggtaa	ctacctgggt	gatgtgatcc	tggatgaagc	agcaaacaaa	780
ggcacgggca	aatggaccag	ccagagtgc	ctggatctcg	gcgaaccgt	gtcgctgatt	840
accgagtctg	tgtttgcacg	ttatatctct	tctctgaaag	atcagctgt	tgccgcatt	900
aaagttctct	ctggcccgca	agcacagcca	gcaggcgaca	aggctgagtt	catcgaaaaa	960
gttcgcgcgt	cgctgtatct	tggcaaaatc	gtttcttacg	ctcaggcgtt	ctctcagctg	1020
cgtgctgcgt	ctgaagagta	caactggat	ctgaactac	gtgaaatgc	gaagatttc	1080
cgtgctggct	gcatcatccg	tgcgcaagttc	ctgcagaaaa	tcaccgatgc	ttatgcccga	1140
aatcccgaga	tcgctaacct	gctgtggct	ccgtacttca	agcaaattgc	cgatgactac	1200
cagcaggcgc	tgcgtgatgt	cggtgttat	gcagtagaca	acggtatccc	ggttccgacc	1260
ttcgcgcgt	cggttgccct	ttacgatagc	taccgtgcc	ctgttctgc	tgcgaacctg	1320
atccaggcac	agcgtgacta	ttccgggtca	catacttata	agcgcattga	taaagaaggt	1380
gtgttccata	ctgaatggct	ggattaa				1407

<210> SEQ ID NO 38
<211> LENGTH: 468
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli
<400> SEQUENCE: 38

Met	Ser	Lys	Gln	Gln	Ile	Gly	Val	Val	Gly	Met	Ala	Val	Met	Gly	Arg
1					5			10			15				
Asn	Leu	Ala	Leu	Asn	Ile	Glu	Ser	Arg	Gly	Tyr	Thr	Val	Ser	Ile	Phe
					20			25			30				
Asn	Arg	Ser	Arg	Glu	Lys	Thr	Glu	Glu	Val	Ile	Ala	Glu	Asn	Pro	Gly
	35				40				45						
Lys	Lys	Leu	Val	Pro	Tyr	Tyr	Thr	Val	Lys	Glu	Phe	Val	Glu	Ser	Leu
					50			55			60				
Glu	Thr	Pro	Arg	Arg	Ile	Leu	Leu	Met	Val	Lys	Ala	Gly	Ala	Gly	Thr
	65				70				75			80			
Asp	Ala	Ala	Ile	Asp	Ser	Leu	Lys	Pro	Tyr	Leu	Asp	Lys	Gly	Asp	Ile
					85				90			95			

US 9,850,505 B2

99**100**

-continued

Ile Ile Asp Gly Gly Asn Thr Phe Phe Gln Asp Thr Ile Arg Arg Asn
 100 105 110

Arg Glu Leu Ser Ala Glu Gly Phe Asn Phe Ile Gly Thr Gly Val Ser
 115 120 125

Gly Gly Glu Glu Gly Ala Leu Lys Gly Pro Ser Ile Met Pro Gly Gly
 130 135 140

Gln Lys Glu Ala Tyr Glu Leu Val Ala Pro Ile Leu Thr Lys Ile Ala
 145 150 155 160

Ala Val Ala Glu Asp Gly Glu Pro Cys Val Thr Tyr Ile Gly Ala Asp
 165 170 175

Gly Ala Gly His Tyr Val Lys Met Val His Asn Gly Ile Glu Tyr Gly
 180 185 190

Asp Met Gln Leu Ile Ala Glu Ala Tyr Ser Leu Leu Lys Gly Gly Leu
 195 200 205

Asn Leu Thr Asn Glu Glu Leu Ala Gln Thr Phe Thr Glu Trp Asn Asn
 210 215 220

Gly Glu Leu Ser Ser Tyr Leu Ile Asp Ile Thr Lys Asp Ile Phe Thr
 225 230 235 240

Lys Lys Asp Glu Asp Gly Asn Tyr Leu Val Asp Val Ile Leu Asp Glu
 245 250 255

Ala Ala Asn Lys Gly Thr Gly Lys Trp Thr Ser Gln Ser Ala Leu Asp
 260 265 270

Leu Gly Glu Pro Leu Ser Leu Ile Thr Glu Ser Val Phe Ala Arg Tyr
 275 280 285

Ile Ser Ser Leu Lys Asp Gln Arg Val Ala Ala Ser Lys Val Leu Ser
 290 295 300

Gly Pro Gln Ala Gln Pro Ala Gly Asp Lys Ala Glu Phe Ile Glu Lys
 305 310 315 320

Val Arg Arg Ala Leu Tyr Leu Gly Lys Ile Val Ser Tyr Ala Gln Gly
 325 330 335

Phe Ser Gln Leu Arg Ala Ala Ser Glu Glu Tyr Asn Trp Asp Leu Asn
 340 345 350

Tyr Gly Glu Ile Ala Lys Ile Phe Arg Ala Gly Cys Ile Ile Arg Ala
 355 360 365

Gln Phe Leu Gln Lys Ile Thr Asp Ala Tyr Ala Glu Asn Pro Gln Ile
 370 375 380

Ala Asn Leu Leu Leu Ala Pro Tyr Phe Lys Gln Ile Ala Asp Asp Tyr
 385 390 395 400

Gln Gln Ala Leu Arg Asp Val Val Ala Tyr Ala Val Gln Asn Gly Ile
 405 410 415

Pro Val Pro Thr Phe Ala Ala Ala Val Ala Tyr Tyr Asp Ser Tyr Arg
 420 425 430

Ala Ala Val Leu Pro Ala Asn Leu Ile Gln Ala Gln Arg Asp Tyr Phe
 435 440 445

Gly Ala His Thr Tyr Lys Arg Ile Asp Lys Glu Gly Val Phe His Thr
 450 455 460

Glu Trp Leu Asp
 465

<210> SEQ ID NO 39

<211> LENGTH: 1344

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

US 9,850,505 B2

101**102**

-continued

<400> SEQUENCE: 39

atggatcaga catattctct ggagtcatc ctcaccatg tccaaaagcg cgaccgaaat	60
caaaccgagt tcgcgcaga cgttcgtgaa gtaatgacca cactctggcc ttttcttcaa	120
caaataatccaa aataatgcaca gatgtcatta ctggagcgctc tggttgaacc ggagcgctg	180
atccagttc gctgttgatg ggttgcgtatc cgcaaccaga tacaggtaa ccgtgcattgg	240
cgtgtgcagt tcagctctgc catcgcccg tacaaggcg gatgcgtt ccatccgtca	300
gttaaccttt ccattctcaa attcctcgcc tttgaacaaa cttcaaaaaa tgccctgact	360
actctgccga tggcggtgg taaaggcgcc agcgatttc atccgaaagg aaaaagcgaa	420
ggtgaagtga tgcgttttg ccaggcgctg atgactgaac tgtatcgcca cctggcg	480
gataccgacg ttccggcagg tgcatacg gttgggtggc tgtaaggctgg ctttatggcg	540
gggatgtga aaaagctctc caacaataacc gcctgcgtct tcaccggtaa gggccttca	600
tttggcgca gtcttattcg cccggaaagct accggctacg gtctggtttta tttcacagaa	660
gcaatgcata aacgccacgg tatgggtttt gaaggatgc gcgttccgt ttctggctcc	720
ggcaacgtcg cccagtagcgc tatcgaaaaa gcgatggaa ttgggtgcgtc tgtgatcact	780
gcgtcagact ccagcgccac tgcgttgtatc gaaagcgat tcacgaaaga gaaactggca	840
cgtcttatcg aaatcaaagc cagccgcgc tatgggtgc ggtcgactgg cagattacgc caaagaattt	900
ggtctggctc atctcgaaagg ccaacagccg tggctctac cgggtgatata cgccctgcct	960
tgcgccaccc agaatgaaact ggtatgtgc gcccgcgc acgttatcgc taatggcg	1020
aaagccgtcg ccgaaggggc aaatatgcgc accaccatcg aagcgactga actgttccag	1080
caggcaggcg tactatggc accgggtaaa gcggctaattg ctgggtggcg cgtacatcg	1140
ggcctggaaa tggcacaaaa cgctgcgcgc ctggctggaa aagccgagaa agttgacgca	1200
cgtttgcac acatcatgct ggtatccac catgcctgtt ttgagcatgg tggtgaaggt	1260
gagcaaacc aactacgtgca gggcgcaac attgcccggg ttgtgaaggt tgccgatgcg	1320
atgcgtggcgc agggtgtat ttaa	1344

<210> SEQ ID NO 40

<211> LENGTH: 447

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 40

Met Asp Gln Thr Tyr Ser Leu Glu Ser Phe Leu Asn His Val Gln Lys			
1	5	10	15
Arg Asp Pro Asn Gln Thr Glu Phe Ala Gln Ala Val Arg Glu Val Met			
20	25	30	
Thr Thr Leu Trp Pro Phe Leu Glu Gln Asn Pro Lys Tyr Arg Gln Met			
35	40	45	
Ser Leu Leu Glu Arg Leu Val Glu Pro Glu Arg Val Ile Gln Phe Arg			
50	55	60	
Val Val Trp Val Asp Asp Arg Asn Gln Ile Gln Val Asn Arg Ala Trp			
65	70	75	80
Arg Val Gln Phe Ser Ser Ala Ile Gly Pro Tyr Lys Gly Gly Met Arg			
85	90	95	
Phe His Pro Ser Val Asn Leu Ser Ile Leu Lys Phe Leu Gly Phe Glu			
100	105	110	
Gln Thr Phe Lys Asn Ala Leu Thr Thr Leu Pro Met Gly Gly Lys			
115	120	125	

US 9,850,505 B2

103

104

-continued

Gly Gly Ser Asp Phe Asp Pro Lys Gly Lys Ser Glu Gly Glu Val Met
130 135 140

Arg Phe Cys Gln Ala Leu Met Thr Glu Leu Tyr Arg His Leu Gly Ala
145 150 155 160

Asp Thr Asp Val Pro Ala Gly Asp Ile Gly Val Gly Gly Arg Glu Val
165 170 175

Gly Phe Met Ala Gly Met Met Lys Lys Leu Ser Asn Asn Thr Ala Cys
180 185 190

Val Phe Thr Gly Lys Leu Ser Phe Gly Gly Ser Leu Ile Arg Pro
195 200 205

Glu Ala Thr Gly Tyr Gly Leu Val Tyr Phe Thr Glu Ala Met Leu Lys
210 215 220

Arg His Gly Met Gly Phe Glu Gly Met Arg Val Ser Val Ser Gly Ser
225 230 235 240

Gly Asn Val Ala Gln Tyr Ala Ile Glu Lys Ala Met Glu Phe Gly Ala
245 250 255

Arg Val Ile Thr Ala Ser Asp Ser Ser Gly Thr Val Val Asp Glu Ser
260 265 270

Gly Phe Thr Lys Glu Lys Leu Ala Arg Leu Ile Glu Ile Lys Ala Ser
275 280 285

Arg Asp Gly Arg Val Ala Asp Tyr Ala Lys Glu Phe Gly Leu Val Tyr
290 295 300

Leu Glu Gly Gln Gln Pro Trp Ser Leu Pro Val Asp Ile Ala Leu Pro
305 310 315 320

Cys Ala Thr Gln Asn Glu Leu Asp Val Asp Ala Ala His Gln Leu Ile
325 330 335

Ala Asn Gly Val Lys Ala Val Ala Glu Gly Ala Asn Met Pro Thr Thr
340 345 350

Ile Glu Ala Thr Glu Leu Phe Gln Gln Ala Gly Val Leu Phe Ala Pro
355 360 365

Gly Lys Ala Ala Asn Ala Gly Gly Val Ala Thr Ser Gly Leu Glu Met
370 375 380

Ala Gln Asn Ala Ala Arg Leu Gly Trp Lys Ala Glu Lys Val Asp Ala
385 390 395 400

Arg Leu His His Ile Met Leu Asp Ile His His Ala Cys Val Glu His
405 410 415

Gly Gly Glu Gly Glu Gln Thr Asn Tyr Val Gln Gly Ala Asn Ile Ala
420 425 430

Gly Phe Val Lys Val Ala Asp Ala Met Leu Ala Gln Gly Val Ile
435 440 445

<210> SEQ ID NO 41

<211> LENGTH: 2283

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 41

atgtccgagc ttaataaaaa gtttagccaca gcctggaaag gtttaccaa aggtgactgg 60

cagaatgaag taaacgtccg tgacttcatt cagaaaaact acactccgta cgagggtgac 120

gagtccttcc tggctggcgc tactgaagcg accaccaccc tgtggacaa agtaatggaa 180

ggcgttaaac tggaaaacgg cactcacgacg ccagttgact ttgacaccgc tggcttcc 240

accatcacct ctcacgacgc tggctacatc aacaaggcgc ttgagaaaat cgttggctcg 300

US 9,850,505 B2

105**106**

-continued

cagactgaag ctccgctgaa acgtgctt atcccgatcg gtggtatcaa aatgatcgaa	360
gtttcctgca aagcgtacaa ccgcgactg gatccgatcg tcaaaaaat cttcaactgaa	420
taccgtaaaa ctcacaacca gggcgtgttc gacgtttaca ctccggacat cctgcgttgc	480
cgttaatctg gtgttctgac cggtctgcca gatgcatatg gccgtggccg tatcatcggt	540
gactaccgtc cggttgcgtc gtacggatc gactacctg tgaaagacaa actggcacag	600
ttcaaccttc tgcaggctga tctggaaaac ggcttaaacc tgaaacagac tatccgtctg	660
cgcgaagaaa tcgctgaaca gcaccgcgtc ctgggtcaga tgaaagaaat ggctgcgaaa	720
taecccgtacg acatctctgg tccggcttacc aacgctcagg aagctatcca gtggacttac	780
ttcggctacc tggctgtgt taagtcttag aacgggtctg caatgtccctt cggtcgttacc	840
tccacccccc tggatgtgtt catcgaaatc gacctgaaag ctggcaagat caccgaacaa	900
gaagcgcagg aaatggttga ccacctggtc atgaaactgc gtatggatcg cttccgtcgt	960
actccggaaat acgatgaaact gttctctggc gacccgatct gggcaaccga atctatcggt	1020
ggtatggccc tcgacggcgtc taccctgggtt accaaaaaaca gttccgttt cctgaacacc	1080
ctgtacccca tgggtccgtc tccggaaatc aacatgacca ttctgtggtc tgaaaaactg	1140
ccgctgaact tcaagaaatt cgccgctaaa gtgtccatcg acaccttcc tctgcgttat	1200
gagaacgatg acctgatgctg tccggacttc aacaacgatg actacgctat tgcttgctgc	1260
gtaagccccgta tgatcggtt taaacaaatg cagttcttcg gtgcgcgtgc aaacctggcg	1320
aaaaccatgc tgcgtcaat caacggccggc gttgacgaaa aactgaaaat gcagggttgg	1380
ccgaagtctg aaccgatcaa aggcgatgtc ctgaactatg atgaagtgtat ggagcgcgtat	1440
gatcaactca tggactggct ggctaaacag tacatcaatg cactgaacat catccactac	1500
atgcacgaca agtacgacta cgaacgcctct ctgtatggcgtc tgacacgaccc tgacgttac	1560
cgcaccatgg cgtgtggat cgcgtgtctg tccgttgcgtc ctgactccct gtctgcaatc	1620
aaatatgcga aagttaaacc gattcgtgac gaagacggtc tggctatcga cttcgaaatc	1680
gaaggcgaat acccgagtt tggtaacaat gatccgcgtg tagatgaccc ggctgttgc	1740
ctggtagaac gtttcatgaa gaaaattcgt aactgcaca cctaccgtga cgctatcccg	1800
actcaagtctg ttctgaccat cacttctaaat gttgtgtatg gtaagaaaac gggtaaacacc	1860
ccagacggcgtc gtcgtgttgg cgcgcgggtc ggacccgggtg ctaaccgtat gcacggcgt	1920
gaccagaaat gtcgtactgact tccgttgcata aactgccgtt tgcttacgt	1980
aaagatggta tctcttacac cttctctatc gttccgttacg cactggtaa agacgacgaa	2040
gttcgttaaga ccaacctggc tggctgtatg gatggttact tccaccacga agcatccatc	2100
gaaggtggtc agcacctgaa cgttaacgtg atgaaccgtg aatgtctgtc cgacgacgt	2160
aaaaacccgg aaaaatatcc gcagctgacc atccgtgtat ctggctacgc agtacgttcc	2220
aactcgtgaa ctaaagaaca gcagcaggac gtttattactc gtacccatc tcaatctatg	2280
taa	2283

<210> SEQ ID NO 42

<211> LENGTH: 760

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 42

Met	Ser	Glu	Leu	Asn	Glu	Lys	Leu	Ala	Thr	Ala	Trp	Glu	Gly	Phe	Thr
1							5			10				15	

US 9,850,505 B2

107

-continued

108

Lys Gly Asp Trp Gln Asn Glu Val Asn Val Arg Asp Phe Ile Gln Lys
 20 25 30

Asn Tyr Thr Pro Tyr Glu Gly Asp Glu Ser Phe Leu Ala Gly Ala Thr
 35 40 45

Glu Ala Thr Thr Thr Leu Trp Asp Lys Val Met Glu Gly Val Lys Leu
 50 55 60

Glu Asn Arg Thr His Ala Pro Val Asp Phe Asp Thr Ala Val Ala Ser
 65 70 75 80

Thr Ile Thr Ser His Asp Ala Gly Tyr Ile Asn Lys Gln Leu Glu Lys
 85 90 95

Ile Val Gly Leu Gln Thr Glu Ala Pro Leu Lys Arg Ala Leu Ile Pro
 100 105 110

Phe Gly Gly Ile Lys Met Ile Glu Gly Ser Cys Lys Ala Tyr Asn Arg
 115 120 125

Glu Leu Asp Pro Met Ile Lys Lys Ile Phe Thr Glu Tyr Arg Lys Thr
 130 135 140

His Asn Gln Gly Val Phe Asp Val Tyr Thr Pro Asp Ile Leu Arg Cys
 145 150 155 160

Arg Lys Ser Gly Val Leu Thr Gly Leu Pro Asp Ala Tyr Gly Arg Gly
 165 170 175

Arg Ile Ile Gly Asp Tyr Arg Arg Val Ala Leu Tyr Gly Ile Asp Tyr
 180 185 190

Leu Met Lys Asp Lys Leu Ala Gln Phe Thr Ser Leu Gln Ala Asp Leu
 195 200 205

Glu Asn Gly Val Asn Leu Glu Gln Thr Ile Arg Leu Arg Glu Glu Ile
 210 215 220

Ala Glu Gln His Arg Ala Leu Gly Gln Met Lys Glu Met Ala Ala Lys
 225 230 235 240

Tyr Gly Tyr Asp Ile Ser Gly Pro Ala Thr Asn Ala Gln Glu Ala Ile
 245 250 255

Gln Trp Thr Tyr Phe Gly Tyr Leu Ala Ala Val Lys Ser Gln Asn Gly
 260 265 270

Ala Ala Met Ser Phe Gly Arg Thr Ser Thr Phe Leu Asp Val Tyr Ile
 275 280 285

Glu Arg Asp Leu Lys Ala Gly Lys Ile Thr Glu Gln Glu Ala Gln Glu
 290 295 300

Met Val Asp His Leu Val Met Lys Leu Arg Met Val Arg Phe Leu Arg
 305 310 315 320

Thr Pro Glu Tyr Asp Glu Leu Phe Ser Gly Asp Pro Ile Trp Ala Thr
 325 330 335

Glu Ser Ile Gly Gly Met Gly Leu Asp Gly Arg Thr Leu Val Thr Lys
 340 345 350

Asn Ser Phe Arg Phe Leu Asn Thr Leu Tyr Thr Met Gly Pro Ser Pro
 355 360 365

Glu Pro Asn Met Thr Ile Leu Trp Ser Glu Lys Leu Pro Leu Asn Phe
 370 375 380

Lys Lys Phe Ala Ala Lys Val Ser Ile Asp Thr Ser Ser Leu Gln Tyr
 385 390 395 400

Glu Asn Asp Asp Leu Met Arg Pro Asp Phe Asn Asn Asp Asp Tyr Ala
 405 410 415

Ile Ala Cys Cys Val Ser Pro Met Ile Val Gly Lys Gln Met Gln Phe
 420 425 430

Phe Gly Ala Arg Ala Asn Leu Ala Lys Thr Met Leu Tyr Ala Ile Asn

US 9,850,505 B2

109

-continued

110

435	440	445
Gly	Gly	Val Asp Glu Lys Leu Lys Met Gln Val Gly Pro Lys Ser Glu
450	455	460
Pro Ile Lys Gly Asp Val Leu Asn Tyr Asp Glu Val Met Glu Arg Met		
465	470	475 480
Asp His Phe Met Asp Trp Leu Ala Lys Gln Tyr Ile Thr Ala Leu Asn		
485	490	495
Ile Ile His Tyr Met His Asp Lys Tyr Ser Tyr Glu Ala Ser Leu Met		
500	505	510
Ala Leu His Asp Arg Asp Val Ile Arg Thr Met Ala Cys Gly Ile Ala		
515	520	525
Gly Leu Ser Val Ala Ala Asp Ser Leu Ser Ala Ile Lys Tyr Ala Lys		
530	535	540
Val Lys Pro Ile Arg Asp Glu Asp Gly Leu Ala Ile Asp Phe Glu Ile		
545	550	555 560
Glu Gly Glu Tyr Pro Gln Phe Gly Asn Asn Asp Pro Arg Val Asp Asp		
565	570	575
Leu Ala Val Asp Leu Val Glu Arg Phe Met Lys Lys Ile Gln Lys Leu		
580	585	590
His Thr Tyr Arg Asp Ala Ile Pro Thr Gln Ser Val Leu Thr Ile Thr		
595	600	605
Ser Asn Val Val Tyr Gly Lys Lys Thr Gly Asn Thr Pro Asp Gly Arg		
610	615	620
Arg Ala Gly Ala Pro Phe Gly Pro Gly Ala Asn Pro Met His Gly Arg		
625	630	635 640
Asp Gln Lys Gly Ala Val Ala Ser Leu Thr Ser Val Ala Lys Leu Pro		
645	650	655
Phe Ala Tyr Ala Lys Asp Gly Ile Ser Tyr Thr Phe Ser Ile Val Pro		
660	665	670
Asn Ala Leu Gly Lys Asp Asp Glu Val Arg Lys Thr Asn Leu Ala Gly		
675	680	685
Leu Met Asp Gly Tyr Phe His His Glu Ala Ser Ile Glu Gly Gly Gln		
690	695	700
His Leu Asn Val Asn Val Met Asn Arg Glu Met Leu Leu Asp Ala Met		
705	710	715 720
Glu Asn Pro Glu Lys Tyr Pro Gln Leu Thr Ile Arg Val Ser Gly Tyr		
725	730	735
Ala Val Arg Phe Asn Ser Leu Thr Lys Glu Gln Gln Asp Val Ile		
740	745	750
Thr Arg Thr Phe Thr Gln Ser Met		
755	760	

<210> SEQ ID NO 43

<211> LENGTH: 768

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 43

atggggccaca tctggagaaa caccgcaatg tcagttattg gtcgcattca ctcccttgaa	60
tcctgtggaa ccgttagacgg cccgggtatt cgctttatca ctttttcca gggctgcctg	120
atgcgcgtcc tgtattgtca taacccgcac acctgggata cgcatgggg taaagaagtt	180
accgttgaag atttgtatgaa ggaagtgggtg acctatcgcc actttatgaa cgcttcggc	240
ggcggcgtta ccgcataccgg cggtgaggca atcctacaag ctgagtttgt tcgtgactgg	300

-continued

ttccgcgcct gcaaaaaaga aggcatccat acctgtctgg acaccaacgg tttgttcgt	360
cgttacgatc cggtgattga tgaactgctg gaagtaaccg acctggtaat gctcgatctc	420
aaacagatga acgacgagat ccaccaaaaat ctgggtggag tttccaacca ccgcacgctg	480
gagttcgcta aatatctggc gaacaaaaat gtgaagggtg ggatccgcta tggtgttgc	540
ccaggctggt ctgacgatga cgattcagcg catgccttg gtgaatttac ccgtgatatg	600
ggcaacgttg agaaaaatcga gctccccc taccacgaac tgggcaaaca caaatgggtg	660
gcaatgggtg aagaatacaa actcgatggt gttaaaccac cgaagaaaga gaccatggaa	720
cgcgtgaaag gcattttga gcagtacggt cataaggcata tggtctaa	768

<210> SEQ ID NO 44

<211> LENGTH: 255

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 44

Met Gly His Ile Trp Arg Asn Thr Ala Met Ser Val Ile Gly Arg Ile	
1 5 10 15	

His Ser Phe Glu Ser Cys Gly Thr Val Asp Gly Pro Gly Ile Arg Phe	
20 25 30	

Ile Thr Phe Phe Gln Gly Cys Leu Met Arg Cys Leu Tyr Cys His Asn	
35 40 45	

Arg Asp Thr Trp Asp Thr His Gly Gly Lys Glu Val Thr Val Glu Asp	
50 55 60	

Leu Met Lys Glu Val Val Thr Tyr Arg His Phe Met Asn Ala Ser GLY	
65 70 75 80	

Gly Gly Val Thr Ala Ser Gly Gly Glu Ala Ile Leu Gln Ala Glu Phe	
85 90 95	

Val Arg Asp Trp Phe Arg Ala Cys Lys Lys Glu Gly Ile His Thr Cys	
100 105 110	

Leu Asp Thr Asn Gly Phe Val Arg Arg Tyr Asp Pro Val Ile Asp Glu	
115 120 125	

Leu Leu Glu Val Thr Asp Leu Val Met Leu Asp Leu Lys Gln Met Asn	
130 135 140	

Asp Glu Ile His Gln Asn Leu Val Gly Val Ser Asn His Arg Thr Leu	
145 150 155 160	

Glu Phe Ala Lys Tyr Leu Ala Asn Lys Asn Val Lys Val Trp Ile Arg	
165 170 175	

Tyr Val Val Val Pro Gly Trp Ser Asp Asp Asp Ser Ala His Arg	
180 185 190	

Leu Gly Glu Phe Thr Arg Asp Met Gly Asn Val Glu Lys Ile Glu Leu	
195 200 205	

Leu Pro Tyr His Glu Leu Gly Lys His Lys Trp Val Ala Met Gly Glu	
210 215 220	

Glu Tyr Lys Leu Asp Gly Val Lys Pro Pro Lys Lys Glu Thr Met Glu	
225 230 235 240	

Arg Val Lys Gly Ile Leu Glu Gln Tyr Gly His Lys Val Met Phe	
245 250 255	

<210> SEQ ID NO 45

<211> LENGTH: 1707

<212> TYPE: DNA

<213> ORGANISM: Zymomonas mobilis

<220> FEATURE:

-continued

<221> NAME/KEY: misc_feature

<222> LOCATION: (622)..(622)

<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 45

atgagttata ctgtcggtac ctat tagcg gageggcttg tccagattgg tctcaagcat	60
cacttcgcag tcgcgggcga ctacaac ctc gtc ttcttgcg acaacctgct tttgaacaaa	120
aacatggagc aggtttattt ctgtAACGAA ctgaactcg gtttcagtgc agaagggtat	180
gctcggtcca aaggcgcagc agcagccgtc gttacctaca gegtccgtgc gtttccgca	240
tttgcgtgtca tcgggtggcgc ctatgcagaa aacc ttccgg ttatccgtat ctccgggtct	300
ccgaacaaca atgaccacgc tgctggtcac gtgttgcac acgctttgg caaaaccgac	360
tatcaactatc agttggaaat ggccaagaac atcacggccg ccgtctgaagc gatttataacc	420
ccggaagaag ctccggctaa aatcgatcac gtgattaaaa ctgctttcg tgagaagaag	480
ccgggttatac tcgaaatcgc ttgcaacatt gcttccatgc cctgcgcgcg tcctggaccg	540
gcaaggcgcac tggttcaatga cgaaggccagc gacgaagctt ctttgaatgc agcgggttggaa	600
gaaaccctga aattcatcgc cnaccgcgc aagttgccg tcctcgctgg cagcaagctg	660
cgcgcagctg gtgctgaaga agctgtgtc aaatttgcgt atgttgcgttggcgcagtt	720
gctaccatgg ctgctgc aaaa aagcttcttc ccagaagaaa acccgcatta catcggtacc	780
tcatgggtt aagttagctta tccgggcgtt gaaaagacg tggaaagaac cgatgcgggtt	840
atcgctctgg ctccctgtt taacgactac tccaccactg tttggacgg tattccgtat	900
cctaagaaac tgggttcgcg tgaaccgcgt tctgtcg ttaacggcat tcgctcccc	960
agcgtccatc tgaaagacta tctgacccgt ttggctcaga aagttccaa gaaaaccggt	1020
gctttggact tcttcaatc cctcaatgc ggtgaactg aagaaaggccgc tccggctgtat	1080
ccgagtgctc cggttgtcaa cgcagaaatc gcccgtcagg tcgaagctt tctgaccgg	1140
aacacgacgg tttatgtca aaccgggtac tcttgggttca atgctcagcg catgaagctc	1200
ccgaacgggtg ctgcgttga atatgaaatg cagtggttgc acattgggtt gtcgggttct	1260
ggccgcctcg gttatgtccgt cggtgtccg gaacgtcgca acatccctat ggttgggtat	1320
gtttccctcc agctgacggc tcagggaaatg gtcagatgg ttgcctgaa actgcccgtt	1380
atcatcttct tggatcaataa ctatggttac accatcgaaat tttatgtca tggatggccg	1440
tacaacaaca tcaagaactg ggattatgcc ggttgcgtt aagtgttcaa cggtacgg	1500
gtttatgaca ggggtgttgg taaaggccctt aaggctaaaa ccgggtggcga actggcagaa	1560
gctatcaagg ttgtctggc aaacaccgac ggcccaaccc tgatcgatg cttcatcggt	1620
cgtgaagact gcaactgaaga attggtcaaa tggggtaagc gcggtgtgc cgccaaacagc	1680
cgtaaggcctg ttaacaagct cctctag	1707

<210> SEQ ID NO 46

<211> LENGTH: 568

<212> TYPE: PRT

<213> ORGANISM: Zymomonas mobilis

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (208)..(208)

<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 46

Met Ser Tyr Thr Val Gly Thr Tyr Leu Ala Glu Arg Leu Val Gln Ile			
1	5	10	15

-continued

Gly Leu Lys His His Phe Ala Val Ala Gly Asp Tyr Asn Leu Val Leu
20 25 30

Leu Asp Asn Leu Leu Leu Asn Lys Asn Met Glu Gln Val Tyr Cys Cys
35 40 45

Asn Glu Leu Asn Cys Gly Phe Ser Ala Glu Gly Tyr Ala Arg Ala Lys
50 55 60

Gly Ala Ala Ala Ala Val Val Thr Tyr Ser Val Gly Ala Leu Ser Ala
65 70 75 80

Phe Asp Ala Ile Gly Gly Ala Tyr Ala Glu Asn Leu Pro Val Ile Leu
85 90 95

Ile Ser Gly Ala Pro Asn Asn Asp His Ala Ala Gly His Val Leu
100 105 110

His His Ala Leu Gly Lys Thr Asp Tyr His Tyr Gln Leu Glu Met Ala
115 120 125

Lys Asn Ile Thr Ala Ala Glu Ala Ile Tyr Thr Pro Glu Glu Ala
130 135 140

Pro Ala Lys Ile Asp His Val Ile Lys Thr Ala Leu Arg Glu Lys Lys
145 150 155 160

Pro Val Tyr Leu Glu Ile Ala Cys Asn Ile Ala Ser Met Pro Cys Ala
165 170 175

Ala Pro Gly Pro Ala Ser Ala Leu Phe Asn Asp Glu Ala Ser Asp Glu
180 185 190

Ala Ser Leu Asn Ala Ala Val Glu Glu Thr Leu Lys Phe Ile Ala Xaa
195 200 205

Arg Asp Lys Val Ala Val Leu Val Gly Ser Lys Leu Arg Ala Ala Gly
210 215 220

Ala Glu Glu Ala Ala Val Lys Phe Ala Asp Ala Leu Gly Gly Ala Val
225 230 235 240

Ala Thr Met Ala Ala Ala Lys Ser Phe Phe Pro Glu Glu Asn Pro His
245 250 255

Tyr Ile Gly Thr Ser Trp Gly Glu Val Ser Tyr Pro Gly Val Glu Lys
260 265 270

Thr Met Lys Glu Ala Asp Ala Val Ile Ala Leu Ala Pro Val Phe Asn
275 280 285

Asp Tyr Ser Thr Thr Gly Trp Thr Asp Ile Pro Asp Pro Lys Lys Leu
290 295 300

Val Leu Ala Glu Pro Arg Ser Val Val Val Asn Gly Ile Arg Phe Pro
305 310 315 320

Ser Val His Leu Lys Asp Tyr Leu Thr Arg Leu Ala Gln Lys Val Ser
325 330 335

Lys Lys Thr Gly Ala Leu Asp Phe Phe Lys Ser Leu Asn Ala Gly Glu
340 345 350

Leu Lys Lys Ala Ala Pro Ala Asp Pro Ser Ala Pro Leu Val Asn Ala
355 360 365

Glu Ile Ala Arg Gln Val Glu Ala Leu Leu Thr Pro Asn Thr Thr Val
370 375 380

Ile Ala Glu Thr Gly Asp Ser Trp Phe Asn Ala Gln Arg Met Lys Leu
385 390 395 400

Pro Asn Gly Ala Arg Val Glu Tyr Glu Met Gln Trp Gly His Ile Gly
405 410 415

Trp Ser Val Pro Ala Ala Phe Gly Tyr Ala Val Gly Ala Pro Glu Arg
420 425 430

Arg Asn Ile Leu Met Val Gly Asp Gly Ser Phe Gln Leu Thr Ala Gln

US 9,850,505 B2

117

118

-continued

435	440	445	
Glu Val Ala Gln Met Val Arg Leu Lys Leu Pro Val Ile Ile Phe Leu			
450	455	460	
Ile Asn Asn Tyr Gly Tyr Thr Ile Glu Val Met Ile His Asp Gly Pro			
465	470	475	480
Tyr Asn Asn Ile Lys Asn Trp Asp Tyr Ala Gly Leu Met Glu Val Phe			
485	490	495	
Asn Gly Asn Gly Gly Tyr Asp Ser Gly Ala Gly Lys Gly Leu Lys Ala			
500	505	510	
Lys Thr Gly Gly Glu Leu Ala Glu Ala Ile Lys Val Ala Leu Ala Asn			
515	520	525	
Thr Asp Gly Pro Thr Leu Ile Glu Cys Phe Ile Gly Arg Glu Asp Cys			
530	535	540	
Thr Glu Glu Leu Val Lys Trp Gly Lys Arg Val Ala Ala Ala Asn Ser			
545	550	555	560
Arg Lys Pro Val Asn Lys Leu Leu			
565			

<210> SEQ ID NO 47
<211> LENGTH: 1152
<212> TYPE: DNA
<213> ORGANISM: *Zymomonas mobilis*

<400> SEQUENCE: 47
atggcttctt caactttta tattccttc gtcaacgaaa tgggcgaagg ttgcgttcaa 60
aaagcaatca aggatcttaa cggcagccgc tttaaaaatg cgctgtatcg ttctgtatct 120
ttcatgaaca aatccggtgt tgtgaaggcag gttgctgacc tgttgaaagc acagggtatt 180
aattctgctg tttatgtgg cgttatggcg aacccgactg ttacccgagt tctggaaaggc 240
cttaagatcc tgaaggataa caattcagac ttgcgtatct ccctcggtgg tggttctccc 300
catgactgcg ccaaagccat cgctctggtc gcaaccaatg gtggtaagt caaagactac 360
gaaggatatcg acaaatactaa gaaacctgcc ctgccttga tgtcaatcaa cacgacggct 420
ggtacggctt ctgaaatgac gcgttctgc atcatcactg atgaagtccg tcacgttaag 480
atggccatttggatccatggatccatggatccatggatccatggatccatggatccatggatcc 540
gttggatgc caaaaggcct gaccggccgc accggatatgg atgctctgac ccacgcattt 600
gaagcttatttcttcaacggc agctactccg atcaccgatg ctgcgcctt gaaggctgeg 660
tccatgatcg ctaagaatct gaagaccgat tgcgacaacg gtaaggatata gcccacgtcg 720
gaagctatgg ctatggccca attcctcgat ggtatggct tcaacaacgc ttgcgttggat 780
tatgtccatcg ctatggctca ccagttgggc ggctactaca acctgcgcga tggtgctcg 840
aacgcgttgc tgctccgca tggtctggct tataacgcct ctgtcgatcg tggtgctcg 900
aaagacgttg gtgttgcata gggctcgat atcgccaatc tcggtgataa agaaggcgca 960
gaagccacca ttcaaggctgt tcgcgatctg gtcgttccat tgggtattcc agccaaatctg 1020
accgagactgg gtgctaagaa agaagatgtg ccgcatttgc ctgaccacgc tctgaaagat 1080
gtttgtgtctc tgaccaaccc gctcagggt gatcagaaag aagttgaaga actcttcctg 1140
aqcqcttctt aa 1152

<210> SEQ ID NO 48
<211> LENGTH: 383
<212> TYPE: PRT
<213> ORGANISM: *Zymomonas mobilis*

-continued

<400> SEQUENCE: 48

Met Ala Ser Ser Thr Phe Tyr Ile Pro Phe Val Asn Glu Met Gly Glu
 1 5 10 15

Gly Ser Leu Glu Lys Ala Ile Lys Asp Leu Asn Gly Ser Gly Phe Lys
 20 25 30

Asn Ala Leu Ile Val Ser Asp Ala Phe Met Asn Lys Ser Gly Val Val
 35 40 45

Lys Gln Val Ala Asp Leu Leu Lys Ala Gln Gly Ile Asn Ser Ala Val
 50 55 60

Tyr Asp Gly Val Met Pro Asn Pro Thr Val Thr Ala Val Leu Glu Gly
 65 70 75 80

Leu Lys Ile Leu Lys Asp Asn Ser Asp Phe Val Ile Ser Leu Gly
 85 90 95

Gly Gly Ser Pro His Asp Cys Ala Lys Ala Ile Ala Leu Val Ala Thr
 100 105 110

Asn Gly Gly Glu Val Lys Asp Tyr Glu Gly Ile Asp Lys Ser Lys Lys
 115 120 125

Pro Ala Leu Pro Leu Met Ser Ile Asn Thr Thr Ala Gly Thr Ala Ser
 130 135 140

Glu Met Thr Arg Phe Cys Ile Ile Thr Asp Glu Val Arg His Val Lys
 145 150 155 160

Met Ala Ile Val Asp Arg His Val Thr Pro Met Val Ser Val Asn Asp
 165 170 175

Pro Leu Leu Met Val Gly Met Pro Lys Gly Leu Thr Ala Ala Thr Gly
 180 185 190

Met Asp Ala Leu Thr His Ala Phe Glu Ala Tyr Ser Ser Thr Ala Ala
 195 200 205

Thr Pro Ile Thr Asp Ala Cys Ala Leu Lys Ala Ala Ser Met Ile Ala
 210 215 220

Lys Asn Leu Lys Thr Ala Cys Asp Asn Gly Lys Asp Met Pro Ala Arg
 225 230 235 240

Glu Ala Met Ala Tyr Ala Gln Phe Leu Ala Gly Met Ala Phe Asn Asn
 245 250 255

Ala Ser Leu Gly Tyr Val His Ala Met Ala His Gln Leu Gly Gly Tyr
 260 265 270

Tyr Asn Leu Pro His Gly Val Cys Asn Ala Val Leu Leu Pro His Val
 275 280 285

Leu Ala Tyr Asn Ala Ser Val Val Ala Gly Arg Leu Lys Asp Val GLY
 290 295 300

Val Ala Met Gly Leu Asp Ile Ala Asn Leu Gly Asp Lys Glu Gly Ala
 305 310 315 320

Glu Ala Thr Ile Gln Ala Val Arg Asp Leu Ala Ala Ser Ile Gly Ile
 325 330 335

Pro Ala Asn Leu Thr Glu Leu Gly Ala Lys Lys Glu Asp Val Pro Leu
 340 345 350

Leu Ala Asp His Ala Leu Lys Asp Ala Cys Ala Leu Thr Asn Pro Arg
 355 360 365

Gln Gly Asp Gln Lys Glu Val Glu Glu Leu Phe Leu Ser Ala Phe
 370 375 380

121

We claim:

1. A microorganism comprising activity-reducing or activity-ablating mutations in endogenous genes encoding a pyruvate dehydrogenase, a pyruvate oxidase, a lactate dehydrogenase, and one or more enzymes selected from the group consisting of a 6-phosphogluconate dehydrogenase and a glutamate dehydrogenase.

2. The microorganism of claim 1 wherein the microorganism comprises an activity-reducing or activity-ablating mutation in an endogenous gene encoding a 6-phosphogluconate dehydrogenase.

3. The microorganism of claim 1 wherein the microorganism comprises an activity-reducing or activity-ablating mutation in an endogenous gene encoding a glutamate dehydrogenase.

4. The microorganism of claim 1 wherein the microorganism comprises an activity-reducing or activity-ablating mutation in an endogenous gene encoding a 6-phosphogluconate dehydrogenase and an endogenous gene encoding a glutamate dehydrogenase.

5. The microorganism of claim 1 further comprising an activity-reducing or activity-ablating mutation in an endogenous gene encoding an enzyme selected from the group consisting of a pyruvate formate lyase and a pyruvate formate lyase activating enzyme.

6. The microorganism of claim 1 wherein the microorganism is modified to express a pyruvate decarboxylase and an alcohol dehydrogenase.

7. The microorganism of claim 1 wherein the microorganism comprises one or more recombinant genes encoding one or more enzymes selected from the group consisting of a pyruvate decarboxylase and an alcohol dehydrogenase.

8. The microorganism of claim 7 further comprising an activity-reducing or activity-ablating mutation in an endogenous gene encoding an enzyme selected from the group consisting of a pyruvate formate lyase and a pyruvate formate lyase activating enzyme.

9. The microorganism of claim 1 wherein the activity-reducing or activity-ablating mutations in the endogenous genes are independently selected from the group consisting of a nucleotide substitution in the endogenous gene, a nucleotide insertion in the endogenous gene, a partial deletion of the endogenous gene, and a complete deletion of the endogenous gene.

10. The microorganism of claim 1 wherein the microorganism is a bacterium or a yeast.

11. The microorganism of claim 1 wherein the microorganism is a bacterium.

12. The microorganism of claim 1 wherein the microorganism is an evolved microorganism produced by sequentially culturing a precursor microorganism in media comprising decreasing concentrations of acetate, wherein the precursor microorganism comprises activity-reducing or activity-ablating mutations in (a) endogenous genes encoding a pyruvate dehydrogenase, a pyruvate oxidase, and a lactate dehydrogenase, and (b) one or more endogenous genes encoding one or more enzymes selected from the group consisting of a 6-phosphogluconate dehydrogenase and a glutamate dehydrogenase, wherein the evolved microorganism exhibits one or more of increased growth rate compared to the precursor microorganism and increased pyruvate production compared to the precursor microorganism, and wherein the evolved microorganism comprises the activity-reducing or activity-ablating mutations in the endogenous genes of (a) and (b).

122

pyruvate production compared to the precursor microorganism, and wherein the evolved microorganism comprises the activity-reducing or activity-ablating mutations in the endogenous genes of (a) and (b).

13. The microorganism of claim 12 wherein the concentrations of acetate in the media in which the precursor microorganism is sequentially cultured to produce the microorganism range from about 0.1 mg/L acetate to about 3 g/L acetate.

14. The microorganism of claim 12 wherein the evolved microorganism further comprises an activity-reducing or activity-ablating mutation in an endogenous gene encoding an enzyme selected from the group consisting of a pyruvate formate lyase and a pyruvate formate lyase activating enzyme.

15. The microorganism of claim 12 wherein the evolved microorganism is modified to express a pyruvate decarboxylase and an alcohol dehydrogenase.

16. The microorganism of claim 12 wherein the evolved microorganism comprises one or more recombinant genes encoding one or more enzymes selected from the group consisting of a pyruvate decarboxylase and an alcohol dehydrogenase.

17. A method of producing a chemical comprising culturing the microorganism of claim 1.

18. The method of claim 17 wherein the microorganism further comprises:

an activity-reducing or activity-ablating mutation in an endogenous gene encoding an enzyme selected from the group consisting of a pyruvate formate lyase and a pyruvate formate lyase activating enzyme; and
one or more recombinant genes encoding one or more enzymes selected from the group consisting of a pyruvate decarboxylase and an alcohol dehydrogenase.

19. The method of claim 17 wherein the culturing comprises culturing the microorganism in a medium, the chemical is selected from the group consisting of pyruvate and ethanol, and the method further comprises purifying the chemical from the medium.

20. The method of claim 17 wherein the culturing comprises culturing the microorganism in a medium comprising a biomass hydrolysate.

21. The method of claim 17 wherein the microorganism is an evolved microorganism produced by sequentially culturing a precursor microorganism in media comprising decreasing concentrations of acetate, wherein the precursor microorganism comprises activity-reducing or activity-ablating mutations in (a) endogenous genes encoding a pyruvate dehydrogenase, a pyruvate oxidase, and a lactate dehydrogenase, and (b) one or more endogenous genes encoding one or more enzymes selected from the group consisting of a 6-phosphogluconate dehydrogenase and a glutamate dehydrogenase, wherein the evolved microorganism exhibits one or more of increased growth rate compared to the precursor microorganism and increased pyruvate production compared to the precursor microorganism, and wherein the evolved microorganism comprises the activity-reducing or activity-ablating mutations in the endogenous genes of (a) and (b).

* * * * *